<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4706844</article-id><article-id pub-id-type="publisher-id">336</article-id><article-id pub-id-type="doi">10.1007/s40261-015-0336-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Huss</surname><given-names>Michael</given-names></name><address><email>M.HUSS@rfk.landeskrankenhaus.de</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Wai</given-names></name><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author" deceased="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0765-8481</contrib-id><name><surname>Ludolph</surname><given-names>Andrea G.</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><aff id="Aff1"><label/>Child and Adolescent Psychiatry of the University Medicine Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany </aff><aff id="Aff2"><label/>Department of Child and Adolescent Psychiatry, School of Paediatrics and Child Health and School of Psychiatry and Clinical Neurosciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Western Australia, Perth, WA Australia </aff><aff id="Aff3"><label/>Department of Health, Complex Attention and Hyperactivity Disorder Service, Perth, WA Australia </aff><aff id="Aff4"><label/>Department of Child and Adolescent Psychiatry/Psychotherapy, University of Ulm, Steinhoevelstrasse 5, 89075 Ulm, Germany </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="ppub"><year>2016</year></pub-date><volume>36</volume><fpage>1</fpage><lpage>25</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><p>Children/adolescents with attention-deficit/hyperactivity disorder (ADHD) may have a poor or inadequate response to psychostimulants or be unable to tolerate their side-effects; furthermore, stimulants may be inappropriate because of co-existing conditions. Only one non-stimulant ADHD pharmacotherapy, the noradrenaline transporter inhibitor atomoxetine, is currently approved for use in Europe. We review recent advances in understanding of the pathophysiology of ADHD with a focus on the roles of catecholamine receptors in context of the &#x003b1;2A-adrenergic receptor agonist guanfacine extended release (GXR), a new non-stimulant treatment option in Europe. Neuroimaging studies of children/adolescents with ADHD show impaired brain maturation, and structural and functional anomalies in brain regions and networks. Neurobiological studies in ADHD and medication response patterns support involvement of monoaminergic neurotransmitters (primarily dopamine and noradrenaline). Guanfacine is a selective &#x003b1;2A-adrenergic receptor agonist that has been shown to improve prefrontal cortical cognitive function, including working memory. The hypothesized mode of action of guanfacine centres on direct stimulation of post-synaptic &#x003b1;2A-adrenergic receptors to enhance noradrenaline neurotransmission. Preclinical data suggest that guanfacine also influences dendritic spine growth and maturation. Clinical trials have demonstrated the efficacy of GXR in ADHD, and it is approved as monotherapy or adjunctive therapy to stimulants in Canada and the USA (for children and adolescents). GXR was approved recently in Europe for the treatment of ADHD in children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. GXR may provide particular benefit for children/adolescents who have specific co-morbidities such as chronic tic disorders or oppositional defiant disorder (or oppositional symptoms) that have failed to respond to first-line treatment options.</p></abstract><funding-group><award-group><funding-source><institution>Shire International GmbH</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Psychostimulants and the non-stimulant atomoxetine increase the extracellular availability of dopamine and noradrenaline at the synaptic cleft. Although methylphenidate is generally the first choice medication for children/adolescents with attention deficit/hyperactivity disorder (ADHD) in Europe, stimulants can be unsuitable for some patients.</td></tr><tr><td align="left">Guanfacine is a selective &#x003b1;2A-adrenergic receptor agonist that acts directly on &#x003b1;2A-adrenergic receptors to enhance noradrenaline neurotransmission; preliminary evidence suggests that guanfacine also influences dendritic spine plasticity in the prefrontal cortex.</td></tr><tr><td align="left">Guanfacine extended-release (GXR) is a new non-stimulant pharmacotherapy for ADHD in Europe for children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. The selective mode of action of GXR may provide particular benefit for children/adolescents who have specific co-morbidities such as chronic tic disorders or oppositional defiant disorder (or oppositional symptoms) that have failed to respond to first-line treatment options.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Attention-deficit/hyperactivity disorder (ADHD) is a complex and multifactorial neurodevelopmental disorder [<xref ref-type="bibr" rid="CR1">1</xref>] that is characterized by age-inappropriate and excessive levels of inattention, hyperactivity and impulsivity [<xref ref-type="bibr" rid="CR2">2</xref>]. ADHD affects approximately 5&#x000a0;% of children and adolescents worldwide [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>] and symptoms persist into adulthood in most cases [<xref ref-type="bibr" rid="CR5">5</xref>]. The disorder is associated with deficits in executive function [<xref ref-type="bibr" rid="CR6">6</xref>], including working memory [<xref ref-type="bibr" rid="CR7">7</xref>], and leads to impairment in a broad range of academic and social activities [<xref ref-type="bibr" rid="CR2">2</xref>]. Emotional dysregulation is increasingly recognized as a common feature of ADHD, and may manifest as extreme irritability, frustration, reactive aggression and temper outbursts [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Common ADHD co-morbidities include oppositional defiant disorder (ODD), conduct disorder and chronic tic disorders including Tourette&#x02019;s syndrome [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Although understanding of the pathophysiology of ADHD has improved greatly in the past decade, treatment options are still limited. The management of ADHD comprises non-pharmacological interventions, such as behavioural therapy, and pharmacotherapy [<xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. The psychostimulants methylphenidate (MPH) and amphetamines were the only available ADHD medications for many years. Stimulants have a good effect size (0.8&#x02013;1.5) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], and MPH is generally recommended in Europe as the first choice medication for children/adolescents with ADHD [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. However, approximately 30&#x000a0;% of children/adolescents with ADHD are unresponsive to a single stimulant medication and approximately 10&#x000a0;% fail to respond to any stimulants [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Others are intolerant of the side effects of stimulants [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Moreover, stimulants may not be the treatment of choice because of a personal or family history of medical conditions, risks of drug diversion or substance abuse, or parental preference [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p>One non-stimulant pharmacotherapy for ADHD, the noradrenaline transporter inhibitor atomoxetine (ATX), is currently approved for use in Europe. The efficacy of ATX in ADHD is well established [<xref ref-type="bibr" rid="CR23">23</xref>], but potential clinical limitations include a delayed onset of action [<xref ref-type="bibr" rid="CR24">24</xref>] and sympathomimetic cardiovascular side effects, which are similar to those of stimulants [<xref ref-type="bibr" rid="CR25">25</xref>]. An alternative non-stimulant medication, particularly one without sympathomimetic cardiovascular side effects, could provide a useful therapeutic option for children/adolescents with ADHD. Guanfacine extended release (GXR; Intuniv) is approved for the treatment of ADHD as monotherapy or adjunctive therapy to stimulants in Canada and the USA (for children and adolescents, 6&#x02013;17 years) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. GXR was approved recently in Europe as part of a comprehensive programme for the treatment of ADHD in children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective [<xref ref-type="bibr" rid="CR28">28</xref>].</p><p>Here we provide an overview of recent advances in our understanding of the pathophysiology of ADHD in the context of GXR. This article is intended to provide a clinical perspective on the neurobiology of ADHD and mode of action of pharmacotherapies. Given the broad scope of this article, a formal systematic literature review was not feasible. Rather, we used our combined clinical experience to develop an up-to-date and practical narrative review providing information on ADHD and pharmacological treatment options, with a focus on clinically relevant recent research findings.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods of Literature Search</title><p>Electronic literature searches via MEDLINE/PubMed were conducted for articles published in English (unlimited by date of publication). Combinations of keywords were used to identify relevant articles, including: &#x02018;Attention deficit disorder with hyperactivity&#x02019;, &#x02018;ADHD&#x02019;, &#x02018;ADD&#x02019;, &#x02018;pathophysiology&#x02019;, &#x02018;neurobiology&#x02019;, &#x02018;neurochemistry&#x02019;, &#x02018;imaging&#x02019;, &#x02018;alpha 2A agonists&#x02019;, &#x02018;guanfacine&#x02019;, &#x02018;guanfacine extended release&#x02019;, &#x02018;GXR&#x02019;, &#x02018;mechanism&#x02019;, &#x02018;psychostimulants&#x02019;, &#x02018;methylphenidate&#x02019;, &#x02018;amphetamine&#x02019;, &#x02018;atomoxetine&#x02019;, &#x02018;contraindicated&#x02019;, &#x02018;adverse events&#x02019;, &#x02018;side effects&#x02019;, &#x02018;cardiovascular disease&#x02019;, &#x02018;hypertension&#x02019;, &#x02018;juvenile hypertension&#x02019;, &#x02018;tics&#x02019;, &#x02018;Tourette&#x02019;s syndrome&#x02019;, &#x02018;conduct disorder&#x02019;, &#x02018;oppositional defiant disorder&#x02019; and &#x02018;oppositional symptoms&#x02019;. The last electronic searches were conducted on 15 July 2015. Meta-analyses, systematic and narrative reviews, and original research articles were included. Criteria for each search were adapted according to the initial number of hits. Formal literature searches were also supplemented with key publications, abstracts and posters that were known to the authors.</p></sec><sec id="Sec3"><title>Pathophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD)</title><p>Although involvement of the prefrontal cortex (PFC) in ADHD has long been recognized, ADHD is now considered to be a neurodevelopmental disorder that affects the whole brain. The PFC regulates high-order cognitive functions, including attention, behaviour, planning and emotion through working memory [<xref ref-type="bibr" rid="CR29">29</xref>]. These executive functions involve extensive neural network connections (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR29">29</xref>]. Recent evidence from systems neuroscience-based studies has demonstrated the importance of circuitry and connectivity involving large-scale neural networks in ADHD [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Accordingly, our understanding of the pathophysiology of ADHD has changed from a model based on specific regional differences to widespread altered connectivity in the whole brain [<xref ref-type="bibr" rid="CR33">33</xref>].<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Regulation of attention, behaviour and emotion through extensive network connections of the prefrontal cortex with other brain regions. Reproduced from Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51:356&#x02013;67, &#x000a9; (2012) with permission from Elsevier</p></caption><graphic xlink:href="40261_2015_336_Fig1_HTML" id="MO1"/></fig></p><sec id="Sec4"><title>Neuroimaging</title><p>Recent advances in neuroimaging have allowed the use of innovative high-resolution computational techniques to identify anatomical and functional anomalies in ADHD. Initial magnetic resonance imaging (MRI) studies in ADHD focused on the morphology of discrete brain regions, whereas more recent investigations have evaluated altered connectivity in large-scale neural networks [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>].</p><p>Neuroanatomical differences between the brains of individuals with ADHD and healthy controls are well established [<xref ref-type="bibr" rid="CR33">33</xref>]. Longitudinal and cross-sectional structural neuroimaging data indicate that ADHD is characterized by a global delay in brain maturation [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Cerebral, cerebellar, grey and white matter volumes are significantly smaller (2.5&#x02013;4&#x000a0;%) among children/adolescents with ADHD compared with normal controls [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Peak cortical thickness is reached significantly later among children/adolescents with ADHD than normal controls (10.5 vs. 7.5&#x000a0;years; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;1.0&#x000a0;&#x000d7;&#x000a0;10&#x02013;20) and the delay is most profound in the lateral PFC (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR36">36</xref>]. A persistently smaller volume of the superior cerebellar vermis has also been reported in children/adolescents with ADHD versus normal controls, and the development trajectory of the cerebellum may be associated with clinical outcome [<xref ref-type="bibr" rid="CR39">39</xref>]. Morphological and volumetric changes of subcortical structures, including the thalamus, basal ganglia and limbic system have also been reported [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR40">40</xref>&#x02013;<xref ref-type="bibr" rid="CR42">42</xref>]. The functional significance of these differences in subcortical structures remains unclear but may represent disruption to neural network architecture in ADHD [<xref ref-type="bibr" rid="CR41">41</xref>].<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Attention-deficit/hyperactivity disorder (ADHD) is characterized by a delay in cortical maturation: <bold>a</bold> dorsal view and <bold>b</bold> right lateral view. View of the cortical regions where peak thickness was attained at each age (<bold>a</bold> 7&#x02013;12&#x000a0;years, <bold>b</bold> 7&#x02013;13&#x000a0;years) in ADHD (<italic>upper rows</italic>) and typically developing controls (<italic>lower rows</italic>). <italic>Darker colours</italic> indicate regions where a quadratic model was not appropriate (and thus a peak age could not be calculated), or the peak age was estimated to lie outside the age range covered. Both groups showed similar sequences of regions that attained peak thickness, but the ADHD group showed considerable delay in reaching this developmental marker. Reproduced with permission from Shaw et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA. 2007;104:19649&#x02013;54. &#x000a9; (2007) National Academy of Sciences, USA</p></caption><graphic xlink:href="40261_2015_336_Fig2_HTML" id="MO2"/></fig></p><p>MRI studies using tractography 3D-modelling techniques have identified altered structural connectivity in white matter tracts among children with ADHD. Diffusion tensor imaging (DTI) provides quantitative data on the integrity of white matter tracts. Reduced volume and integrity of white matter tracts between the thalamus and striatum, hippocampus and PFC have been demonstrated in children with ADHD versus controls [<xref ref-type="bibr" rid="CR42">42</xref>]. A meta-analysis of data from DTI studies (<italic>n</italic>&#x000a0;=&#x000a0;15) suggests that the most consistent alterations in white matter integrity may be found in the right anterior corona radiata, right forceps minor, bilateral internal capsule and left cerebellum [<xref ref-type="bibr" rid="CR43">43</xref>]. Abnormal connectivity and microstructural integrity in white matter linking the frontal lobe, striatum and cerebellum in children/adolescents with ADHD have also been demonstrated [<xref ref-type="bibr" rid="CR44">44</xref>]. Moreover, in this study the altered connectivity in some fibre bundles correlated with attentional performance [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p>Network dysfunction in ADHD has been examined systematically using functional neuroimaging. Widespread differences in functional activation between patients with ADHD and normal controls have been described and suggest distinct domain-specific neurofunctional deficits [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Functional MRI (fMRI) provides a measure of the activity of neural regions involved at rest or during a particular task [<xref ref-type="bibr" rid="CR33">33</xref>]. Meta-analyses of fMRI data have shown consistent right fronto-striatal dysfunction during inhibition- and attention-related tasks among patients with ADHD [<xref ref-type="bibr" rid="CR46">46</xref>]. Attention tasks (data sets <italic>n</italic>&#x000a0;=&#x000a0;13) involved the dorsolateral PFC, parietal and cerebellar areas. Inhibition tasks (data sets <italic>n</italic>&#x000a0;=&#x000a0;21) involved the inferior frontal cortex, supplementary motor area and anterior cingulate cortex. A further meta-analysis of data from fMRI studies (<italic>n</italic>&#x000a0;=&#x000a0;11) showed hypoactivation in the left fronto-parieto-cerebellar areas during timing tasks in ADHD [<xref ref-type="bibr" rid="CR45">45</xref>].</p><p>Recent data indicate that ADHD is associated with dysfunction in large-scale neural networks, including the default-mode network (DMN) [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. The DMN describes a distinctive set of reciprocally oscillating brain regions that, in normal controls, are active during the resting state and suppressed during goal-directed tasks [<xref ref-type="bibr" rid="CR47">47</xref>]; in contrast, task-specific neural activity during goal-directed tasks is reduced in patients with ADHD [<xref ref-type="bibr" rid="CR46">46</xref>]. Resting-state fMRI data have shown dysfunctional connectivity in the DMN in affected children/adolescents and adults versus controls, which supports the hypothesis that ADHD is related to delayed or disrupted maturation of the DMN [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR48">48</xref>&#x02013;<xref ref-type="bibr" rid="CR50">50</xref>]. A comprehensive meta-analysis of fMRI studies (<italic>n</italic>&#x000a0;=&#x000a0;55) showed evidence of dysfunction in the DMN and multiple other neuronal systems involved in high-level cognitive functions (executive function and attention) [<xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, recent data demonstrate altered connectivity in the DMN and other large-scale networks, and structural abnormalities in the dorsolateral PFC and anterior cingulate cortex [<xref ref-type="bibr" rid="CR32">32</xref>]. Importantly, this modality-spanning study provides evidence of spatial correspondence in the pattern of structural and functional alterations in ADHD [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec5"><title>Neurochemistry</title><p>Dysregulated early brain network development (aberrant apoptosis, neurogenesis, neuritogenesis and synaptogenesis) may cause an imbalance in dopamine, noradrenaline and other neurotransmitter systems [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Although animal models do not exactly match ADHD, they provide a useful method of studying the molecular pathophysiology of this complex neurodevelopmental disorder [<xref ref-type="bibr" rid="CR53">53</xref>]. The spontaneously hypertensive rat (SHR) is considered to be the most valid available animal model for ADHD; others, including the Coloboma mouse and actin depolymerizing factor and n-cofilin double mutant mouse models, also provide good approximations. Recent advances in imaging modalities, such as positron emission tomography (PET) and magnetic resonance spectroscopy, have enabled investigation of the neurochemistry of ADHD in humans.</p><sec id="Sec6"><title>Dopamine and Noradrenaline</title><p>Dysregulation of monoaminergic neurotransmitter systems, primarily dopamine and noradrenaline, is hypothesized to play a central role in the pathophysiology of ADHD [<xref ref-type="bibr" rid="CR33">33</xref>]. Involvement of the dopaminergic system is highlighted by the validity of neonatal 6-hydroxy-dopamine lesioned rats and dopamine transporter (DAT) knockout mice as ADHD models [<xref ref-type="bibr" rid="CR54">54</xref>]. The SHR model has reduced levels of &#x003b3;-aminobutyric acid (GABA), which interacts with both the dopaminergic and adrenergic systems in the hippocampus [<xref ref-type="bibr" rid="CR55">55</xref>]. Alpha2A-adrenergic receptors in the dorsolateral PFC are involved in the regulation of locomotor hyperactivity in primates [<xref ref-type="bibr" rid="CR56">56</xref>]. Dysregulated dopamine metabolism among treatment-na&#x000ef;ve young adults with ADHD has been demonstrated in a PET study using a radiolabelled dopamine precursor [<xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, PET imaging of treatment-na&#x000ef;ve adult humans with ADHD has shown a reduction in dopamine (D2/D3) receptors in the caudate and limbic system, which correlates with symptoms of inattention [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p>Dopamine and adrenergic receptors are members of the G protein-coupled receptor superfamily of membrane proteins. Dopamine receptors may be classified as either D1 (D1 and D5 subtype) or D2 (D2, D3 and D4 subtype) receptors [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Adrenergic receptors mediate physiological responses to adrenaline and noradrenaline. Alpha and &#x003b2; adrenergic receptors are recognized and each has several subtypes [<xref ref-type="bibr" rid="CR61">61</xref>&#x02013;<xref ref-type="bibr" rid="CR63">63</xref>]. &#x003b1;1-Adrenergic receptors are primarily located in smooth muscle, whereas &#x003b1;2-adrenergic receptors are found predominantly in the central nervous system (CNS) and peripheral sympathetic nervous system. Three distinct subtypes of human &#x003b1;2-adrenergic receptors (&#x003b1;2A-, &#x003b1;2B- and &#x003b1;2C-) have been identified [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Alpha2B-adrenergic receptors are most prevalent in the thalamus, whereas &#x003b1;2A- and &#x003b1;2C-adrenergic receptors are widespread throughout the brain [<xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. The &#x003b1;2A-adrenergic receptor is the most common subtype found in the PFC [<xref ref-type="bibr" rid="CR68">68</xref>].</p><p>In the PFC, &#x003b1;2A-adrenergic and D1 receptors are located predominantly on the dendritic spines of pyramidal neurons [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Dendritic spines are tiny protrusions from a neuronal dendrite that interconnect via glutaminergic synapses with other pyramidal neurons in the PFC to form complex neural networks [<xref ref-type="bibr" rid="CR29">29</xref>]. Noradrenaline and dopamine powerfully modulate network connectivity through their effects on &#x003b1;2A-adrenergic and D1 receptors on dendritic spines [<xref ref-type="bibr" rid="CR29">29</xref>]. Imbalances in the fine-tuning of pyramidal neurons by noradrenaline and/or dopamine in the PFC affect information processing and are believed to underlie the symptoms of ADHD.</p><p>Stimulation of D1 receptors by dopamine is believed to increase the production of cyclic adenosine monophosphate (cAMP), thereby opening hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels near the synapse (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR71">71</xref>]. An open channel causes the signal to &#x02018;leak out&#x02019;, thus shunting inputs out of the dendritic spine [<xref ref-type="bibr" rid="CR72">72</xref>] and weakening network connections [<xref ref-type="bibr" rid="CR73">73</xref>]. Conversely, stimulation of &#x003b1;2A-adrenergic receptors by noradrenaline inhibits cAMP signalling, thereby closing HCN channels [<xref ref-type="bibr" rid="CR72">72</xref>]. Closure of the channel allows the signal to be conducted down the pyramidal neuron. In theory, noradrenaline strengthens the appropriate &#x02018;signal&#x02019; between neurons with shared inputs, whereas dopamine reduces &#x02018;noise&#x02019; by dissipating inappropriate network connections [<xref ref-type="bibr" rid="CR72">72</xref>]. Thus, dopamine and noradrenaline have contrasting but complementary actions to increase the &#x02018;signal-to-noise ratio&#x02019; in the PFC [<xref ref-type="bibr" rid="CR72">72</xref>].<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Noradrenaline and dopamine modulate the strength of network connections at dendritic spines in the prefrontal cortex to influence information processing. Methylphenidate (MPH) primarily blocks the dopamine transporter; amphetamines (AMPs) block the dopamine and noradrenaline transporters, and increase output of dopamine; atomoxetine (ATX) blocks the noradrenaline transporter. Guanfacine (G) directly stimulates postsynaptic &#x003b1;2A-adrenergic receptors and thereby closes hyperpolarization-activated cyclic nucleotide-gated (HCN) channels in the post-synaptic neuron and enhances noradrenaline neurotransmission. Adapted from Wang M et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129:397&#x02013;410 &#x000a9; (2007) with permission from Elsevier and Arnsten AF, Rubia K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J Am Acad Child Adolesc Psychiatry. 2012;51:356&#x02013;67, &#x000a9; (2012) with permission from Elsevier</p></caption><graphic xlink:href="40261_2015_336_Fig3_HTML" id="MO3"/></fig></p><p>Moderate stimulation of &#x003b1;2A-adrenergic receptors in the PFC improves working memory in animal models and humans [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. Similarly, moderate stimulation of D1 receptors in the PFC enhances working memory performance [<xref ref-type="bibr" rid="CR71">71</xref>]. Both noradrenaline and dopamine concentrations in the synaptic cleft have an &#x02018;inverted U-shaped&#x02019; effect on working memory, in which too much or too little of either neurotransmitter impairs PFC function (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>) [<xref ref-type="bibr" rid="CR73">73</xref>]. Excessive levels of noradrenaline at the synapse leads to binding of noradrenaline to other adrenergic receptor subtypes on distant synapses and impairs working memory [<xref ref-type="bibr" rid="CR73">73</xref>]. Likewise, excessive levels of dopamine may result in the recruitment of other dopamine receptor subtypes [<xref ref-type="bibr" rid="CR73">73</xref>].<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Inverted U-shaped influence of noradrenaline (NA) and dopamine (DA) on the prefrontal cortex (PFC). Both NA and DA have an &#x02018;inverted U-shaped&#x02019; influence on PFC physiology and cognitive performance; too little or too much of either neurotransmitter impairs PFC function. Adapted with permission from Macmillan Publishers Ltd from Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10:410&#x02013;22</p></caption><graphic xlink:href="40261_2015_336_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec7"><title>Other Neurotransmitters</title><p>ADHD probably results from interplay between several dysfunctional neurotransmitter systems. Another monoaminergic neurotransmitter, serotonin, is postulated to play a role in ADHD. Paediatric major depressive disorder and paediatric obsessive compulsive disorder share some neuropsychological deficits and affected neural circuits with ADHD [<xref ref-type="bibr" rid="CR29">29</xref>]. Selective serotonin re-uptake inhibitors are an effective treatment for these two disorders and it has been suggested that they act to normalize serotonergic regulation of emotion and inhibitory control [<xref ref-type="bibr" rid="CR29">29</xref>]. Moreover, 5HT1B knockout mice exhibit hyperactivity, and attention- and sensation-seeking behaviour [<xref ref-type="bibr" rid="CR76">76</xref>]. Association studies have identified links between various serotonergic genes and ADHD and there may be a particular association between the serotonin receptor gene, <italic>HTR1B</italic>, and the inattentive subtype of ADHD [<xref ref-type="bibr" rid="CR77">77</xref>].</p><p>Recent evidence suggests that dysfunction in the glutamatergic neurotransmitter system plays a role in the pathophysiology of ADHD [<xref ref-type="bibr" rid="CR78">78</xref>]. Glutamate is the main excitatory neurotransmitter in the human brain, and a key neuronal growth factor [<xref ref-type="bibr" rid="CR79">79</xref>]; the glutamate <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA) receptor NR2 subunit controls synaptic plasticity and memory function during brain development [<xref ref-type="bibr" rid="CR80">80</xref>]. In vivo data indicate that the glutamatergic system is hyperfunctional in the PFC of the SHR [<xref ref-type="bibr" rid="CR81">81</xref>]. In addition, increased glutamatergic tone in children with untreated ADHD versus controls [<xref ref-type="bibr" rid="CR82">82</xref>] and effects on glutamatergic systems following pharmacotherapy have been detected in magnetic resonance spectroscopy studies [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Recent data suggest that glutamine levels may be increased among children (but not adults) with ADHD versus controls [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p>Preliminary data suggest that histamine may also be associated with ADHD. Histaminergic pathways are associated with arousal, learning and memory [<xref ref-type="bibr" rid="CR86">86</xref>&#x02013;<xref ref-type="bibr" rid="CR88">88</xref>]. Histamine H3 receptor antagonists improve the performance of the SHR in inhibitory avoidance tasks, thus suggesting a tentative role in the treatment of ADHD [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. In addition, MPH and ATX are reported to increase histamine release in the PFC of the SHR [<xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR91">91</xref>, <xref ref-type="bibr" rid="CR92">92</xref>].</p></sec></sec><sec id="Sec8"><title>Genetics</title><p>The pathophysiology of ADHD has a strong genetic component [<xref ref-type="bibr" rid="CR93">93</xref>]. Heritability of the disorder is estimated to range from 60 to 80&#x000a0;% [<xref ref-type="bibr" rid="CR93">93</xref>]. Candidate gene studies have also shown a number of gene variants to be associated with ADHD, including those coding for synaptosomal-associated protein 25 (SNAP-25), dopamine receptors (DRD4) and the DAT (DAT1) [<xref ref-type="bibr" rid="CR94">94</xref>]. Pooled molecular genetics data support the involvement in genes coding for regulators of synaptic plasticity, including CTNNA2 and KALRN, and cell adhesion molecules in ADHD [<xref ref-type="bibr" rid="CR95">95</xref>]. However, each gene variant is likely to contribute only a small individual effect [<xref ref-type="bibr" rid="CR33">33</xref>]. Complex &#x02018;gene&#x02013;gene&#x02019; and &#x02018;gene&#x02013;environment&#x02019; interactions may explain how individual genes modify the response to environmental or biological variables [<xref ref-type="bibr" rid="CR96">96</xref>].</p></sec></sec><sec id="Sec9"><title>Pharmacological Treatment of ADHD</title><p>An understanding of the pathophysiology of ADHD and modes of action of pharmacotherapies may help clinicians select the medication with the most appropriate efficacy and safety profile to match the individual needs of each patient [<xref ref-type="bibr" rid="CR33">33</xref>]. The complex modes of action of ADHD pharmacotherapies are not fully understood. Nonetheless, all empirically effective medications seem to enhance signalling of dopamine and/or noradrenaline in the CNS (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR72">72</xref>]. The stimulants (MPH and amphetamines) and ATX act indirectly to increase the availability of noradrenaline and dopamine in the synaptic cleft, whereas guanfacine has a direct effect on post-synaptic &#x003b1;2A-adrenergic receptors (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Summary of the modes of action of stimulant and non-stimulant pharmacotherapies in attention-deficit/hyperactivity disorder (ADHD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Pharmacotherapy</th><th align="left">Mechanism of action</th></tr></thead><tbody><tr><td align="left" colspan="2">Stimulants</td></tr><tr><td align="left">&#x000a0;Amphetamine<sup>a</sup>
</td><td align="left">Blocks dopamine and noradrenaline transporters and increases output of dopamine</td></tr><tr><td align="left">&#x000a0;Methylphenidate<sup>a</sup>
</td><td align="left">Primarily acts by blocking the dopamine transporter to increase dopamine levels</td></tr><tr><td align="left" colspan="2">Non-stimulants</td></tr><tr><td align="left">&#x000a0;Atomoxetine</td><td align="left">Blocks the noradrenaline transporter to moderately increase dopamine and noradrenaline levels</td></tr><tr><td align="left">&#x000a0;Clonidine<sup>b</sup>
</td><td align="left">Directly stimulates post-synaptic &#x003b1;2A-adrenergic receptors; also binds to other &#x003b1;2-adrenergic receptor subtypes</td></tr><tr><td align="left">&#x000a0;Guanfacine<sup>c</sup>
</td><td align="left">Directly stimulates post-synaptic &#x003b1;2A-adrenergic receptors to enhance noradrenaline neurotransmission</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Short- and long-acting formulations are approved for the treatment of ADHD in Europe</p><p>
<sup>b</sup>Not approved for the treatment of ADHD in Europe</p><p>
<sup>c</sup>Guanfacine immediate release is not approved for the treatment of ADHD</p></table-wrap-foot></table-wrap></p><sec id="Sec10"><title>&#x003b1;2-Adrenergic Receptor Agonists</title><p>Interest in the use of &#x003b1;2-adrenergic receptor agonists for the treatment of ADHD began 30&#x000a0;years ago [<xref ref-type="bibr" rid="CR97">97</xref>]. Early studies focused on immediate-release clonidine and, later, guanfacine [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Clonidine engages equally with all three &#x003b1;2-adrenergic receptor subtypes, and also binds to imidazoline I<sub>1</sub> receptors [<xref ref-type="bibr" rid="CR98">98</xref>&#x02013;<xref ref-type="bibr" rid="CR100">100</xref>]. In contrast, guanfacine has higher affinity for the &#x003b1;2A- than &#x003b1;2B- or &#x003b1;2C-adrenergic receptor subtypes [<xref ref-type="bibr" rid="CR101">101</xref>, <xref ref-type="bibr" rid="CR102">102</xref>]. Indeed, receptor-binding studies have shown guanfacine to be the most selective &#x003b1;2A-adrenergic receptor agonist available [<xref ref-type="bibr" rid="CR103">103</xref>] and is, thus, referred to as a &#x02018;selective&#x02019; &#x003b1;2A-adrenergic receptor agonist.</p><p>Clinical use of immediate-release clonidine and guanfacine is limited by their pharmacokinetic (PK) profiles [<xref ref-type="bibr" rid="CR98">98</xref>]. Rapid absorption of immediate-release &#x003b1;2-adrenergic receptor agonists leads to high peak plasma concentrations that are associated with side-effects such as sedation and a dry mouth; rapid clearance necessitates frequent dosing through the day [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Extended-release formulations of guanfacine and clonidine have been developed to overcome these PK issues. Extended-release clonidine is approved for the treatment of ADHD as monotherapy or adjunctive therapy in children/adolescents in the USA [<xref ref-type="bibr" rid="CR105">105</xref>]. GXR is approved for the treatment of ADHD as monotherapy or adjunctive therapy in Canada and the USA (for children and adolescents) [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], and was approved recently in Europe as part of a comprehensive programme for the treatment of children and adolescents with ADHD for whom stimulants are not suitable, not tolerated or have been shown to be ineffective [<xref ref-type="bibr" rid="CR28">28</xref>].</p><sec id="Sec11"><title>Guanfacine Extended Release (GXR)</title><p>Guanfacine directly stimulates postsynaptic &#x003b1;2A-adrenergic receptors to enhance noradrenaline neurotransmission (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR98">98</xref>, <xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]. The stimulation of &#x003b1;2A-adrenergic receptors in the PFC produces a beneficial effect on cognitive function. Improvement in attention, working memory and learning with guanfacine has been demonstrated in animal studies [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR106">106</xref>&#x02013;<xref ref-type="bibr" rid="CR115">115</xref>]. A beneficial effect of guanfacine has also been shown on impulsive decision-making behaviour in rats and impulsive self-injurious behaviour in rhesus macaques [<xref ref-type="bibr" rid="CR116">116</xref>&#x02013;<xref ref-type="bibr" rid="CR118">118</xref>]. Moreover, guanfacine (29&#x000a0;&#x000b5;g/kg single dose administered orally) improved spatial working memory and planning in a double-blind, placebo-controlled trial in healthy adults [<xref ref-type="bibr" rid="CR75">75</xref>]. Guanfacine (1&#x000a0;mg single dose administered orally) has also been shown to modulate emotional biasing of cognitive control in healthy adults [<xref ref-type="bibr" rid="CR119">119</xref>, <xref ref-type="bibr" rid="CR120">120</xref>].</p><p>fMRI data show that the effect of guanfacine on emotional biasing of cognitive control in healthy adults is associated with altered functional connectivity between the right and left amygdala and PFC [<xref ref-type="bibr" rid="CR120">120</xref>]. Preliminary fMRI data suggest that clinical response to GXR (1&#x000a0;mg/day titrated to maximum 4&#x000a0;mg/day) in children/adolescents with ADHD is associated with reduced activation in the right midcingulate and left posterior cingulate cortices [<xref ref-type="bibr" rid="CR121">121</xref>]. In vivo rat pharmacological MRI data support differing effects of guanfacine in specific areas of the brain [<xref ref-type="bibr" rid="CR122">122</xref>]; functional blood oxygenation level dependent responses suggest that guanfacine increases neuronal activity in the frontal cortex but decreases activity in the basal ganglia (caudate, putamen and nucleus accumbens) and entorhinal cortex [<xref ref-type="bibr" rid="CR122">122</xref>].</p><p>Three hypotheses, based on in vitro and in vivo animal model data, have been proposed to explain the underlying physiological mechanism of action of guanfacine: (1) the HCN channel and network hypothesis; (2) the excitatory postsynaptic current (EPSC) network hypothesis; and (3) the spinogenic hypothesis.</p><p>(1) The HCN channel and network hypothesis provides a short-term mechanism by which &#x003b1;2A-adrenergic receptor agonists may regulate PFC networks. As previously described, stimulation of post-synaptic &#x003b1;2A-adrenergic receptors inhibits the production of cAMP, leading to closure of HCN channels and strengthening of the functional connectivity of PFC microcircuits. Blockade of HCN channels in superficial layers (II/III) of the rat PFC improves working memory performance [<xref ref-type="bibr" rid="CR69">69</xref>] and guanfacine strengthens delay-related firing of PFC neurons during working memory tasks in electrophysiological primate studies [<xref ref-type="bibr" rid="CR69">69</xref>].</p><p>(2) Stimulation of &#x003b1;2A-adrenergic receptors also suppresses excitatory synaptic inputs in pyramidal neurons [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. As described above, SHR model data suggest that the glutamatergic system is hyperfunctional in ADHD [<xref ref-type="bibr" rid="CR81">81</xref>]. The EPSC network hypothesis is derived from in vitro and in vivo studies of rats and suggests that guanfacine may suppress glutamate transmission in deep layers (V&#x02013;VI) of the medial PFC via complex intracellular signalling pathways [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>].</p><p>Further, it has been proposed that the intracellular pathways controlling HCN channels and the suppression of glutamate transmission may be linked [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. As such, &#x003b1;2A-adrenergic receptor activation may trigger both mechanisms, which work together to fine tune the synaptic inputs of pyramidal cells during different physiological conditions [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. It is hypothesized that HCN channel control (in layers II/III of the PFC) may predominate at low guanfacine doses, whereas the EPSC network (in layers V&#x02013;VI) is principally affected at high doses [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. Indeed, neuronal firing in the PFC during working memory tasks is enhanced by low guanfacine doses and suppressed at high doses [<xref ref-type="bibr" rid="CR69">69</xref>], whereas EPSC network effects can be demonstrated only at relatively high doses [<xref ref-type="bibr" rid="CR123">123</xref>]. Thus, guanfacine seems to improve the signal-to-noise ratio in the PFC predominantly through an effect on HCN channels, but may also protect it during extreme stress (when noradrenaline is excessively released) through effects on the EPSC network [<xref ref-type="bibr" rid="CR123">123</xref>].</p><p>(3) The spinogenic hypothesis describes a long-term effect of &#x003b1;2A-adrenergic receptor agonists mediated via dendritic spines. Dendritic spines can change rapidly in shape, volume and number [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>]. As previously described, dendritic spine plasticity in the PFC plays a key role in learning and memory [<xref ref-type="bibr" rid="CR126">126</xref>]. &#x003b1;2A-adrenergic receptor agonists, such as guanfacine, increase the length and density of dendritic spines of cultured mouse cortical neurons [<xref ref-type="bibr" rid="CR127">127</xref>, <xref ref-type="bibr" rid="CR128">128</xref>]. Guanfacine increases the expression of synaptic protein PSD95 and promotes the maturation of dendritic spines of cultured rat cortical neurons [<xref ref-type="bibr" rid="CR129">129</xref>]. Indeed, recent data show that guanfacine prevents dendritic spine loss in the PFC and protects working memory performance in rats exposed to chronic stress [<xref ref-type="bibr" rid="CR115">115</xref>].</p><p>&#x003b1;2A-Adrenergic receptor agonists also inhibit sympathetic nervous system activity. Guanfacine stimulates post-synaptic &#x003b1;2A-adrenergic receptors in the vasomotor centre of the brainstem to reduce peripheral sympathetic tone, and may also activate peripheral presynaptic &#x003b1;2A-adrenergic receptors [<xref ref-type="bibr" rid="CR130">130</xref>&#x02013;<xref ref-type="bibr" rid="CR132">132</xref>]. Overall, guanfacine acts to decrease heart rate and vascular resistance [<xref ref-type="bibr" rid="CR133">133</xref>]. Indeed, guanfacine was originally developed as an immediate-release formulation and clinically utilized as a centrally acting antihypertensive agent [<xref ref-type="bibr" rid="CR134">134</xref>]. Guanfacine is associated with less potent hypotensive and sedative effects than is clonidine [<xref ref-type="bibr" rid="CR135">135</xref>]. Data from a recent meta-analysis suggest that the relative risk of fatigue and somnolence is higher with extended-release clonidine than GXR as monotherapy for ADHD (10.86 [<italic>p</italic>&#x000a0;=&#x000a0;0.02] and 3.21 [<italic>p</italic>&#x000a0;=&#x000a0;0.0008], respectively, vs placebo) [<xref ref-type="bibr" rid="CR136">136</xref>]. The selective affinity of guanfacine for &#x003b1;2A-adrenergic receptors is believed to underlie the differing physiological effects of these two &#x003b1;2A-adrenergic receptor agonists [<xref ref-type="bibr" rid="CR98">98</xref>]. Detailed description of the pharmacodynamic and pharmacokinetic properties and posology of GXR are beyond the scope of this review, but information is available elsewhere for the interested reader [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>].</p></sec></sec><sec id="Sec12"><title>Other ADHD Pharmacotherapies</title><p>Stimulants (various formulations of short- and long-acting MPH and amphetamines including lisdexamfetamine dimesylate) and ATX are approved for the treatment of ADHD in specific patient populations in many European countries and other regions. Stimulants and ATX act to block the re-uptake of dopamine and/or noradrenaline into the presynaptic neuron. Re-uptake by the presynaptic noradrenaline (norepinephrine) transporter (NET) is the main process by which the effects of noradrenaline are terminated in the CNS [<xref ref-type="bibr" rid="CR139">139</xref>]. Similarly, dopamine is cleared from the synaptic cleft by re-uptake via the DAT; however, in the PFC, dopamine is also recognized by NETs [<xref ref-type="bibr" rid="CR140">140</xref>].</p><p>Human and primate PET studies indicate that MPH binds predominantly to DATs in the striatum [<xref ref-type="bibr" rid="CR141">141</xref>, <xref ref-type="bibr" rid="CR142">142</xref>]. Accordingly, the therapeutic effect of MPH in ADHD is believed to be primarily due to the blockade of DATs, which increases dopamine levels at the synapse (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR143">143</xref>, <xref ref-type="bibr" rid="CR144">144</xref>]. Preliminary data suggest that MPH may also downregulate dopamine turnover in children/adolescents with ADHD [<xref ref-type="bibr" rid="CR57">57</xref>]. In addition, human PET data suggest that MPH also binds to NETs, but the clinical relevance of this is currently unclear [<xref ref-type="bibr" rid="CR145">145</xref>]. Effects of MPH on neuronal remodelling in the nucleus accumbens, striatum and other brain regions have also been demonstrated [<xref ref-type="bibr" rid="CR146">146</xref>&#x02013;<xref ref-type="bibr" rid="CR148">148</xref>]. Chronic exposure of mice to MPH increases dendritic spine density [<xref ref-type="bibr" rid="CR146">146</xref>], and a sustained effect of MPH on synaptic gene and protein expression and synaptic and dendritic spine structure has been shown in rat models [<xref ref-type="bibr" rid="CR147">147</xref>, <xref ref-type="bibr" rid="CR148">148</xref>].</p><p>Amphetamines inhibit the re-uptake of dopamine and noradrenaline from the synaptic cleft and induce an efflux of dopamine into the synapse in the PFC, striatum and nucleus accumbens (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR149">149</xref>, <xref ref-type="bibr" rid="CR150">150</xref>]. Amphetamines are a competitive substrate for the re-uptake transporters NET and DAT [<xref ref-type="bibr" rid="CR151">151</xref>]. Inside neurons, amphetamines bind with the vesicular monoamine transporter 2 (VMAT2), thereby preventing the translocation of monoamines into intraneuronal storage vesicles [<xref ref-type="bibr" rid="CR151">151</xref>]. Amphetamines also weakly inhibit monoamine oxidase (particularly monoamine oxidase A), which reduces intracellular catabolism of neurotransmitters [<xref ref-type="bibr" rid="CR152">152</xref>]. As the concentration of neurotransmitters in the presynaptic neuron increases, the direction of action of the re-uptake transporter changes direction causing an efflux into the synapse [<xref ref-type="bibr" rid="CR151">151</xref>].</p><p>The non-stimulant ATX inhibits NETs to moderately increase noradrenaline and dopamine levels in the PFC by indirect action (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) [<xref ref-type="bibr" rid="CR153">153</xref>]. ATX is reported to have no effect on dopamine efflux in the striatum or nucleus accumbens [<xref ref-type="bibr" rid="CR153">153</xref>]. In vitro rodent data suggest that ATX may also block NMDA receptors on cortical and hippocampal neurons, thus affecting glutamatergic transmission [<xref ref-type="bibr" rid="CR154">154</xref>]. A sustained effect of ATX on synaptic mRNA and proteins involved in neuronal plasticity has been demonstrated in rats [<xref ref-type="bibr" rid="CR155">155</xref>], and a preliminary report of sustained maintenance of clinical response after discontinuation of long-term ATX warrants further investigation [<xref ref-type="bibr" rid="CR156">156</xref>]. There seems to be some overlap in the neurophysiological effects of stimulants and ATX. Data from in vitro and in vivo animal studies suggest that both MPH and ATX may indirectly stimulate D1 and &#x003b1;2-adrenergic receptors on post-synaptic neurons in the PFC [<xref ref-type="bibr" rid="CR157">157</xref>&#x02013;<xref ref-type="bibr" rid="CR159">159</xref>]. Human fMRI and arterial spin labelling MRI data also indicate common spatial patterns of brain activity after administration of MPH and ATX [<xref ref-type="bibr" rid="CR160">160</xref>, <xref ref-type="bibr" rid="CR161">161</xref>].</p><p>Stimulants are the most widely prescribed class of pharmacotherapy for ADHD but may not be suitable for all children/adolescents [<xref ref-type="bibr" rid="CR162">162</xref>, <xref ref-type="bibr" rid="CR163">163</xref>]. Patients may have a contraindication to MPH or amphetamines, or experience inadequate symptom control or side-effects [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Common side-effects of stimulant treatment include loss of appetite, weight loss and sleep disturbance [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR164">164</xref>, <xref ref-type="bibr" rid="CR165">165</xref>]. Long-acting formulations of MPH have been developed to allow once-daily dosing. However, long-acting MPH does not provide 24-h coverage [<xref ref-type="bibr" rid="CR166">166</xref>], so some children/adolescents may experience troublesome symptoms of ADHD during the evening, night or early morning. In addition, recent work has shown that MPH causes chronic changes to pyramidal neuron function and synaptic plasticity in the juvenile rat PFC [<xref ref-type="bibr" rid="CR167">167</xref>, <xref ref-type="bibr" rid="CR168">168</xref>], and the implication of these findings on human neurodevelopment remains unknown. Early PET evidence also suggests that long-term MPH therapy upregulates DATs in the striatum; this could reduce treatment efficacy and lead to ADHD symptom rebound on drug cessation, including during drug holidays [<xref ref-type="bibr" rid="CR169">169</xref>]. As such, some clinicians may seek alternative treatment options for their patients.</p></sec></sec><sec id="Sec13"><title>Clinical Considerations on GXR</title><p>GXR directly stimulates &#x003b1;2A-adrenergic receptors and, according to the HCN channel and network hypotheses, thereby improves the &#x02018;signal-to-noise&#x02019; ratio in the PFC. The selective effects of GXR may translate into clinical benefit for patients who require an alternative pharmacotherapy for ADHD. GXR is readily absorbed after oral ingestion and exhibits a linear PK profile in children and adults [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>]. Peak plasma concentration is achieved approximately 5&#x000a0;h after oral administration of a single dose of GXR [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR170">170</xref>] and it has a long excretion half-life (of approximately 17&#x000a0;h) in adults [<xref ref-type="bibr" rid="CR137">137</xref>]. Thus, the prolonged-release tablets provide a broad and flat GXR concentration profile [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>] that allows once-daily dosing [<xref ref-type="bibr" rid="CR171">171</xref>]. GXR is bound moderately (70&#x000a0;%) to plasma proteins and metabolized primarily by cytochrome P450 (CYP) 3A4; plasma levels are affected by CYP3A4/5 inducers and inhibitors, such as ketoconazole [<xref ref-type="bibr" rid="CR26">26</xref>].</p><sec id="Sec14"><title>Clinical Data on GXR in ADHD</title><p>Clinical trial data show that GXR is effective for the treatment of children and adolescents with ADHD as monotherapy or when administered as adjunctive therapy with stimulants [<xref ref-type="bibr" rid="CR172">172</xref>&#x02013;<xref ref-type="bibr" rid="CR179">179</xref>]. Pivotal trial data on GXR are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Once-daily GXR significantly reduces ADHD core symptoms versus placebo among patients aged 6&#x02013;17&#x000a0;years, and improvement is observed within 2&#x000a0;weeks of starting GXR treatment [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR176">176</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. A significant improvement in functional outcomes (including Clinical Global Impressions of Improvement scale and Weiss Functional Impairment Rating Scale-Parent Report domains) with GXR was also observed in clinical trials [<xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]. The effect size of GXR monotherapy on ADHD Rating Scale version IV (ADHD-RS-IV) symptom scores in double-blind, placebo-controlled, pivotal trials ranges from 0.43 to 0.86 (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). This is lower than the effect size of stimulants but similar to that reported for ATX (0.59&#x02013;0.67) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Head-to-head clinical direct comparison trial data are not available and to our knowledge not currently planned. Indirect comparisons, which must be interpreted cautiously in general, suggest that GXR may confer greater ADHD symptom control than does ATX [<xref ref-type="bibr" rid="CR177">177</xref>, <xref ref-type="bibr" rid="CR181">181</xref>]. However, indirect comparisons should be replicated or supported by direct comparisons before being taken as scientific basis for clinical decision making.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Efficacy data from pivotal trials of GXR</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study design</th><th align="left">Primary efficacy endpoint</th><th align="left">Key clinical findings (primary endpoint and effect size)</th></tr></thead><tbody><tr><td align="left" colspan="3">GXR as monotherapy</td></tr><tr><td align="left">&#x000a0;A randomized, multi-centre, double-blind, parallel-group, placebo-controlled, fixed-dose escalation study conducted in the USA [<xref ref-type="bibr" rid="CR173">173</xref>]<break/>&#x000a0;Children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD (<italic>N</italic>&#x000a0;=&#x000a0;345)<break/>&#x000a0;GXR dose: 2, 3 and 4&#x000a0;mg/day</td><td align="left">Change in ADHD-RS-IV total score from baseline to endpoint</td><td align="left">Significant reduction in placebo-adjusted LS mean change from baseline in ADHD-RS-IV total scores in all GXR groups: &#x02212;7.7 (<italic>p</italic>&#x000a0;=&#x000a0;0.0002), &#x02212;7.95 (<italic>p</italic>&#x000a0;=&#x000a0;0.0001) and &#x02212;10.39 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001) for the GXR 2, 3 and 4&#x000a0;mg/day groups, respectively<break/>GXR effect size: 0.64, 0.66 and 0.86 for the 2, 3 and 4&#x000a0;mg/day groups, respectively (post hoc analysis)</td></tr><tr><td align="left">&#x000a0;A randomized, double-blind, parallel-group, multi-centre, placebo-controlled, dose-ranging study conducted in the USA [<xref ref-type="bibr" rid="CR176">176</xref>]<break/>&#x000a0;Children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD (<italic>N</italic>&#x000a0;=&#x000a0;324)<break/>&#x000a0;GXR dose: 1&#x02013;4&#x000a0;mg/day</td><td align="left">Change in ADHD-RS-IV total score from baseline to endpoint</td><td align="left">Significant reduction in placebo-adjusted LS mean change in ADHD-RS-IV total scores in all GXR groups: &#x02212;6.75 (<italic>p</italic>&#x000a0;=&#x000a0;0.0041), &#x02212;5.41 (<italic>p</italic>&#x000a0;=&#x000a0;0.0176), &#x02212;7.34 (<italic>p</italic>&#x000a0;=&#x000a0;0.0016) and &#x02212;7.88 (<italic>p</italic>&#x000a0;=&#x000a0;0.0006) in the GXR 1<sup>a</sup>, 2, 3 and 4&#x000a0;mg/day groups, respectively<break/>GXR effect size: 0.53, 0.43, 0.58 and 0.62 for the GXR 1<sup>a</sup>, 2, 3 and 4&#x000a0;mg/day groups, respectively (post hoc analysis)</td></tr><tr><td align="left">&#x000a0;A double-blind, randomized, multi-centre, placebo-controlled, dose-optimization study conducted in the USA [<xref ref-type="bibr" rid="CR179">179</xref>]<break/>&#x000a0;Children (aged 6&#x02013;12&#x000a0;years) with ADHD (<italic>N</italic>&#x000a0;=&#x000a0;340)<break/>&#x000a0;GXR dose: 1&#x02013;4&#x000a0;mg/day (morning or evening dosing)</td><td align="left">Change in ADHD-RS-IV total score from baseline to Visit 10 (LOCF)</td><td align="left">Significant reduction in LS mean change in ADHD-RS-IV total scores: &#x02212;20.0, &#x02212;19.8 and &#x02212;20.1 for the GXR all active, GXR morning and GXR evening dosing groups, respectively (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 for all groups vs. placebo)<break/>GXR effect size: 0.77, 0.75 and 0.78 for the GXR all active, GXR morning and GXR evening dosing groups, respectively</td></tr><tr><td align="left">&#x000a0;A study comprising an open-label optimization phase followed by a double-blind, placebo-controlled, multi-centre, randomized withdrawal phase, conducted in the EU, USA and Canada [<xref ref-type="bibr" rid="CR231">231</xref>]<break/>&#x000a0;Children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD (<italic>N</italic>&#x000a0;=&#x000a0;528) [<xref ref-type="bibr" rid="CR231">231</xref>]<break/>&#x000a0;GXR dose: 1&#x02013;7&#x000a0;mg/day</td><td align="left">Proportion of treatment failures<sup>b</sup> [<xref ref-type="bibr" rid="CR231">231</xref>]</td><td align="left">Treatment failure occurred in 49&#x000a0;% of the GXR vs. 65&#x000a0;% of the placebo group (<italic>p</italic>&#x000a0;=&#x000a0;0.006) [<xref ref-type="bibr" rid="CR231">231</xref>]<break/>GXR effect size<sup>c</sup> (at end of randomized withdrawal phase): 0.51<sup>d</sup>
</td></tr><tr><td align="left">&#x000a0;A randomized, double-blind, multi-centre, parallel-group, placebo- and active-controlled (ATX reference arm), dose-optimization study conducted in the EU, USA and Canada [<xref ref-type="bibr" rid="CR177">177</xref>]<break/>&#x000a0;Children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD (<italic>N</italic>&#x000a0;=&#x000a0;338)<break/>&#x000a0;GXR dose: 0.05&#x02013;0.12&#x000a0;mg/kg/day</td><td align="left">Change in ADHD-RS-IV total score from baseline to Visit 15</td><td align="left">Significant reduction in placebo-adjusted LS mean change from baseline in ADHD-RS-IV total score for GXR was &#x02212;8.9 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001)<break/>GXR effect size: 0.76 (ATX effect size: 0.32)</td></tr><tr><td align="left" colspan="3">GXR as adjunctive therapy</td></tr><tr><td align="left">&#x000a0;A double-blind, randomized, multi-centre, placebo-controlled, dose-optimization study conducted in the USA [<xref ref-type="bibr" rid="CR178">178</xref>, <xref ref-type="bibr" rid="CR180">180</xref>]<break/>&#x000a0;Children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD and a suboptimal response to stimulants (<italic>N</italic>&#x000a0;=&#x000a0;461)<break/>&#x000a0;GXR dose: 1&#x02013;4&#x000a0;mg/day (morning or evening dosing) plus current long-acting, oral stimulant (amphetamine or methylphenidate)</td><td align="left">Change in ADHD-RS-IV total score from baseline to endpoint</td><td align="left">Significant reduction in placebo-adjusted LS mean change in ADHD-RS-IV total scores in both GXR groups: &#x02212;4.5 (<italic>p</italic>&#x000a0;=&#x000a0;0.002) and &#x02212;5.3 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) GXR morning plus stimulant and GXR evening plus stimulant dosing groups<break/>GXR effect size: 0.38 and 0.45 for the GXR morning plus stimulant and GXR evening plus stimulant dosing groups, respectively</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADHD</italic> attention-deficit/hyperactivity disorder, <italic>ADHD</italic>-<italic>RS</italic>-<italic>IV</italic> ADHD Rating Scale IV, <italic>ATX</italic> atomoxetine, <italic>GXR</italic> guanfacine extended release, <italic>LOCF</italic> last observation carried forward, <italic>LS</italic> least squares</p><p>
<sup>a</sup>1&#x000a0;mg dose group weight-restricted to &#x0003c;110&#x000a0;lb</p><p>
<sup>b</sup>Treatment failure defined as &#x02265;50&#x000a0;% increase in ADHD-RS-IV total score and &#x02265;2 point increase in Clinical Global Impression-Severity score at two consecutive visits vs double-blind randomized withdrawal phase baseline</p><p>
<sup>c</sup>For the change from baseline in LS mean ADHD-RS-IV total score (secondary endpoint)</p><p>
<sup>d</sup>Newcorn et al. EPA-0666&#x02014;long-term maintenance of efficacy of extended-release guanfacine hydrochloride (GXR) in children and adolescents with attention-deficit/hyperactivity disorder (ADHD): double-blind, placebo-controlled, multicentre, phase 3 randomized withdrawal study. Poster presented at 22nd European Congress of Psychiatry, March 2014</p></table-wrap-foot></table-wrap></p><p>GXR has a broad, smooth and sustained concentration profile (that contrasts with the variable plasma levels associated with long-acting MPH) [<xref ref-type="bibr" rid="CR137">137</xref>, <xref ref-type="bibr" rid="CR138">138</xref>, <xref ref-type="bibr" rid="CR166">166</xref>]. Administration of GXR in either the morning or evening is associated with significant and clinically meaningful improvements in ADHD symptoms (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) [<xref ref-type="bibr" rid="CR179">179</xref>]. At least 10&#x02013;12&#x000a0;weeks of ATX treatment are required to achieve a full response [<xref ref-type="bibr" rid="CR24">24</xref>]. Data suggest that GXR has a faster onset of efficacy than does ATX (significant placebo-adjusted improvement in ADHD-RS-IV total score observed at Week 1 and Week 3, respectively), although findings should be interpreted cautiously as this study was not designed or powered to compare active treatments [<xref ref-type="bibr" rid="CR177">177</xref>].<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Guanfacine extended release (GXR) monotherapy administered in either the morning or evening improves attention-deficit hyperactivity disorder (ADHD) symptoms. Mean change from baseline in ADHD Rating Scale version IV (ADHD-RS-IV) total score among patients receiving GXR. <italic>p</italic> values based on type III sum of squares from an analysis of covariance model. <sup>a</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05 vs. placebo based on change from baseline (Visit 2). <sup>c</sup>
<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 vs. placebo based on change from baseline (Visit 2). Reproduced with permission from Newcorn et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry. 2013;52:921&#x02013;30. &#x000a9; (2013) with permission from Elsevier. <italic>LOCF</italic> last observation carried forward, <italic>LS</italic> least squares, <italic>SEM</italic> standard error of the mean</p></caption><graphic xlink:href="40261_2015_336_Fig5_HTML" id="MO5"/></fig></p><p>The safety and tolerability of GXR have been well established in clinical trials and post-marketing experience in Canada and the USA. Treatment with GXR seems to be generally well tolerated [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR177">177</xref>]. The most frequently reported adverse events associated with GXR in an open-label extension study were somnolence (30.4&#x000a0;%), headache (26.3&#x000a0;%), fatigue (14.2&#x000a0;%) and sedation (13.3&#x000a0;%) [<xref ref-type="bibr" rid="CR172">172</xref>]. Somnolence/sedation (6&#x000a0;%) and fatigue (2&#x000a0;%) were the most common adverse reactions leading to discontinuation of GXR monotherapy from two large USA studies [<xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR176">176</xref>]. Indeed, dose-dependent sedative effects are well described but tend to be transient [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR175">175</xref>, <xref ref-type="bibr" rid="CR182">182</xref>].</p><p>GXR is associated with modest dose-dependent reductions in blood pressure and heart rate but hypotension and bradycardia may occur [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR173">173</xref>, <xref ref-type="bibr" rid="CR175">175</xref>]. Cardiovascular effects are reported most frequently in the first month of treatment [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]. Transient hypertension following abrupt discontinuation of GXR has also been reported so the dose should be tapered gradually in decrements of no more than 1&#x000a0;mg every 3&#x02013;7&#x000a0;days [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. GXR is associated with QT/QTc prolongation; however, it has a stabilizing effect on cardiac restitution, in line with a lack of arrhythmia liability [<xref ref-type="bibr" rid="CR183">183</xref>, <xref ref-type="bibr" rid="CR184">184</xref>].</p><p>GXR is associated with growth that is similar to normative data [<xref ref-type="bibr" rid="CR26">26</xref>]. ATX carries a black box warning of suicidal ideation [<xref ref-type="bibr" rid="CR185">185</xref>, <xref ref-type="bibr" rid="CR186">186</xref>] but, reassuringly, there are no reports to date of an increased risk of suicide-related behaviour with GXR. Additional information on contraindications, precautions and adverse reactions associated with GXR is available in the Summary of Product Characteristics as reviewed by the European Medicines Agency [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec15"><title>Practical Applications of GXR in ADHD Clinical Practice</title><p>Because of its distinct mode of action, GXR may offer a particularly useful alternative treatment option for specific patient populations. The prevalence of ADHD and some commonly co-existing conditions are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. The prevalence of most individual co-morbid conditions among patients with ADHD is relatively low but, when considered together, represents a sizable population with substantial impairment that may be poorly managed using stimulants alone. Clinical efficacy and safety data support the use of GXR among patients with a suboptimal response to stimulants, chronic tic disorders (including Tourette&#x02019;s syndrome) and/or ODD (or oppositional symptoms; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>).<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Prevalence of attention-deficit/hyperactivity disorder (ADHD) and some commonly co-existing conditions for which stimulants are not suitable, not tolerated or have been shown to be ineffective</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Range of prevalence of condition among patients with ADHD</th><th align="left">Range of prevalence of ADHD among patients with condition</th></tr></thead><tbody><tr><td align="left" colspan="3">Stimulants associated with a suboptimal response, contraindicated or potentially unsuitable</td></tr><tr><td align="left">&#x000a0;Suboptimal response to stimulant</td><td align="left">11&#x02013;44&#x000a0;% [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR232">232</xref>&#x02013;<xref ref-type="bibr" rid="CR236">236</xref>]</td><td align="left">N/A</td></tr><tr><td align="left">&#x000a0;Intolerant of stimulant side-effects</td><td align="left">2&#x02013;8&#x000a0;% [<xref ref-type="bibr" rid="CR235">235</xref>, <xref ref-type="bibr" rid="CR237">237</xref>]</td><td align="left">N/A</td></tr><tr><td align="left">&#x000a0;Chronic tic disorders (including Tourette&#x02019;s syndrome)</td><td align="left">1&#x02013;33&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR238">238</xref>&#x02013;<xref ref-type="bibr" rid="CR246">246</xref>]</td><td align="left">11&#x02013;73&#x000a0;% [<xref ref-type="bibr" rid="CR241">241</xref>, <xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR244">244</xref>, <xref ref-type="bibr" rid="CR247">247</xref>&#x02013;<xref ref-type="bibr" rid="CR251">251</xref>]</td></tr><tr><td align="left">&#x000a0;Cardiovascular disorders (including hypertension and tachycardia)</td><td align="left">No data found</td><td align="left">70&#x000a0;% in HLHS [<xref ref-type="bibr" rid="CR252">252</xref>]</td></tr><tr><td align="left" colspan="3">Problems relating to emotional regulation and impulse control</td></tr><tr><td align="left">&#x000a0;Emotional dysregulation</td><td align="left">11&#x02013;66&#x000a0;% [<xref ref-type="bibr" rid="CR253">253</xref>&#x02013;<xref ref-type="bibr" rid="CR258">258</xref>]</td><td align="left">No data found</td></tr><tr><td align="left">&#x000a0;Oppositional defiant disorder</td><td align="left">12&#x02013;67&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR238">238</xref>&#x02013;<xref ref-type="bibr" rid="CR240">240</xref>, <xref ref-type="bibr" rid="CR242">242</xref>, <xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>, <xref ref-type="bibr" rid="CR259">259</xref>&#x02013;<xref ref-type="bibr" rid="CR264">264</xref>]</td><td align="left">30&#x000a0;% [<xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td align="left">&#x000a0;Conduct disorder</td><td align="left">5&#x02013;46&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR238">238</xref>&#x02013;<xref ref-type="bibr" rid="CR240">240</xref>, <xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>, <xref ref-type="bibr" rid="CR246">246</xref>, <xref ref-type="bibr" rid="CR260">260</xref>&#x02013;<xref ref-type="bibr" rid="CR264">264</xref>]</td><td align="left">40&#x000a0;% [<xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td align="left" colspan="3">Addictive behaviour</td></tr><tr><td align="left">&#x000a0;Eating disorders</td><td align="left">1&#x02013;16&#x000a0;% [<xref ref-type="bibr" rid="CR239">239</xref>, <xref ref-type="bibr" rid="CR243">243</xref>, <xref ref-type="bibr" rid="CR245">245</xref>, <xref ref-type="bibr" rid="CR265">265</xref>, <xref ref-type="bibr" rid="CR266">266</xref>]</td><td align="left">10&#x000a0;% [<xref ref-type="bibr" rid="CR243">243</xref>]</td></tr><tr><td align="left">&#x000a0;Substance abuse/dependence</td><td align="left">2&#x02013;16&#x000a0;% [<xref ref-type="bibr" rid="CR238">238</xref>, <xref ref-type="bibr" rid="CR239">239</xref>, <xref ref-type="bibr" rid="CR245">245</xref>, <xref ref-type="bibr" rid="CR262">262</xref>, <xref ref-type="bibr" rid="CR267">267</xref>]</td><td align="left">54&#x000a0;% (children) [<xref ref-type="bibr" rid="CR268">268</xref>]<break/>18&#x02013;31&#x000a0;% (adolescents) [<xref ref-type="bibr" rid="CR268">268</xref>, <xref ref-type="bibr" rid="CR269">269</xref>]</td></tr></tbody></table><table-wrap-foot><p>
<italic>HLHS</italic> hypoplastic left heart syndrome, <italic>N/A</italic> not applicable</p></table-wrap-foot></table-wrap><table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Specific populations of patients with attention-deficit hyperactivity disorder (ADHD) for whom guanfacine extended release (GXR) or guanfacine immediate release<sup>a</sup> has demonstrated clinical efficacy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study design</th><th align="left">Key findings</th></tr></thead><tbody><tr><td align="left" colspan="2">Patients with a suboptimal response to stimulants</td></tr><tr><td align="left">&#x000a0;An open-label, dose-optimization study of children/adolescents (aged 6&#x02013;17&#x000a0;years) with a suboptimal response to MPH (<italic>n</italic>&#x000a0;=&#x000a0;42) or amphetamine (<italic>n</italic>&#x000a0;=&#x000a0;33) [<xref ref-type="bibr" rid="CR187">187</xref>]</td><td align="left">Adjunctive GXR was associated with a significant improvement in ADHD-RS-IV total scores (&#x02212;16.1, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001)</td></tr><tr><td align="left">&#x000a0;A randomized, placebo-controlled trial of children/adolescents (aged 6&#x02013;17&#x000a0;years) with a suboptimal response to extended-release MPH or amphetamine, who received adjunctive GXR (morning dosing <italic>n</italic>&#x000a0;=&#x000a0;150; evening dosing <italic>n</italic>&#x000a0;=&#x000a0;152) or adjunctive placebo (<italic>n</italic>&#x000a0;=&#x000a0;153) [<xref ref-type="bibr" rid="CR178">178</xref>]</td><td align="left">Adjunctive GXR significantly improved ADHD-RS-IV total scores (placebo-adjusted least squares mean reductions: &#x02212;4.5 for GXR morning dosing [<italic>p</italic>&#x000a0;=&#x000a0;0.002] and &#x02212;5.3 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001] for GXR evening dosing)</td></tr><tr><td align="left">&#x000a0;A pre-specified analysis of data from children/adolescents (aged 6&#x02013;17&#x000a0;years) in an RCT and the open-label phase of a randomized withdrawal trial [<xref ref-type="bibr" rid="CR188">188</xref>]</td><td align="left">GXR monotherapy was associated with significant improvement in ADHD-RS-IV total scores in both prior-MPH-treated and stimulant-na&#x000ef;ve patients (difference in least squares mean vs placebo: &#x02212;9.8 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; <italic>n</italic>&#x000a0;=&#x000a0;45] and &#x02212;7.6 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; <italic>n</italic>&#x000a0;=&#x000a0;60], respectively, for the RCT and &#x02212;24.3 [<italic>n</italic>&#x000a0;=&#x000a0;221] and &#x02212;26.7 [<italic>n</italic>&#x000a0;=&#x000a0;206], respectively, for the LTE trial [descriptive statistics only])</td></tr><tr><td align="left" colspan="2">Patients with chronic tic disorders (including Tourette&#x02019;s syndrome)</td></tr><tr><td align="left">&#x000a0;An open-label study of guanfacine immediate release among children (aged 8&#x02013;16&#x000a0;years) with ADHD and Tourette&#x02019;s syndrome (<italic>n</italic>&#x000a0;=&#x000a0;10) [<xref ref-type="bibr" rid="CR194">194</xref>]</td><td align="left">Guanfacine immediate release was associated with improvement in the A task of the Continuous Performance Test (commission errors, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.02; omission errors, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and the severity of motor and phonic tics (both <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.02)</td></tr><tr><td align="left">&#x000a0;A randomized, placebo-controlled trial of guanfacine immediate release among children (aged 7&#x02013;14&#x000a0;years) with ADHD and tic disorders (<italic>n</italic>&#x000a0;=&#x000a0;34) [<xref ref-type="bibr" rid="CR195">195</xref>]</td><td align="left">Guanfacine immediate release improved ADHD-RS total scores (37 vs. 8&#x000a0;%; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) and Yale Global Tic Severity Scale scores (31&#x000a0;% vs. 0; <italic>p</italic>&#x000a0;=&#x000a0;0.05) versus placebo</td></tr><tr><td align="left" colspan="2">Patients with oppositional defiant disorder (or oppositional symptoms)</td></tr><tr><td align="left">&#x000a0;A randomized, double-blind, placebo-controlled, dose-optimization study of children (aged 6&#x02013;12&#x000a0;years) with ADHD and oppositional symptoms (GXR, <italic>n</italic>&#x000a0;=&#x000a0;138 and placebo, <italic>n</italic>&#x000a0;=&#x000a0;79) [<xref ref-type="bibr" rid="CR174">174</xref>]</td><td align="left">GXR significantly improved ADHD-RS-IV total scores and CPRS-R:L oppositional subscale scores compared with placebo (&#x02212;23.8 vs. &#x02212;11.5 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001] and &#x02212;10.9 vs. &#x02212;6.8 [<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001]). A post hoc analysis showed high correlation between improvement of oppositional and ADHD symptoms (<italic>r</italic>&#x000a0;=&#x000a0;0.74) [<xref ref-type="bibr" rid="CR174">174</xref>]</td></tr><tr><td align="left">&#x000a0;A matching-adjusted indirect comparison of randomized, double-blind, placebo-controlled trial data to assess the efficacy of GXR (<italic>n</italic>&#x000a0;=&#x000a0;58) and ATX (<italic>n</italic>&#x000a0;=&#x000a0;98) in reducing oppositional symptoms among children (mean age 10&#x000a0;years) with ADHD and ODD or oppositional/disruptive symptoms [<xref ref-type="bibr" rid="CR200">200</xref>]</td><td align="left">GXR was associated with a greater reduction in mean CPRS-R:S, oppositional subscale scores compared with ATX (&#x02212;5.0 vs. &#x02212;2.4; <italic>p</italic>&#x000a0;=&#x000a0;0.01)</td></tr><tr><td align="left">&#x000a0;An assessment of the effect of GXR adjunctive to psychostimulant on oppositional symptoms using data from a multicentre, randomized, double-blind, placebo-controlled, dose-optimization study of children/adolescents (aged 6&#x02013;17&#x000a0;years) with a suboptimal response to a stimulant alone [<xref ref-type="bibr" rid="CR201">201</xref>]. Patients received GXR (1&#x02013;4&#x000a0;mg/day) administered in the morning (<italic>n</italic>&#x000a0;=&#x000a0;86) or evening (<italic>n</italic>&#x000a0;=&#x000a0;93), or placebo (<italic>n</italic>&#x000a0;=&#x000a0;95)</td><td align="left">GXR adjunctive to a stimulant significantly improved CPRS&#x02013;R:L oppositional subscale scores (placebo-adjusted least square mean change from baseline: GXR morning &#x02212;3.6 [<italic>p</italic>&#x000a0;=&#x000a0;0.001] and GXR evening &#x02212;2.7 [<italic>p</italic>&#x000a0;=&#x000a0;0.013]) in a predefined subgroup with oppositional symptoms. A post hoc analysis showed no significant improvement in CPRS&#x02013;R:L oppositional subscale scores among children/adolescents with a diagnosis of ODD (<italic>n</italic>&#x000a0;=&#x000a0;90; although the analysis may have been underpowered to detect a difference between groups)</td></tr></tbody></table><table-wrap-foot><p>
<italic>ADHD</italic>-<italic>RS</italic>-<italic>IV</italic> ADHD Rating Scale IV, <italic>CPRS</italic>-<italic>R:L</italic> Conners&#x02019; Parent Rating Scale-Revised: Long Form, <italic>CPRS</italic>-<italic>R:S</italic> Conners&#x02019; Parent Rating Scale-Revised: Short Form, <italic>LTE</italic> long-term efficacy, <italic>MPH</italic> methylphenidate, <italic>ODD</italic> oppositional defiant disorder, <italic>RCT</italic> randomized controlled trial</p><p>
<sup>a</sup>Guanfacine immediate release is not approved for the treatment of ADHD</p></table-wrap-foot></table-wrap></p><sec id="Sec16"><title>Suboptimal Response to Stimulants</title><p>GXR is approved for the treatment of ADHD as adjunctive therapy to stimulant medications in Canada and the USA (for children and adolescents). In an open-label trial of children/adolescents with a suboptimal response to long-acting MPH or amphetamine monotherapy, adjunctive GXR was associated with improvement in ADHD symptom scores from baseline (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR187">187</xref>]. These results were validated in a randomized controlled trial (RCT) of children/adolescents with suboptimal response to long-acting MPH or amphetamines, in which adjunctive GXR significantly improved ADHD symptom scores versus adjunctive placebo (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR178">178</xref>]. In a recent pre-specified subgroup analysis of phase III trial data, GXR monotherapy was associated with a significant improvement in ADHD-RS-IV total scores in both prior-MPH-treated and stimulant-na&#x000ef;ve children/adolescents (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), whereas ATX was associated with a significant improvement in ADHD-RS-IV total scores in stimulant-na&#x000ef;ve patients only (RCT data only; difference in least squares mean vs. placebo: &#x02212;5.0 [<italic>p</italic>&#x000a0;=&#x000a0;0.022] and &#x02212;1.8 [<italic>p</italic>&#x000a0;=&#x000a0;0.452]) [<xref ref-type="bibr" rid="CR188">188</xref>]. Appropriately designed randomized studies are needed to confirm the findings of these subgroup analyses and further support treatment sequencing decisions for individuals with ADHD.</p></sec><sec id="Sec17"><title>Tics and Related Problems</title><p>Some patients with tic disorders benefit from stimulant medication, as improved concentration can suppress tics; however, others may find that tics are induced or exacerbated [<xref ref-type="bibr" rid="CR189">189</xref>]. The benefit of &#x003b1;2-adrenergic receptor agonists on both ADHD and co-morbid tic disorders has been demonstrated in a number of studies [<xref ref-type="bibr" rid="CR190">190</xref>&#x02013;<xref ref-type="bibr" rid="CR193">193</xref>]. Guanfacine was effective in reducing tics in two small studies of children with ADHD and co-morbid tic disorders (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR194">194</xref>, <xref ref-type="bibr" rid="CR195">195</xref>]. A systematic review and meta-analysis of data from RCTs (<italic>n</italic>&#x000a0;=&#x000a0;6) demonstrated benefit of &#x003b1;2-adrenergic receptor agonists in treating tics among patients with ADHD [<xref ref-type="bibr" rid="CR196">196</xref>]. At present, the use of GXR/guanfacine for tic disorders in children/adolescents is strongly recommended in Canadian, but not European, treatment guidelines [<xref ref-type="bibr" rid="CR197">197</xref>, <xref ref-type="bibr" rid="CR198">198</xref>].</p></sec><sec id="Sec18"><title>Emotional Dysregulation and Oppositional Defiant Disorder (ODD) Problems</title><p>Emotional dysregulation is a common feature of ADHD and is also present in other psychiatric disorders [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Dysfunction of a neural network comprising the orbitofrontal cortex, ventral striatum and amygdala is implicated in emotional dysregulation [<xref ref-type="bibr" rid="CR8">8</xref>]. Guanfacine modulates emotional responses [<xref ref-type="bibr" rid="CR119">119</xref>] and has been shown to reduce feelings of frustration among children with ADHD [<xref ref-type="bibr" rid="CR199">199</xref>]. GXR (vs. placebo) significantly reduced oppositional symptoms among children aged 6&#x02013;12&#x000a0;years with ADHD and co-morbid oppositional symptoms [<xref ref-type="bibr" rid="CR174">174</xref>], and was associated with significantly greater reduction in oppositional subscale scores than was ATX (<italic>p</italic>&#x000a0;=&#x000a0;0.01; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR200">200</xref>]. Furthermore, adjunctive GXR significantly reduced oppositional symptoms among children/adolescents (aged 6&#x02013;17&#x000a0;years) with ADHD and oppositional symptoms (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) [<xref ref-type="bibr" rid="CR201">201</xref>]. It has been postulated that GXR reduces symptoms of aggression by strengthening orbitofrontal cortical regulation of emotion [<xref ref-type="bibr" rid="CR29">29</xref>]. GXR could offer a useful treatment option for patients with ADHD who experience severe impairment due to emotional dysregulation.</p></sec><sec id="Sec19"><title>Intolerable Side Effects of Stimulants</title><p>GXR could hypothetically benefit other specific populations of patients with ADHD, as inferred by its distinct mode of action. This may include patients who experience intolerable side effects of stimulant medications. Weight loss is a commonly reported side effect of stimulants, and ADHD per se may also be associated with dysregulated growth [<xref ref-type="bibr" rid="CR202">202</xref>, <xref ref-type="bibr" rid="CR203">203</xref>]. Clinicians may prefer to avoid using stimulants among patients with pre-existing low body mass index, as even relatively minor stimulant-related weight reduction may be associated with long-term changes in body composition [<xref ref-type="bibr" rid="CR204">204</xref>]. In such cases, using, or switching to, a non-stimulant medication can provide a helpful alternative management strategy [<xref ref-type="bibr" rid="CR205">205</xref>].</p></sec><sec id="Sec20"><title>Hypertension or Other Cardiovascular Disorders</title><p>Juvenile hypertension is being increasingly recognized as an important public health issue [<xref ref-type="bibr" rid="CR206">206</xref>&#x02013;<xref ref-type="bibr" rid="CR208">208</xref>]. Hypertension is estimated to affect up to 6&#x000a0;% of children and adolescents and up to 40&#x000a0;% of those who are overweight or obese [<xref ref-type="bibr" rid="CR206">206</xref>, <xref ref-type="bibr" rid="CR209">209</xref>]. Stimulants and ATX have sympathomimetic effects on the cardiovascular system, including small but significant increases in blood pressure and heart rate [<xref ref-type="bibr" rid="CR25">25</xref>]. Accordingly, stimulants and ATX are contraindicated for patients with underlying cardiovascular disorders that could be compromised by an increase in blood pressure or heart rate [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR210">210</xref>]. Thus, a thorough history and examination are required prior to initiation of stimulant treatment to exclude a personal or family history of cardiovascular disorders [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR186">186</xref>]. GXR does not cause hypertension or affect cardiac re-polarization but may reduce heart rate and blood pressure [<xref ref-type="bibr" rid="CR131">131</xref>]. Thus, children/adolescents with ADHD and co-existing tachycardia, juvenile hypertension (or prehyper-tension) or other cardiovascular symptoms could potentially benefit from GXR [<xref ref-type="bibr" rid="CR189">189</xref>].</p></sec><sec id="Sec21"><title>Substance Use Disorder and Impulsivity Problems</title><p>Children, and adolescents in particular, who have ADHD are impulsive and novelty seeking, and therefore are inherently at higher risk of substance use disorder (SUD) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR211">211</xref>]. Unlike stimulants, GXR (and ATX) does not stimulate the nucleus accumbens, which is involved in the regulation of reward-related behaviour [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR212">212</xref>]. By inference and despite a meta-analysis that demonstrated no association between stimulant use and increased SUD risks [<xref ref-type="bibr" rid="CR213">213</xref>], GXR could provide a useful additional treatment option for patients who are at particularly high risk of SUD, unable to abstain from substance misuse despite stimulant treatment, or those with family members who are known to misuse drugs. Indeed, guanfacine has been shown to improve resistance to impulsive behaviour in a primate model and human studies [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR214">214</xref>]. ADHD is a risk factor for children being obese or overweight [<xref ref-type="bibr" rid="CR215">215</xref>], and dysregulated, impulsive over-eating behaviours are believed to contribute to weight gain [<xref ref-type="bibr" rid="CR216">216</xref>]. Thus, GXR could theoretically offer a beneficial treatment option for patients with ADHD and associated obesity related to impulsive over-eating.</p></sec><sec id="Sec22"><title>Circadian Cycle and/or Sleep Problems</title><p>The use of GXR to target specific periods of the circadian cycle may be a key application in clinical practice. The early morning routine can be a particularly challenging time of day for families of children with ADHD [<xref ref-type="bibr" rid="CR217">217</xref>]. Our clinical experience suggests that executive functional deficit resulting in disorganized or oppositional behaviour before the morning dose of ADHD medication is a common and severely disruptive problem. Recent data suggest that GXR administered in the morning may result in a reduced total sleep time versus placebo among children with ADHD and pre-existing sleep problems (&#x02212;57 vs. +31&#x000a0;min; <italic>p</italic>&#x000a0;=&#x000a0;0.005) [<xref ref-type="bibr" rid="CR218">218</xref>]. The author suggests a possible link between reduced sleep time with GXR and daytime somnolence [<xref ref-type="bibr" rid="CR218">218</xref>]; however, as this study was terminated early and thus lacks sufficient statistical power, it should be considered as preliminary evidence that needs further investigation. Stimulants in particular may cause sleep disturbances if administered in the evening so should be administered at this time only very cautiously [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR219">219</xref>], whereas GXR can be administered either in the morning or in the evening [<xref ref-type="bibr" rid="CR179">179</xref>]. The mode of action of GXR infers that administration in the evening could help children with ADHD to sleep and wake up relatively symptom-free. Indeed, recent data show that morning or evening administration of GXR significantly improves ADHD-related symptoms in the morning and throughout the day (as assessed by modified Connors&#x02019; Parent Rating Scale&#x02013;Revised: Short Form total scores; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001 vs. placebo at Week 8 regardless of the time of GXR administration) [<xref ref-type="bibr" rid="CR220">220</xref>]. GXR administered in the morning or evening adjunctively with a psychostimulant is also associated with improvement in morning symptoms of ADHD [<xref ref-type="bibr" rid="CR180">180</xref>].</p></sec></sec><sec id="Sec23"><title>Other Potential Clinical Applications of GXR</title><p>Previous studies also suggest that GXR, through its specific mode of action on the PFC, could offer an effective therapy for conditions other than ADHD. Post-traumatic stress disorder (PTSD) is associated with excessive noradrenaline release [<xref ref-type="bibr" rid="CR221">221</xref>] and PFC dysfunction may contribute to the inadequate inhibition of traumatic memories [<xref ref-type="bibr" rid="CR221">221</xref>]. Indeed, there is substantial symptom overlap and co-morbidity between ADHD and PTSD [<xref ref-type="bibr" rid="CR222">222</xref>]. Rat studies have shown that guanfacine reverses stress-induced PFC deficits while not exacerbating conditioned fear [<xref ref-type="bibr" rid="CR112">112</xref>, <xref ref-type="bibr" rid="CR223">223</xref>]. Moreover, GXR (1&#x02013;4&#x000a0;mg administered once daily) was found to reduce the severity of traumatic stress symptoms among children/adolescents in an open-label pilot study [<xref ref-type="bibr" rid="CR224">224</xref>].</p><p>&#x003b1;2A-Adrenergic receptor agonists, including guanfacine, have also been studied in other PFC-associated cognitive disorders. Early data suggest that guanfacine may have beneficial effects in the treatment of attention disorders associated with neurological conditions [<xref ref-type="bibr" rid="CR225">225</xref>&#x02013;<xref ref-type="bibr" rid="CR227">227</xref>]. Improvement with guanfacine has been reported among selected patients who have mild traumatic brain injury, visual neglect following stroke, and deficits in arousal and sustained attention following acute disseminated encephalomyelitis [<xref ref-type="bibr" rid="CR225">225</xref>&#x02013;<xref ref-type="bibr" rid="CR227">227</xref>]. In a rat study, guanfacine has been reported to prevent hypobaric hypoxia-induced spatial working memory deficits and neurodegeneration [<xref ref-type="bibr" rid="CR228">228</xref>]. The results suggest a potential role for GXR in improving prefrontal cognitive function during high altitude exposure [<xref ref-type="bibr" rid="CR228">228</xref>].</p></sec></sec><sec id="Sec24"><title>Future Perspectives</title><p>Further research into the pathophysiology and aetiological heterogeneity of ADHD and the modes of action of effective pharmacotherapies will increase the use of individualized patient management strategies [<xref ref-type="bibr" rid="CR229">229</xref>]. The identification of patients with ADHD who are likely to respond to specific treatments and/or avoid side effects using baseline demographic or clinical characteristics (including co-morbidities and adverse reaction profiles) could improve outcomes [<xref ref-type="bibr" rid="CR230">230</xref>]. Matching individual patients with the most appropriate treatment strategy would help to better address the needs of patients and their families and improve the cost-effectiveness of care [<xref ref-type="bibr" rid="CR230">230</xref>]. Advances in the neurobiology of ADHD will also help to drive the research and development of new therapeutic options.</p></sec><sec id="Sec25" sec-type="conclusion"><title>Conclusions</title><p>This article provides an overview of recent advances in neurobiology of ADHD and the mode of action of guanfacine. An understanding of the neurobiology of ADHD and available treatment options will help clinicians make informed decisions to optimize the care of patients who require an alternative pharmacotherapy. ADHD is a neurodevelopmental disorder that affects synaptic transmission and growth factors throughout the brain. Data from neurobiological studies and medication response patterns in clinical trials support a key role for dopamine and noradrenaline in ADHD. Psychostimulants, and the non-stimulant ATX, increase the extracellular availability of these catecholamines at the synaptic cleft. Although stimulants are the most widely prescribed treatment for ADHD, they can be unsuitable for a sizable proportion of patients.</p><p>The selective &#x003b1;2A-adrenergic receptor agonist, GXR, is an alternative non-stimulant ADHD pharmacotherapy. According to the HCN channel and network hypotheses, guanfacine acts directly on &#x003b1;2A-adrenergic receptors to enhance noradrenaline neurotransmission. Animal studies also provide preliminary evidence that guanfacine influences dendritic spine plasticity in the PFC. GXR is a new non-stimulant pharmacotherapy for ADHD in Europe for children and adolescents for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. The selective mode of action of GXR may provide particular benefit for children/adolescents who have specific comorbidities such as chronic tic disorders or ODD (or oppositional symptoms) that have failed to respond to first-line treatment options.</p></sec></body><back><fn-group><fn><p>Andrea G. Ludolph&#x02014;Deceased September 2015.</p></fn></fn-group><ack><p>This review was funded by Shire International GmbH. The authors determined the scope of the review. Under their direction, Hannah Wills, MBChB, CMPP, an employee of Caudex, Oxford, UK, provided writing assistance for development of the manuscript drafts, assisted with the collation of author comments, and performed exploratory literature searches. Debby Moss, PhD, and Joanna Wright, DPhil, also employees of Caudex, Oxford, UK, contributed to the initial literature searches and provided writing assistance for the manuscript outline. Editorial assistance in formatting, proofreading, copy-editing and fact checking was also provided by Caudex. Shire International GmbH provided funding to Caudex, Oxford, UK, for support in writing, editing, managing reviews, coordinating and collating comments for this manuscript. Antonia Panayi from Shire International GmbH also reviewed and edited the manuscript for scientific accuracy. Shire develops and manufactures treatments for psychiatric disorders including ADHD. The content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in <italic>Clinical Drug Investigation</italic> was made by the authors independently. </p><p>Michael Huss and Wai Chen would like to acknowledge the extraordinary commitment and contribution made by Andrea Ludolph to this article and her role as corresponding author until her sad and untimely death shortly before publication.</p></ack><notes notes-type="conflict-interest"><title>Compliance with Ethical Standards</title><sec id="FPar2"><title>Conflict of interest</title><p>MH has received unrestricted grants to conduct Investigator Initiated Trials (IIT) with products of Engelhard Arzneimittel and Medice. He has received speaker honoraria, travel support and served as an advisor for Lilly, Shire, Medice, Novartis, Engelhard Arzneimittel, Actelion, and Lundbeck. He also holds an international patent on Doppler radar to assess ADHD. WC has received research support from Shire, honoraria for lecturing and consultancy for Flynn Pharma, Janssen and Shire, and support for attending meetings from Janssen and Shire. WC was a member of advisory boards for Shire. AL has received unrestricted grants from Medice and Novartis to investigate modes of action of methylphenidate in vitro. She has received speaker honoraria from Shire and Lilly and served as an advisor for Shire.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group><source>Diagnostic and statistical manual of mental disorders, Fifth Edition (DSM-5)</source><year>2013</year><publisher-loc>Arlington</publisher-loc><publisher-name>American Psychiatric Publishing</publisher-name></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">NICE. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. 2013. <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/qs39">https://www.nice.org.uk/guidance/qs39</ext-link>. Accessed 3 Mar 2015.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huss</surname><given-names>M</given-names></name><name><surname>Holling</surname><given-names>H</given-names></name><name><surname>Kurth</surname><given-names>BM</given-names></name><name><surname>Schlack</surname><given-names>R</given-names></name></person-group><article-title>How often are German children and adolescents diagnosed with ADHD? Prevalence based on the judgment of health care professionals: results of the German health and examination survey (KiGGS)</article-title><source>Eur Child Adolesc Psychiatry</source><year>2008</year><volume>17</volume><issue>Suppl 1</issue><fpage>52</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s00787-008-1006-z</pub-id><?supplied-pmid 19132304?><pub-id pub-id-type="pmid">19132304</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polanczyk</surname><given-names>G</given-names></name><name><surname>de Lima</surname><given-names>MS</given-names></name><name><surname>Horta</surname><given-names>BL</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Rohde</surname><given-names>LA</given-names></name></person-group><article-title>The worldwide prevalence of ADHD: a systematic review and metaregression analysis</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>942</fpage><lpage>948</lpage><pub-id pub-id-type="doi">10.1176/ajp.2007.164.6.942</pub-id><?supplied-pmid 17541055?><pub-id pub-id-type="pmid">17541055</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos-Quiroga</surname><given-names>JA</given-names></name><name><surname>Montoya</surname><given-names>A</given-names></name><name><surname>Kutzelnigg</surname><given-names>A</given-names></name><name><surname>Deberdt</surname><given-names>W</given-names></name><name><surname>Sobanski</surname><given-names>E</given-names></name></person-group><article-title>Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines</article-title><source>Curr Med Res Opin</source><year>2013</year><volume>29</volume><fpage>1093</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1185/03007995.2013.812961</pub-id><?supplied-pmid 23742051?><pub-id pub-id-type="pmid">23742051</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambek</surname><given-names>R</given-names></name><name><surname>Tannock</surname><given-names>R</given-names></name><name><surname>Dalsgaard</surname><given-names>S</given-names></name><name><surname>Trillingsgaard</surname><given-names>A</given-names></name><name><surname>Damm</surname><given-names>D</given-names></name><name><surname>Thomsen</surname><given-names>PH</given-names></name></person-group><article-title>Executive dysfunction in school-age children with ADHD</article-title><source>J Atten Disord</source><year>2011</year><volume>15</volume><fpage>646</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1177/1087054710370935</pub-id><?supplied-pmid 20858784?><pub-id pub-id-type="pmid">20858784</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasper</surname><given-names>LJ</given-names></name><name><surname>Alderson</surname><given-names>RM</given-names></name><name><surname>Hudec</surname><given-names>KL</given-names></name></person-group><article-title>Moderators of working memory deficits in children with attention-deficit/hyperactivity disorder (ADHD): a meta-analytic review</article-title><source>Clin Psychol Rev</source><year>2012</year><volume>32</volume><fpage>605</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.cpr.2012.07.001</pub-id><?supplied-pmid 22917740?><pub-id pub-id-type="pmid">22917740</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>Stringaris</surname><given-names>A</given-names></name><name><surname>Nigg</surname><given-names>J</given-names></name><name><surname>Leibenluft</surname><given-names>E</given-names></name></person-group><article-title>Emotion dysregulation in attention deficit hyperactivity disorder</article-title><source>Am J Psychiatry</source><year>2014</year><volume>171</volume><fpage>276</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2013.13070966</pub-id><?supplied-pmid 24480998?><pub-id pub-id-type="pmid">24480998</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Manor</surname><given-names>I</given-names></name><name><surname>Huss</surname><given-names>M</given-names></name></person-group><article-title>Attention-deficit/hyperactivity disorder in adults: update on clinical presentation and care</article-title><source>Neuropsychiatry</source><year>2014</year><volume>4</volume><fpage>109</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.2217/npy.14.16</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>MTA Cooperative Group</collab></person-group><article-title>A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD</article-title><source>Arch Gen Psychiatry</source><year>1999</year><volume>56</volume><fpage>1073</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.56.12.1073</pub-id><pub-id pub-id-type="pmid">10591283</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>CM</given-names></name><name><surname>Steinhausen</surname><given-names>HC</given-names></name></person-group><article-title>Comorbid mental disorders in children and adolescents with attention-deficit/hyperactivity disorder in a large nationwide study</article-title><source>Atten Defic Hyperact Disord</source><year>2015</year><volume>7</volume><fpage>27</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1007/s12402-014-0142-1</pub-id><?supplied-pmid 24942707?><pub-id pub-id-type="pmid">24942707</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgson</surname><given-names>K</given-names></name><name><surname>Hutchinson</surname><given-names>AD</given-names></name><name><surname>Denson</surname><given-names>L</given-names></name></person-group><article-title>Nonpharmacological treatments for ADHD: a meta-analytic review</article-title><source>J Atten Disord</source><year>2014</year><volume>18</volume><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1177/1087054712444732</pub-id><?supplied-pmid 22647288?><pub-id pub-id-type="pmid">22647288</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>E</given-names></name><name><surname>Dopfner</surname><given-names>M</given-names></name><name><surname>Sergeant</surname><given-names>J</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name><etal/></person-group><article-title>European clinical guidelines for hyperkinetic disorder&#x02014;first upgrade</article-title><source>Eur Child Adolesc Psychiatry</source><year>2004</year><volume>13</volume><issue>Suppl 1</issue><fpage>i7</fpage><lpage>i30</lpage><?supplied-pmid 15322953?><pub-id pub-id-type="pmid">15322953</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">NICE. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72 (2008; includes 2013 updates). 2013. <ext-link ext-link-type="uri" xlink:href="http://www.nice.org.uk/guidance/cg72/evidence/cg72-attention-deficit-hyperactivity-disorder-adhd-full-guideline-2">http://www.nice.org.uk/guidance/cg72/evidence/cg72-attention-deficit-hyperactivity-disorder-adhd-full-guideline-2</ext-link>. Accessed 13 Mar 2015.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name></person-group><article-title>Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis</article-title><source>Eur Child Adolesc Psychiatry</source><year>2010</year><volume>19</volume><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1007/s00787-009-0054-3</pub-id><?supplied-pmid 19763664?><pub-id pub-id-type="pmid">19763664</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths</article-title><source>Pharm Ther</source><year>2009</year><volume>34</volume><fpage>678</fpage><lpage>694</lpage></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnold</surname><given-names>LE</given-names></name></person-group><article-title>Methylphenidate vs. amphetamine: comparative review</article-title><source>J Atten Disord</source><year>2000</year><volume>3</volume><fpage>200</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1177/108705470000300403</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Wilens</surname><given-names>T</given-names></name><name><surname>Harding</surname><given-names>M</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name></person-group><article-title>Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1996</year><volume>35</volume><fpage>409</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1097/00004583-199604000-00008</pub-id><?supplied-pmid 8919704?><pub-id pub-id-type="pmid">8919704</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name><name><surname>Danckaerts</surname><given-names>M</given-names></name><etal/></person-group><article-title>Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents</article-title><source>J Child Psychol Psychiatry</source><year>2013</year><volume>54</volume><fpage>227</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1111/jcpp.12036</pub-id><?supplied-pmid 23294014?><pub-id pub-id-type="pmid">23294014</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gajria</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Sikirica</surname><given-names>V</given-names></name><name><surname>Greven</surname><given-names>P</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder&#x02014;a systematic literature review</article-title><source>Neuropsychiatr Dis Treat</source><year>2014</year><volume>10</volume><fpage>1543</fpage><lpage>1569</lpage><?supplied-pmid 25187718?><pub-id pub-id-type="pmid">25187718</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolraich</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>L</given-names></name><name><surname>Brown</surname><given-names>RT</given-names></name><name><surname>DuPaul</surname><given-names>G</given-names></name><name><surname>Earls</surname><given-names>M</given-names></name><name><surname>Feldman</surname><given-names>HM</given-names></name><etal/></person-group><article-title>ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents</article-title><source>Pediatrics</source><year>2011</year><volume>128</volume><fpage>1007</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1542/peds.2011-2654</pub-id><?supplied-pmid 22003063?><pub-id pub-id-type="pmid">22003063</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matza</surname><given-names>LS</given-names></name><name><surname>Secnik</surname><given-names>K</given-names></name><name><surname>Rentz</surname><given-names>AM</given-names></name><name><surname>Mannix</surname><given-names>S</given-names></name><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><etal/></person-group><article-title>Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report</article-title><source>Qual Life Res</source><year>2005</year><volume>14</volume><fpage>735</fpage><lpage>747</lpage><?supplied-pmid 16022066?><pub-id pub-id-type="pmid">16022066</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2014</year><volume>53</volume><fpage>174</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2013.11.005</pub-id><?supplied-pmid 24472252?><pub-id pub-id-type="pmid">24472252</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bushe</surname><given-names>CJ</given-names></name><name><surname>Savill</surname><given-names>NC</given-names></name></person-group><article-title>Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009&#x02013;2011: focus on clinical efficacy and safety</article-title><source>J Psychopharmacol</source><year>2014</year><volume>28</volume><fpage>204</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1177/0269881113478475</pub-id><?supplied-pmid 23438503?><pub-id pub-id-type="pmid">23438503</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Raga</surname><given-names>J</given-names></name><name><surname>Knecht</surname><given-names>C</given-names></name><name><surname>Szerman</surname><given-names>N</given-names></name><name><surname>Martinez</surname><given-names>MI</given-names></name></person-group><article-title>Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder</article-title><source>CNS Drugs</source><year>2013</year><volume>27</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1007/s40263-012-0019-9</pub-id><?supplied-pmid 23160939?><pub-id pub-id-type="pmid">23160939</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Shire. Intuniv US prescribing information. 2014. <ext-link ext-link-type="uri" xlink:href="http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf">http://pi.shirecontent.com/PI/PDFs/Intuniv_USA_ENG.pdf</ext-link>. Accessed 2 Feb 2015.</mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Shire Canada Inc. INTUNIV XR product monograph. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.shirecanada.com/en/documents/INTUNIV_XR_PM_EN.pdf">http://www.shirecanada.com/en/documents/INTUNIV_XR_PM_EN.pdf</ext-link>. Accessed 20 Oct 2015.</mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Shire Pharmaceuticals Ireland Limited. Intuniv summary of product characteristics. 2015. <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003759/WC500195130.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003759/WC500195130.pdf</ext-link>. Accessed 20 Oct 2015</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2012</year><volume>51</volume><fpage>356</fpage><lpage>367</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2012.01.008</pub-id><?supplied-pmid 22449642?><pub-id pub-id-type="pmid">22449642</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greven</surname><given-names>CU</given-names></name><name><surname>Bralten</surname><given-names>J</given-names></name><name><surname>Mennes</surname><given-names>M</given-names></name><name><surname>O&#x02019;Dwyer</surname><given-names>L</given-names></name><name><surname>van Hulzen</surname><given-names>KJ</given-names></name><name><surname>Rommelse</surname><given-names>N</given-names></name><etal/></person-group><article-title>Developmentally stable whole-brain volume reductions and developmentally sensitive caudate and putamen volume alterations in those with attention-deficit/hyperactivity disorder and their unaffected siblings</article-title><source>JAMA Psychiatry</source><year>2015</year><volume>72</volume><fpage>490</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.3162</pub-id><?supplied-pmid 25785435?><pub-id pub-id-type="pmid">25785435</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Chabernaud</surname><given-names>C</given-names></name><name><surname>Proal</surname><given-names>E</given-names></name><name><surname>Di Martino</surname><given-names>A</given-names></name><name><surname>Milham</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Toward systems neuroscience of ADHD: a meta-analysis of 55 fMRI studies</article-title><source>Am J Psychiatry</source><year>2012</year><volume>169</volume><fpage>1038</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2012.11101521</pub-id><?supplied-pmid 22983386?><pub-id pub-id-type="pmid">22983386</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>D</given-names></name><name><surname>Angstadt</surname><given-names>M</given-names></name><name><surname>Welsh</surname><given-names>RC</given-names></name><name><surname>Sripada</surname><given-names>C</given-names></name></person-group><article-title>Modality-spanning deficits in attention-deficit/hyperactivity disorder in functional networks, gray matter, and white matter</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>16555</fpage><lpage>16566</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3156-14.2014</pub-id><?supplied-pmid 25505309?><pub-id pub-id-type="pmid">25505309</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name></person-group><article-title>The neurobiology and genetics of attention-deficit/hyperactivity disorder (ADHD): what every clinician should know</article-title><source>Eur J Paediatr Neurol</source><year>2012</year><volume>16</volume><fpage>422</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2012.01.009</pub-id><?supplied-pmid 22306277?><pub-id pub-id-type="pmid">22306277</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocchi</surname><given-names>L</given-names></name><name><surname>Bramati</surname><given-names>IE</given-names></name><name><surname>Zalesky</surname><given-names>A</given-names></name><name><surname>Furukawa</surname><given-names>E</given-names></name><name><surname>Fontenelle</surname><given-names>LF</given-names></name><name><surname>Moll</surname><given-names>J</given-names></name><etal/></person-group><article-title>Altered functional brain connectivity in a non-clinical sample of young adults with attention-deficit/hyperactivity disorder</article-title><source>J Neurosci</source><year>2012</year><volume>32</volume><fpage>17753</fpage><lpage>17761</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3272-12.2012</pub-id><?supplied-pmid 23223295?><pub-id pub-id-type="pmid">23223295</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sripada</surname><given-names>C</given-names></name><name><surname>Kessler</surname><given-names>D</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Welsh</surname><given-names>RC</given-names></name><name><surname>Prem</surname><given-names>KK</given-names></name><name><surname>Angstadt</surname><given-names>M</given-names></name></person-group><article-title>Disrupted network architecture of the resting brain in attention-deficit/hyperactivity disorder</article-title><source>Hum Brain Mapp</source><year>2014</year><volume>35</volume><fpage>4693</fpage><lpage>4705</lpage><pub-id pub-id-type="doi">10.1002/hbm.22504</pub-id><?supplied-pmid 24668728?><pub-id pub-id-type="pmid">24668728</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>Eckstrand</surname><given-names>K</given-names></name><name><surname>Sharp</surname><given-names>W</given-names></name><name><surname>Blumenthal</surname><given-names>J</given-names></name><name><surname>Lerch</surname><given-names>JP</given-names></name><name><surname>Greenstein</surname><given-names>D</given-names></name><etal/></person-group><article-title>Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation</article-title><source>Proc Natl Acad Sci USA</source><year>2007</year><volume>104</volume><fpage>19649</fpage><lpage>19654</lpage><pub-id pub-id-type="doi">10.1073/pnas.0707741104</pub-id><?supplied-pmid 18024590?><pub-id pub-id-type="pmid">18024590</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellanos</surname><given-names>FX</given-names></name><name><surname>Lee</surname><given-names>PP</given-names></name><name><surname>Sharp</surname><given-names>W</given-names></name><name><surname>Jeffries</surname><given-names>NO</given-names></name><name><surname>Greenstein</surname><given-names>DK</given-names></name><name><surname>Clasen</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>1740</fpage><lpage>1748</lpage><pub-id pub-id-type="doi">10.1001/jama.288.14.1740</pub-id><?supplied-pmid 12365958?><pub-id pub-id-type="pmid">12365958</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidya</surname><given-names>CJ</given-names></name></person-group><article-title>Neurodevelopmental abnormalities in ADHD</article-title><source>Curr Top Behav Neurosci</source><year>2012</year><volume>9</volume><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/7854_2011_138</pub-id><?supplied-pmid 21541845?><pub-id pub-id-type="pmid">21541845</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackie</surname><given-names>S</given-names></name><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>Lenroot</surname><given-names>R</given-names></name><name><surname>Pierson</surname><given-names>R</given-names></name><name><surname>Greenstein</surname><given-names>DK</given-names></name><name><surname>Nugent</surname><given-names>TF</given-names><suffix>III</suffix></name><etal/></person-group><article-title>Cerebellar development and clinical outcome in attention deficit hyperactivity disorder</article-title><source>Am J Psychiatry</source><year>2007</year><volume>164</volume><fpage>647</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1176/ajp.2007.164.4.647</pub-id><?supplied-pmid 17403979?><pub-id pub-id-type="pmid">17403979</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plessen</surname><given-names>KJ</given-names></name><name><surname>Bansal</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Whiteman</surname><given-names>R</given-names></name><name><surname>Amat</surname><given-names>J</given-names></name><name><surname>Quackenbush</surname><given-names>GA</given-names></name><etal/></person-group><article-title>Hippocampus and amygdala morphology in attention-deficit/hyperactivity disorder</article-title><source>Arch Gen Psychiatry</source><year>2006</year><volume>63</volume><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.63.7.795</pub-id><?supplied-pmid 16818869?><pub-id pub-id-type="pmid">16818869</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>A</given-names></name><name><surname>Crocetti</surname><given-names>D</given-names></name><name><surname>Adler</surname><given-names>M</given-names></name><name><surname>Mahone</surname><given-names>EM</given-names></name><name><surname>Denckla</surname><given-names>MB</given-names></name><name><surname>Miller</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Basal ganglia volume and shape in children with attention deficit hyperactivity disorder</article-title><source>Am J Psychiatry</source><year>2009</year><volume>166</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2008.08030426</pub-id><?supplied-pmid 19015232?><pub-id pub-id-type="pmid">19015232</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Kimball</surname><given-names>AE</given-names></name><name><surname>Kelly</surname><given-names>MS</given-names></name><name><surname>Lesser</surname><given-names>I</given-names></name><name><surname>Branch</surname><given-names>C</given-names></name></person-group><article-title>Thalamic shape and connectivity abnormalities in children with attention-deficit/hyperactivity disorder</article-title><source>Psychiatry Res</source><year>2012</year><volume>204</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1016/j.pscychresns.2012.04.011</pub-id><?supplied-pmid 23149038?><pub-id pub-id-type="pmid">23149038</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Ewijk</surname><given-names>H</given-names></name><name><surname>Heslenfeld</surname><given-names>DJ</given-names></name><name><surname>Zwiers</surname><given-names>MP</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><name><surname>Oosterlaan</surname><given-names>J</given-names></name></person-group><article-title>Diffusion tensor imaging in attention deficit/hyperactivity disorder: a systematic review and meta-analysis</article-title><source>Neurosci Biobehav Rev</source><year>2012</year><volume>36</volume><fpage>1093</fpage><lpage>1106</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.01.003</pub-id><?supplied-pmid 22305957?><pub-id pub-id-type="pmid">22305957</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>SB</given-names></name><name><surname>Zalesky</surname><given-names>A</given-names></name><name><surname>Fornito</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Connectomic disturbances in attention-deficit/hyperactivity disorder: a whole-brain tractography analysis</article-title><source>Biol Psychiatry</source><year>2014</year><volume>76</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.12.013</pub-id><?supplied-pmid 24503470?><pub-id pub-id-type="pmid">24503470</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>H</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>Mataix-Cols</surname><given-names>D</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Meta-analysis of fMRI studies of timing in attention-deficit hyperactivity disorder (ADHD)</article-title><source>Neurosci Biobehav Rev</source><year>2012</year><volume>36</volume><fpage>2248</fpage><lpage>2256</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.08.003</pub-id><?supplied-pmid 22922163?><pub-id pub-id-type="pmid">22922163</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>H</given-names></name><name><surname>Radua</surname><given-names>J</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Mataix-Cols</surname><given-names>D</given-names></name><name><surname>Rubia</surname><given-names>K</given-names></name></person-group><article-title>Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><fpage>185</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.277</pub-id><?supplied-pmid 23247506?><pub-id pub-id-type="pmid">23247506</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raichle</surname><given-names>ME</given-names></name><name><surname>MacLeod</surname><given-names>AM</given-names></name><name><surname>Snyder</surname><given-names>AZ</given-names></name><name><surname>Powers</surname><given-names>WJ</given-names></name><name><surname>Gusnard</surname><given-names>DA</given-names></name><name><surname>Shulman</surname><given-names>GL</given-names></name></person-group><article-title>A default mode of brain function</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1073/pnas.98.2.676</pub-id><?supplied-pmid 11209064?><pub-id pub-id-type="pmid">11209064</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fair</surname><given-names>DA</given-names></name><name><surname>Posner</surname><given-names>J</given-names></name><name><surname>Nagel</surname><given-names>BJ</given-names></name><name><surname>Bathula</surname><given-names>D</given-names></name><name><surname>Dias</surname><given-names>TG</given-names></name><name><surname>Mills</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Atypical default network connectivity in youth with attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2010</year><volume>68</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.07.003</pub-id><?supplied-pmid 20728873?><pub-id pub-id-type="pmid">20728873</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>H</given-names></name><name><surname>Skokauskas</surname><given-names>N</given-names></name><name><surname>Mulligan</surname><given-names>A</given-names></name><name><surname>Donohoe</surname><given-names>G</given-names></name><name><surname>Mullins</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><etal/></person-group><article-title>Attention network hypoconnectivity with default and affective network hyperconnectivity in adults diagnosed with attention-deficit/hyperactivity disorder in childhood</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><fpage>1329</fpage><lpage>1337</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.2174</pub-id><?supplied-pmid 24132732?><pub-id pub-id-type="pmid">24132732</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castellanos</surname><given-names>FX</given-names></name><name><surname>Margulies</surname><given-names>DS</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Uddin</surname><given-names>LQ</given-names></name><name><surname>Ghaffari</surname><given-names>M</given-names></name><name><surname>Kirsch</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2008</year><volume>63</volume><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.06.025</pub-id><?supplied-pmid 17888409?><pub-id pub-id-type="pmid">17888409</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>A</given-names></name><name><surname>Archer</surname><given-names>T</given-names></name></person-group><article-title>Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD</article-title><source>Neurotox Res</source><year>2004</year><volume>6</volume><fpage>435</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1007/BF03033280</pub-id><?supplied-pmid 15639778?><pub-id pub-id-type="pmid">15639778</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>HC</given-names></name><name><surname>Rosa</surname><given-names>P</given-names></name><name><surname>Pryds</surname><given-names>O</given-names></name><name><surname>Karrebaek</surname><given-names>H</given-names></name><name><surname>Lunding</surname><given-names>J</given-names></name><name><surname>Cumming</surname><given-names>P</given-names></name><etal/></person-group><article-title>ADHD: increased dopamine receptor availability linked to attention deficit and low neonatal cerebral blood flow</article-title><source>Dev Med Child Neurol</source><year>2004</year><volume>46</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1111/j.1469-8749.2004.tb00469.x</pub-id><?supplied-pmid 14995087?><pub-id pub-id-type="pmid">14995087</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purper-Ouakil</surname><given-names>D</given-names></name><name><surname>Ramoz</surname><given-names>N</given-names></name><name><surname>Lepagnol-Bestel</surname><given-names>AM</given-names></name><name><surname>Gorwood</surname><given-names>P</given-names></name><name><surname>Simonneau</surname><given-names>M</given-names></name></person-group><article-title>Neurobiology of attention deficit/hyperactivity disorder</article-title><source>Pediatr Res</source><year>2011</year><volume>69</volume><fpage>69R</fpage><lpage>76R</lpage><pub-id pub-id-type="doi">10.1203/PDR.0b013e318212b40f</pub-id><?supplied-pmid 21289544?><pub-id pub-id-type="pmid">21289544</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Kooij</surname><given-names>MA</given-names></name><name><surname>Glennon</surname><given-names>JC</given-names></name></person-group><article-title>Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder</article-title><source>Neurosci Biobehav Rev</source><year>2007</year><volume>31</volume><fpage>597</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2006.12.002</pub-id><?supplied-pmid 17316796?><pub-id pub-id-type="pmid">17316796</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterley</surname><given-names>TL</given-names></name><name><surname>Howells</surname><given-names>FM</given-names></name><name><surname>Russell</surname><given-names>VA</given-names></name></person-group><article-title>Evidence for reduced tonic levels of GABA in the hippocampus of an animal model of ADHD, the spontaneously hypertensive rat</article-title><source>Brain Res</source><year>2013</year><volume>1541</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2013.10.023</pub-id><?supplied-pmid 24161405?><pub-id pub-id-type="pmid">24161405</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>CL</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>Locomotor hyperactivity induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys</article-title><source>Biol Psychiatry</source><year>2005</year><volume>57</volume><fpage>192</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2004.11.004</pub-id><?supplied-pmid 15652880?><pub-id pub-id-type="pmid">15652880</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludolph</surname><given-names>AG</given-names></name><name><surname>Kassubek</surname><given-names>J</given-names></name><name><surname>Schmeck</surname><given-names>K</given-names></name><name><surname>Glaser</surname><given-names>C</given-names></name><name><surname>Wunderlich</surname><given-names>A</given-names></name><name><surname>Buck</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Dopaminergic dysfunction in attention deficit hyperactivity disorder (ADHD), differences between pharmacologically treated and never treated young adults: a 3,4-dihdroxy-6-[18F]fluorophenyl-<sc>l</sc>-alanine PET study</article-title><source>Neuroimage</source><year>2008</year><volume>41</volume><fpage>718</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2008.02.025</pub-id><?supplied-pmid 18424180?><pub-id pub-id-type="pmid">18424180</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Newcorn</surname><given-names>J</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><name><surname>Solanto</surname><given-names>MV</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder</article-title><source>Arch Gen Psychiatry</source><year>2007</year><volume>64</volume><fpage>932</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.64.8.932</pub-id><?supplied-pmid 17679638?><pub-id pub-id-type="pmid">17679638</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dearry</surname><given-names>A</given-names></name><name><surname>Gingrich</surname><given-names>JA</given-names></name><name><surname>Falardeau</surname><given-names>P</given-names></name><name><surname>Fremeau</surname><given-names>RT</given-names><suffix>Jr</suffix></name><name><surname>Bates</surname><given-names>MD</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name></person-group><article-title>Molecular cloning and expression of the gene for a human D1 dopamine receptor</article-title><source>Nature</source><year>1990</year><volume>347</volume><fpage>72</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1038/347072a0</pub-id><?supplied-pmid 2144334?><pub-id pub-id-type="pmid">2144334</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandy</surname><given-names>DK</given-names></name><name><surname>Marchionni</surname><given-names>MA</given-names></name><name><surname>Makam</surname><given-names>H</given-names></name><name><surname>Stofko</surname><given-names>RE</given-names></name><name><surname>Alfano</surname><given-names>M</given-names></name><name><surname>Frothingham</surname><given-names>L</given-names></name><etal/></person-group><article-title>Cloning of the cDNA and gene for a human D2 dopamine receptor</article-title><source>Proc Natl Acad Sci USA</source><year>1989</year><volume>86</volume><fpage>9762</fpage><lpage>9766</lpage><pub-id pub-id-type="doi">10.1073/pnas.86.24.9762</pub-id><?supplied-pmid 2532362?><pub-id pub-id-type="pmid">2532362</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomasney</surname><given-names>JW</given-names></name><name><surname>Lorenz</surname><given-names>W</given-names></name><name><surname>Allen</surname><given-names>LF</given-names></name><name><surname>King</surname><given-names>K</given-names></name><name><surname>Regan</surname><given-names>JW</given-names></name><name><surname>Yang-Feng</surname><given-names>TL</given-names></name><etal/></person-group><article-title>Expansion of the alpha 2-adrenergic receptor family: cloning and characterization of a human alpha 2-adrenergic receptor subtype, the gene for which is located on chromosome 2</article-title><source>Proc Natl Acad Sci USA</source><year>1990</year><volume>87</volume><fpage>5094</fpage><lpage>5098</lpage><pub-id pub-id-type="doi">10.1073/pnas.87.13.5094</pub-id><?supplied-pmid 2164221?><pub-id pub-id-type="pmid">2164221</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinberg</surname><given-names>DH</given-names></name><name><surname>Trivedi</surname><given-names>P</given-names></name><name><surname>Tan</surname><given-names>CP</given-names></name><name><surname>Mitra</surname><given-names>S</given-names></name><name><surname>Perkins-Barrow</surname><given-names>A</given-names></name><name><surname>Borkowski</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c</article-title><source>Biochem Biophys Res Commun</source><year>1994</year><volume>201</volume><fpage>1296</fpage><lpage>1304</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1994.1845</pub-id><?supplied-pmid 8024574?><pub-id pub-id-type="pmid">8024574</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emorine</surname><given-names>LJ</given-names></name><name><surname>Marullo</surname><given-names>S</given-names></name><name><surname>Briend-Sutren</surname><given-names>MM</given-names></name><name><surname>Patey</surname><given-names>G</given-names></name><name><surname>Tate</surname><given-names>K</given-names></name><name><surname>Delavier-Klutchko</surname><given-names>C</given-names></name><etal/></person-group><article-title>Molecular characterization of the human beta 3-adrenergic receptor</article-title><source>Science</source><year>1989</year><volume>245</volume><fpage>1118</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1126/science.2570461</pub-id><?supplied-pmid 2570461?><pub-id pub-id-type="pmid">2570461</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Matsui</surname><given-names>H</given-names></name><name><surname>Kobilka</surname><given-names>TS</given-names></name><name><surname>Yang-Feng</surname><given-names>TL</given-names></name><name><surname>Francke</surname><given-names>U</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor</article-title><source>Science</source><year>1987</year><volume>238</volume><fpage>650</fpage><lpage>656</lpage><pub-id pub-id-type="doi">10.1126/science.2823383</pub-id><?supplied-pmid 2823383?><pub-id pub-id-type="pmid">2823383</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regan</surname><given-names>JW</given-names></name><name><surname>Kobilka</surname><given-names>TS</given-names></name><name><surname>Yang-Feng</surname><given-names>TL</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name></person-group><article-title>Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic receptor subtype</article-title><source>Proc Natl Acad Sci USA</source><year>1988</year><volume>85</volume><fpage>6301</fpage><lpage>6305</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.17.6301</pub-id><?supplied-pmid 2842764?><pub-id pub-id-type="pmid">2842764</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheinin</surname><given-names>M</given-names></name><name><surname>Lomasney</surname><given-names>JW</given-names></name><name><surname>Hayden-Hixson</surname><given-names>DM</given-names></name><name><surname>Schambra</surname><given-names>UB</given-names></name><name><surname>Caron</surname><given-names>MG</given-names></name><name><surname>Lefkowitz</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain</article-title><source>Brain Res Mol Brain Res</source><year>1994</year><volume>21</volume><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/0169-328X(94)90386-7</pub-id><?supplied-pmid 8164514?><pub-id pub-id-type="pmid">8164514</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talley</surname><given-names>EM</given-names></name><name><surname>Rosin</surname><given-names>DL</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Guyenet</surname><given-names>PG</given-names></name><name><surname>Lynch</surname><given-names>KR</given-names></name></person-group><article-title>Distribution of alpha 2A-adrenergic receptor-like immunoreactivity in the rat central nervous system</article-title><source>J Comp Neurol</source><year>1996</year><volume>372</volume><fpage>111</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9861(19960812)372:1&#x0003c;111::AID-CNE8&#x0003e;3.0.CO;2-6</pub-id><?supplied-pmid 8841924?><pub-id pub-id-type="pmid">8841924</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aoki</surname><given-names>C</given-names></name><name><surname>Venkatesan</surname><given-names>C</given-names></name><name><surname>Go</surname><given-names>CG</given-names></name><name><surname>Forman</surname><given-names>R</given-names></name><name><surname>Kurose</surname><given-names>H</given-names></name></person-group><article-title>Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons</article-title><source>Cereb Cortex</source><year>1998</year><volume>8</volume><fpage>269</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1093/cercor/8.3.269</pub-id><?supplied-pmid 9617922?><pub-id pub-id-type="pmid">9617922</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>BP</given-names></name><name><surname>Paspalas</surname><given-names>CD</given-names></name><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Simen</surname><given-names>A</given-names></name><name><surname>Duque</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex</article-title><source>Cell</source><year>2007</year><volume>129</volume><fpage>397</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.03.015</pub-id><?supplied-pmid 17448997?><pub-id pub-id-type="pmid">17448997</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smiley</surname><given-names>JF</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Ciliax</surname><given-names>BJ</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><article-title>D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines</article-title><source>Proc Natl Acad Sci USA</source><year>1994</year><volume>91</volume><fpage>5720</fpage><lpage>5724</lpage><pub-id pub-id-type="doi">10.1073/pnas.91.12.5720</pub-id><?supplied-pmid 7911245?><pub-id pub-id-type="pmid">7911245</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vijayraghavan</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Birnbaum</surname><given-names>SG</given-names></name><name><surname>Williams</surname><given-names>GV</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory</article-title><source>Nat Neurosci</source><year>2007</year><volume>10</volume><fpage>376</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/nn1846</pub-id><?supplied-pmid 17277774?><pub-id pub-id-type="pmid">17277774</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex</article-title><source>J Pediatr</source><year>2009</year><volume>154</volume><fpage>I-S43</fpage><?supplied-pmid 20596295?><pub-id pub-id-type="pmid">20596295</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Stress signalling pathways that impair prefrontal cortex structure and function</article-title><source>Nat Rev Neurosci</source><year>2009</year><volume>10</volume><fpage>410</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1038/nrn2648</pub-id><?supplied-pmid 19455173?><pub-id pub-id-type="pmid">19455173</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>BP</given-names></name><name><surname>Stark</surname><given-names>D</given-names></name><name><surname>Verduzco</surname><given-names>L</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals</article-title><source>Learn Mem</source><year>2006</year><volume>13</volume><fpage>770</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1101/lm.298006</pub-id><?supplied-pmid 17101879?><pub-id pub-id-type="pmid">17101879</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakala</surname><given-names>P</given-names></name><name><surname>Riekkinen</surname><given-names>M</given-names></name><name><surname>Sirvio</surname><given-names>J</given-names></name><name><surname>Koivisto</surname><given-names>E</given-names></name><name><surname>Kejonen</surname><given-names>K</given-names></name><name><surname>Vanhanen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Guanfacine, but not clonidine, improves planning and working memory performance in humans</article-title><source>Neuropsychopharmacology</source><year>1999</year><volume>20</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(98)00127-4</pub-id><?supplied-pmid 10192826?><pub-id pub-id-type="pmid">10192826</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>D</given-names></name><name><surname>Buhot</surname><given-names>MC</given-names></name><name><surname>Hen</surname><given-names>R</given-names></name><name><surname>Hofer</surname><given-names>M</given-names></name></person-group><article-title>Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice</article-title><source>Behav Neurosci</source><year>1999</year><volume>113</volume><fpage>587</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1037/0735-7044.113.3.587</pub-id><?supplied-pmid 10443785?><pub-id pub-id-type="pmid">10443785</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smoller</surname><given-names>JW</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Arbeitman</surname><given-names>L</given-names></name><name><surname>Doyle</surname><given-names>AE</given-names></name><name><surname>Fagerness</surname><given-names>J</given-names></name><name><surname>Perlis</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD</article-title><source>Biol Psychiatry</source><year>2006</year><volume>59</volume><fpage>460</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2005.07.017</pub-id><?supplied-pmid 16197923?><pub-id pub-id-type="pmid">16197923</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrey</surname><given-names>NJ</given-names></name><name><surname>MacMaster</surname><given-names>FP</given-names></name><name><surname>Gaudet</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>MH</given-names></name></person-group><article-title>Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2007</year><volume>17</volume><fpage>11</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1089/cap.2006.0008</pub-id><?supplied-pmid 17343550?><pub-id pub-id-type="pmid">17343550</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikonomidou</surname><given-names>C</given-names></name><name><surname>Bosch</surname><given-names>F</given-names></name><name><surname>Miksa</surname><given-names>M</given-names></name><name><surname>Bittigau</surname><given-names>P</given-names></name><name><surname>Vockler</surname><given-names>J</given-names></name><name><surname>Dikranian</surname><given-names>K</given-names></name><etal/></person-group><article-title>Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain</article-title><source>Science</source><year>1999</year><volume>283</volume><fpage>70</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.283.5398.70</pub-id><?supplied-pmid 9872743?><pub-id pub-id-type="pmid">9872743</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gambrill</surname><given-names>AC</given-names></name><name><surname>Barria</surname><given-names>A</given-names></name></person-group><article-title>NMDA receptor subunit composition controls synaptogenesis and synapse stabilization</article-title><source>Proc Natl Acad Sci USA</source><year>2011</year><volume>108</volume><fpage>5855</fpage><lpage>5860</lpage><pub-id pub-id-type="doi">10.1073/pnas.1012676108</pub-id><?supplied-pmid 21427228?><pub-id pub-id-type="pmid">21427228</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>EM</given-names></name><name><surname>Pomerleau</surname><given-names>F</given-names></name><name><surname>Huettl</surname><given-names>P</given-names></name><name><surname>Gerhardt</surname><given-names>GA</given-names></name><name><surname>Glaser</surname><given-names>PE</given-names></name></person-group><article-title>Aberrant glutamate signaling in the prefrontal cortex and striatum of the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><fpage>3019</fpage><lpage>3029</lpage><pub-id pub-id-type="doi">10.1007/s00213-014-3479-4</pub-id><?supplied-pmid 24682500?><pub-id pub-id-type="pmid">24682500</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacMaster</surname><given-names>FP</given-names></name><name><surname>Carrey</surname><given-names>N</given-names></name><name><surname>Sparkes</surname><given-names>S</given-names></name><name><surname>Kusumakar</surname><given-names>V</given-names></name></person-group><article-title>Proton spectroscopy in medication-free pediatric attention-deficit/hyperactivity disorder</article-title><source>Biol Psychiatry</source><year>2003</year><volume>53</volume><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/S0006-3223(02)01401-4</pub-id><?supplied-pmid 12547476?><pub-id pub-id-type="pmid">12547476</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrey</surname><given-names>N</given-names></name><name><surname>MacMaster</surname><given-names>FP</given-names></name><name><surname>Fogel</surname><given-names>J</given-names></name><name><surname>Sparkes</surname><given-names>S</given-names></name><name><surname>Waschbusch</surname><given-names>D</given-names></name><name><surname>Sullivan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Metabolite changes resulting from treatment in children with ADHD: a 1H-MRS study</article-title><source>Clin Neuropharmacol</source><year>2003</year><volume>26</volume><fpage>218</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1097/00002826-200307000-00013</pub-id><?supplied-pmid 12897644?><pub-id pub-id-type="pmid">12897644</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiguna</surname><given-names>T</given-names></name><name><surname>Guerrero</surname><given-names>AP</given-names></name><name><surname>Wibisono</surname><given-names>S</given-names></name><name><surname>Sastroasmoro</surname><given-names>S</given-names></name></person-group><article-title>Effect of 12-week administration of 20-mg long-acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school-age children in Indonesia: a study using 1H magnetic resonance spectroscopy (MRS)</article-title><source>Clin Neuropharmacol</source><year>2012</year><volume>35</volume><fpage>81</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1097/WNF.0b013e3182452572</pub-id><?supplied-pmid 22318191?><pub-id pub-id-type="pmid">22318191</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollmann</surname><given-names>S</given-names></name><name><surname>Ghisleni</surname><given-names>C</given-names></name><name><surname>Poil</surname><given-names>SS</given-names></name><name><surname>Martin</surname><given-names>E</given-names></name><name><surname>Ball</surname><given-names>J</given-names></name><name><surname>Eich-Hochli</surname><given-names>D</given-names></name><etal/></person-group><article-title>Developmental changes in gamma-aminobutyric acid levels in attention-deficit/hyperactivity disorder</article-title><source>Transl Psychiatry</source><year>2015</year><volume>5</volume><fpage>e589</fpage><pub-id pub-id-type="doi">10.1038/tp.2015.79</pub-id><?supplied-pmid 26101852?><pub-id pub-id-type="pmid">26101852</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Kaneko</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors</article-title><source>Neurosci Res</source><year>2007</year><volume>57</volume><fpage>306</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.neures.2006.10.020</pub-id><?supplied-pmid 17145090?><pub-id pub-id-type="pmid">17145090</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><mixed-citation publication-type="other">He C, Luo F, Chen X, Chen F, Li C, Ren S, et al. Superficial layer-specific histaminergic modulation of medial entorhinal cortex required for spatial learning. Cereb Cortex. 2015 <bold>(Epub ahead of print)</bold>.</mixed-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>RH</given-names></name><name><surname>Chee</surname><given-names>MJ</given-names></name><name><surname>Kroeger</surname><given-names>D</given-names></name><name><surname>Ferrari</surname><given-names>LL</given-names></name><name><surname>Maratos-Flier</surname><given-names>E</given-names></name><name><surname>Scammell</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Optogenetic-mediated release of histamine reveals distal and autoregulatory mechanisms for controlling arousal</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>6023</fpage><lpage>6029</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4838-13.2014</pub-id><?supplied-pmid 24760861?><pub-id pub-id-type="pmid">24760861</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>GB</given-names></name><name><surname>Pan</surname><given-names>JB</given-names></name><name><surname>Esbenshade</surname><given-names>TA</given-names></name><name><surname>Bennani</surname><given-names>YL</given-names></name><name><surname>Black</surname><given-names>LA</given-names></name><name><surname>Faghih</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup</article-title><source>Behav Brain Res</source><year>2002</year><volume>131</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/S0166-4328(01)00379-5</pub-id><?supplied-pmid 11844582?><pub-id pub-id-type="pmid">11844582</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>WC</given-names></name><name><surname>Bonini</surname><given-names>JS</given-names></name><name><surname>Bevilaqua</surname><given-names>LR</given-names></name><name><surname>Izquierdo</surname><given-names>I</given-names></name><name><surname>Cammarota</surname><given-names>M</given-names></name></person-group><article-title>Histamine enhances inhibitory avoidance memory consolidation through a H2 receptor-dependent mechanism</article-title><source>Neurobiol Learn Mem</source><year>2006</year><volume>86</volume><fpage>100</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2006.01.001</pub-id><?supplied-pmid 16488163?><pub-id pub-id-type="pmid">16488163</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>LL</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lei</surname><given-names>GF</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Wang</surname><given-names>YW</given-names></name><name><surname>Sun</surname><given-names>RP</given-names></name></person-group><article-title>Atomoxetine increases histamine release and improves learning deficits in an animal model of attention-deficit hyperactivity disorder: the spontaneously hypertensive rat</article-title><source>Basic Clin Pharmacol Toxicol</source><year>2008</year><volume>102</volume><fpage>527</fpage><lpage>532</lpage><pub-id pub-id-type="doi">10.1111/j.1742-7843.2008.00230.x</pub-id><?supplied-pmid 18346050?><pub-id pub-id-type="pmid">18346050</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horner</surname><given-names>WE</given-names></name><name><surname>Johnson</surname><given-names>DE</given-names></name><name><surname>Schmidt</surname><given-names>AW</given-names></name><name><surname>Rollema</surname><given-names>H</given-names></name></person-group><article-title>Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex</article-title><source>Eur J Pharmacol</source><year>2007</year><volume>558</volume><fpage>96</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2006.11.048</pub-id><?supplied-pmid 17198700?><pub-id pub-id-type="pmid">17198700</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Froehlich</surname><given-names>TE</given-names></name><name><surname>Anixt</surname><given-names>JS</given-names></name><name><surname>Loe</surname><given-names>IM</given-names></name><name><surname>Chirdkiatgumchai</surname><given-names>V</given-names></name><name><surname>Kuan</surname><given-names>L</given-names></name><name><surname>Gilman</surname><given-names>RC</given-names></name></person-group><article-title>Update on environmental risk factors for attention-deficit/hyperactivity disorder</article-title><source>Curr Psychiatry Rep</source><year>2011</year><volume>13</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1007/s11920-011-0221-3</pub-id><?supplied-pmid 21779823?><pub-id pub-id-type="pmid">21779823</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gizer</surname><given-names>IR</given-names></name><name><surname>Ficks</surname><given-names>C</given-names></name><name><surname>Waldman</surname><given-names>ID</given-names></name></person-group><article-title>Candidate gene studies of ADHD: a meta-analytic review</article-title><source>Hum Genet</source><year>2009</year><volume>126</volume><fpage>51</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1007/s00439-009-0694-x</pub-id><?supplied-pmid 19506906?><pub-id pub-id-type="pmid">19506906</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lesch</surname><given-names>KP</given-names></name><name><surname>Timmesfeld</surname><given-names>N</given-names></name><name><surname>Renner</surname><given-names>TJ</given-names></name><name><surname>Halperin</surname><given-names>R</given-names></name><name><surname>Roser</surname><given-names>C</given-names></name><name><surname>Nguyen</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Molecular genetics of adult ADHD: converging evidence from genome-wide association and extended pedigree linkage studies</article-title><source>J Neural Transm</source><year>2008</year><volume>115</volume><fpage>1573</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1007/s00702-008-0119-3</pub-id><?supplied-pmid 18839057?><pub-id pub-id-type="pmid">18839057</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolas</surname><given-names>M</given-names></name><name><surname>Klump</surname><given-names>KL</given-names></name><name><surname>Burt</surname><given-names>SA</given-names></name></person-group><article-title>Youth appraisals of inter-parental conflict and genetic and environmental contributions to attention-deficit hyperactivity disorder: examination of GxE effects in a twin sample</article-title><source>J Abnorm Child Psychol</source><year>2012</year><volume>40</volume><fpage>543</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1007/s10802-011-9583-6</pub-id><?supplied-pmid 22006350?><pub-id pub-id-type="pmid">22006350</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Jin</surname><given-names>LE</given-names></name></person-group><article-title>Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale</article-title><source>Yale J Biol Med</source><year>2012</year><volume>85</volume><fpage>45</fpage><lpage>58</lpage><?supplied-pmid 22461743?><pub-id pub-id-type="pmid">22461743</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name></person-group><article-title>Alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data</article-title><source>J Child Adolesc Psychopharmacol</source><year>2007</year><volume>17</volume><fpage>393</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1089/cap.2006.0098</pub-id><?supplied-pmid 17822336?><pub-id pub-id-type="pmid">17822336</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>S</given-names></name><name><surname>Porter</surname><given-names>AC</given-names></name><name><surname>Neubig</surname><given-names>RR</given-names></name></person-group><article-title>The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors</article-title><source>J Pharmacol Exp Ther</source><year>1994</year><volume>271</volume><fpage>1558</fpage><lpage>1565</lpage><?supplied-pmid 7996470?><pub-id pub-id-type="pmid">7996470</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernsberger</surname><given-names>P</given-names></name><name><surname>Meeley</surname><given-names>MP</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name><name><surname>Reis</surname><given-names>DJ</given-names></name></person-group><article-title>Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla</article-title><source>Eur J Pharmacol</source><year>1987</year><volume>134</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(87)90125-7</pub-id><?supplied-pmid 3030779?><pub-id pub-id-type="pmid">3030779</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>S</given-names></name><name><surname>Wikberg</surname><given-names>JE</given-names></name></person-group><article-title>Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound</article-title><source>Eur J Pharmacol</source><year>1991</year><volume>202</volume><fpage>235</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(91)90299-6</pub-id><?supplied-pmid 1666366?><pub-id pub-id-type="pmid">1666366</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>S</given-names></name><name><surname>Muceniece</surname><given-names>R</given-names></name><name><surname>Rangel</surname><given-names>N</given-names></name><name><surname>Tiger</surname><given-names>G</given-names></name><name><surname>Wikberg</surname><given-names>JE</given-names></name></person-group><article-title>Comparison of the binding activities of some drugs on alpha 2A, alpha 2B and alpha 2C-adrenoceptors and non-adrenergic imidazoline sites in the guinea pig</article-title><source>Pharmacol Toxicol</source><year>1995</year><volume>76</volume><fpage>353</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0773.1995.tb00161.x</pub-id><?supplied-pmid 7479575?><pub-id pub-id-type="pmid">7479575</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uhlen</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Chhajlani</surname><given-names>V</given-names></name><name><surname>Felder</surname><given-names>CC</given-names></name><name><surname>Wikberg</surname><given-names>JE</given-names></name></person-group><article-title>[3H]-MK 912 binding delineates two alpha 2-adrenoceptor subtypes in rat CNS one of which is identical with the cloned pA2d alpha 2-adrenoceptor</article-title><source>Br J Pharmacol</source><year>1992</year><volume>106</volume><fpage>986</fpage><lpage>995</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1992.tb14446.x</pub-id><?supplied-pmid 1356570?><pub-id pub-id-type="pmid">1356570</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallee</surname><given-names>FR</given-names></name></person-group><article-title>The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder</article-title><source>Postgrad Med</source><year>2010</year><volume>122</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3810/pgm.2010.09.2204</pub-id><?supplied-pmid 20861591?><pub-id pub-id-type="pmid">20861591</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Concordia Pharmaceuticals Inc. Kapvay (clonidine hydrochloride) extended-release tablets. 2014. <ext-link ext-link-type="uri" xlink:href="http://www.kapvay.com/pdf/kapvay-conc-v1-USPI.pdf">http://www.kapvay.com/pdf/kapvay-conc-v1-USPI.pdf</ext-link>. Accessed 28 Jan 2015.</mixed-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawaura</surname><given-names>K</given-names></name><name><surname>Karasawa</surname><given-names>J</given-names></name><name><surname>Chaki</surname><given-names>S</given-names></name><name><surname>Hikichi</surname><given-names>H</given-names></name></person-group><article-title>Stimulation of postsynapse adrenergic alpha2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder</article-title><source>Behav Brain Res</source><year>2014</year><volume>270</volume><fpage>349</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.bbr.2014.05.044</pub-id><?supplied-pmid 24882610?><pub-id pub-id-type="pmid">24882610</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franowicz</surname><given-names>JS</given-names></name><name><surname>Kessler</surname><given-names>LE</given-names></name><name><surname>Borja</surname><given-names>CM</given-names></name><name><surname>Kobilka</surname><given-names>BK</given-names></name><name><surname>Limbird</surname><given-names>LE</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine</article-title><source>J Neurosci</source><year>2002</year><volume>22</volume><fpage>8771</fpage><lpage>8777</lpage><?supplied-pmid 12351753?><pub-id pub-id-type="pmid">12351753</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rama</surname><given-names>P</given-names></name><name><surname>Linnankoski</surname><given-names>I</given-names></name><name><surname>Tanila</surname><given-names>H</given-names></name><name><surname>Pertovaara</surname><given-names>A</given-names></name><name><surname>Carlson</surname><given-names>S</given-names></name></person-group><article-title>Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys</article-title><source>Pharmacol Biochem Behav</source><year>1996</year><volume>55</volume><fpage>415</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(96)00111-6</pub-id><?supplied-pmid 8951983?><pub-id pub-id-type="pmid">8951983</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avery</surname><given-names>RA</given-names></name><name><surname>Franowicz</surname><given-names>JS</given-names></name><name><surname>Studholme</surname><given-names>C</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task</article-title><source>Neuropsychopharmacology</source><year>2000</year><volume>23</volume><fpage>240</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(00)00111-1</pub-id><?supplied-pmid 10942848?><pub-id pub-id-type="pmid">10942848</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decamp</surname><given-names>E</given-names></name><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Schneider</surname><given-names>JS</given-names></name></person-group><article-title>Effects of the alpha-2 adrenoceptor agonist guanfacine on attention and working memory in aged non-human primates</article-title><source>Eur J Neurosci</source><year>2011</year><volume>34</volume><fpage>1018</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9568.2011.07815.x</pub-id><?supplied-pmid 21883531?><pub-id pub-id-type="pmid">21883531</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>ZX</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys</article-title><source>Brain Res</source><year>2004</year><volume>1024</volume><fpage>176</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2004.07.062</pub-id><?supplied-pmid 15451380?><pub-id pub-id-type="pmid">15451380</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>XC</given-names></name><name><surname>Ma</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>The alpha(2A)-adrenoceptor agonist guanfacine improves spatial learning but not fear conditioning in rats</article-title><source>Sheng Li Xue Bao</source><year>2007</year><volume>59</volume><fpage>739</fpage><lpage>744</lpage><?supplied-pmid 18157465?><pub-id pub-id-type="pmid">18157465</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagvolden</surname><given-names>T</given-names></name></person-group><article-title>The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD)</article-title><source>Behav Brain Funct</source><year>2006</year><volume>2</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/1744-9081-2-41</pub-id><?supplied-pmid 17173664?><pub-id pub-id-type="pmid">17173664</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Cai</surname><given-names>JX</given-names></name><name><surname>Goldman-Rakic</surname><given-names>PS</given-names></name></person-group><article-title>The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes</article-title><source>J Neurosci</source><year>1988</year><volume>8</volume><fpage>4287</fpage><lpage>4298</lpage><?supplied-pmid 2903226?><pub-id pub-id-type="pmid">2903226</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hains</surname><given-names>AB</given-names></name><name><surname>Yabe</surname><given-names>Y</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Chronic stimulation of alpha-2A-adrenoceptors with guanfacine protects rodent prefrontal cortex dendritic spines and cognition from the effects of chronic stress</article-title><source>Neurobiol Stress</source><year>2015</year><volume>2</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ynstr.2015.01.001</pub-id><?supplied-pmid 25664335?><pub-id pub-id-type="pmid">25664335</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>AB</given-names></name><name><surname>Economidou</surname><given-names>D</given-names></name><name><surname>Theobald</surname><given-names>DE</given-names></name><name><surname>Zou</surname><given-names>MF</given-names></name><name><surname>Newman</surname><given-names>AH</given-names></name><name><surname>Spoelder</surname><given-names>M</given-names></name><etal/></person-group><article-title>Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists</article-title><source>Psychopharmacology</source><year>2012</year><volume>219</volume><fpage>341</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2408-z</pub-id><?supplied-pmid 21761147?><pub-id pub-id-type="pmid">21761147</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abela</surname><given-names>AR</given-names></name><name><surname>Chudasama</surname><given-names>Y</given-names></name></person-group><article-title>Noradrenergic alpha-receptor stimulation in the ventral hippocampus reduces impulsive decision-making</article-title><source>Psychopharmacology</source><year>2014</year><volume>231</volume><fpage>521</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1007/s00213-013-3262-y</pub-id><?supplied-pmid 24062084?><pub-id pub-id-type="pmid">24062084</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>ZT</given-names></name><name><surname>Rice</surname><given-names>KA</given-names></name><name><surname>Soto</surname><given-names>PL</given-names></name><name><surname>Pate</surname><given-names>KA</given-names></name><name><surname>Weed</surname><given-names>MR</given-names></name><name><surname>Ator</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior</article-title><source>Transl Psychiatry.</source><year>2015</year><volume>5</volume><fpage>e567</fpage><pub-id pub-id-type="doi">10.1038/tp.2015.61</pub-id><?supplied-pmid 25989141?><pub-id pub-id-type="pmid">25989141</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KP</given-names></name><name><surname>Clerkin</surname><given-names>SM</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Halperin</surname><given-names>JM</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name></person-group><article-title>Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control</article-title><source>Psychopharmacology</source><year>2013</year><volume>226</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s00213-012-2893-8</pub-id><?supplied-pmid 23086020?><pub-id pub-id-type="pmid">23086020</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KP</given-names></name><name><surname>Clerkin</surname><given-names>SM</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Halperin</surname><given-names>JM</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>Guanfacine modulates the emotional biasing of amygdala-prefrontal connectivity for cognitive control</article-title><source>Eur Neuropsychopharmacol</source><year>2014</year><volume>24</volume><fpage>1444</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.06.016</pub-id><?supplied-pmid 25059532?><pub-id pub-id-type="pmid">25059532</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><mixed-citation publication-type="other">Bedard AC, Schulz KP, Krone B, Pedraza J, Duhoux S, Halperin JM, et al. Neural mechanisms underlying the therapeutic actions of guanfacine treatment in youth with ADHD: a pilot fMRI study. Psychiatry Res. 2015;231:353&#x02013;6.</mixed-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Easton</surname><given-names>N</given-names></name><name><surname>Shah</surname><given-names>YB</given-names></name><name><surname>Marshall</surname><given-names>FH</given-names></name><name><surname>Fone</surname><given-names>KC</given-names></name><name><surname>Marsden</surname><given-names>CA</given-names></name></person-group><article-title>Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast</article-title><source>Psychopharmacology</source><year>2006</year><volume>189</volume><fpage>369</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0558-1</pub-id><?supplied-pmid 17016709?><pub-id pub-id-type="pmid">17016709</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>SS</given-names></name><name><surname>Luo</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>Signaling mechanism underlying alpha -adrenergic suppression of excitatory synaptic transmission in the medial prefrontal cortex of rats</article-title><source>Eur J Neurosci</source><year>2013</year><volume>38</volume><fpage>2364</fpage><lpage>2373</lpage><pub-id pub-id-type="doi">10.1111/ejn.12257</pub-id><?supplied-pmid 23701442?><pub-id pub-id-type="pmid">23701442</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>XH</given-names></name><name><surname>Ji</surname><given-names>JZ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>Stimulation of alpha2-adrenoceptors suppresses excitatory synaptic transmission in the medial prefrontal cortex of rat</article-title><source>Neuropsychopharmacology</source><year>2008</year><volume>33</volume><fpage>2263</fpage><lpage>2271</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301603</pub-id><?supplied-pmid 17957212?><pub-id pub-id-type="pmid">17957212</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calabrese</surname><given-names>B</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name><name><surname>Halpain</surname><given-names>S</given-names></name></person-group><article-title>Development and regulation of dendritic spine synapses</article-title><source>Physiology (Bethesda)</source><year>2006</year><volume>21</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1152/physiol.00042.2005</pub-id><pub-id pub-id-type="pmid">16443821</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasai</surname><given-names>H</given-names></name><name><surname>Matsuzaki</surname><given-names>M</given-names></name><name><surname>Noguchi</surname><given-names>J</given-names></name><name><surname>Yasumatsu</surname><given-names>N</given-names></name><name><surname>Nakahara</surname><given-names>H</given-names></name></person-group><article-title>Structure-stability-function relationships of dendritic spines</article-title><source>Trends Neurosci</source><year>2003</year><volume>26</volume><fpage>360</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/S0166-2236(03)00162-0</pub-id><?supplied-pmid 12850432?><pub-id pub-id-type="pmid">12850432</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Vidovic</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>MM</given-names></name><name><surname>Lu</surname><given-names>QY</given-names></name><name><surname>Song</surname><given-names>ZM</given-names></name></person-group><article-title>Activation of alpha 2A adrenoceptors alters dendritic spine development and the expression of spinophilin in cultured cortical neurones</article-title><source>Brain Res</source><year>2008</year><volume>1199</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2007.12.073</pub-id><?supplied-pmid 18262173?><pub-id pub-id-type="pmid">18262173</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>ZM</given-names></name><name><surname>Abou-Zeid</surname><given-names>O</given-names></name><name><surname>Fang</surname><given-names>YY</given-names></name></person-group><article-title>Alpha2a adrenoceptors regulate phosphorylation of microtubule-associated protein-2 in cultured cortical neurons</article-title><source>Neuroscience</source><year>2004</year><volume>123</volume><fpage>405</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2003.09.018</pub-id><?supplied-pmid 14698748?><pub-id pub-id-type="pmid">14698748</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>WW</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>BM</given-names></name></person-group><article-title>Stimulation of &#x003b1;2A-adrenoceptors promotes the maturation of dendritic spines in cultured neurons of the medial prefrontal cortex</article-title><source>Mol Cell Neurosci</source><year>2012</year><volume>49</volume><fpage>205</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2011.10.001</pub-id><?supplied-pmid 22015717?><pub-id pub-id-type="pmid">22015717</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber</surname><given-names>ND</given-names></name><name><surname>Reid</surname><given-names>JL</given-names></name></person-group><article-title>Comparison of the actions of centrally and peripherally administered clonidine and guanfacine in the rabbit: investigation of the differences</article-title><source>Br J Pharmacol</source><year>1982</year><volume>77</volume><fpage>641</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.1982.tb09342.x</pub-id><?supplied-pmid 6758908?><pub-id pub-id-type="pmid">6758908</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sorkin</surname><given-names>EM</given-names></name><name><surname>Heel</surname><given-names>RC</given-names></name></person-group><article-title>Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension</article-title><source>Drugs.</source><year>1986</year><volume>31</volume><fpage>301</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.2165/00003495-198631040-00003</pub-id><?supplied-pmid 3519177?><pub-id pub-id-type="pmid">3519177</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Zwieten</surname><given-names>PA</given-names></name><name><surname>Chalmers</surname><given-names>JP</given-names></name></person-group><article-title>Different types of centrally acting antihypertensives and their targets in the central nervous system</article-title><source>Cardiovasc Drugs Ther</source><year>1994</year><volume>8</volume><fpage>787</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1007/BF00877397</pub-id><?supplied-pmid 7742257?><pub-id pub-id-type="pmid">7742257</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldstein</surname><given-names>CA</given-names></name><name><surname>Cohen</surname><given-names>AA</given-names></name><name><surname>Sabaris</surname><given-names>RP</given-names></name><name><surname>Burucua</surname><given-names>JE</given-names></name></person-group><article-title>Hemodynamic effects of guanfacine in essential hypertension</article-title><source>Clin Ther</source><year>1984</year><volume>6</volume><fpage>325</fpage><lpage>334</lpage><?supplied-pmid 6373009?><pub-id pub-id-type="pmid">6373009</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saameli</surname><given-names>K</given-names></name><name><surname>Jerie</surname><given-names>P</given-names></name><name><surname>Scholtysik</surname><given-names>G</given-names></name></person-group><article-title>Guanfacine and other centrally acting drugs in antihypertensive therapy; pharmacological and clinical aspects</article-title><source>Clin Exp Hypertens A.</source><year>1982</year><volume>4</volume><fpage>209</fpage><lpage>219</lpage><?supplied-pmid 6280899?><pub-id pub-id-type="pmid">6280899</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kugler</surname><given-names>J</given-names></name><name><surname>Seus</surname><given-names>R</given-names></name><name><surname>Krauskopf</surname><given-names>R</given-names></name><name><surname>Brecht</surname><given-names>HM</given-names></name><name><surname>Raschig</surname><given-names>A</given-names></name></person-group><article-title>Differences in psychic performance with guanfacine and clonidine in normotensive subjects</article-title><source>Br J Clin Pharmacol</source><year>1980</year><volume>10</volume><issue>Suppl 1</issue><fpage>71S</fpage><lpage>80S</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1980.tb04909.x</pub-id><?supplied-pmid 6994783?><pub-id pub-id-type="pmid">6994783</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirota</surname><given-names>T</given-names></name><name><surname>Schwartz</surname><given-names>S</given-names></name><name><surname>Correll</surname><given-names>CU</given-names></name></person-group><article-title>Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2014</year><volume>53</volume><fpage>153</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2013.11.009</pub-id><?supplied-pmid 24472251?><pub-id pub-id-type="pmid">24472251</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swearingen</surname><given-names>D</given-names></name><name><surname>Pennick</surname><given-names>M</given-names></name><name><surname>Shojaei</surname><given-names>A</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Fiske</surname><given-names>K</given-names></name></person-group><article-title>A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults</article-title><source>Clin Ther</source><year>2007</year><volume>29</volume><fpage>617</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2007.04.016</pub-id><?supplied-pmid 17617285?><pub-id pub-id-type="pmid">17617285</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boellner</surname><given-names>SW</given-names></name><name><surname>Pennick</surname><given-names>M</given-names></name><name><surname>Fiske</surname><given-names>K</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Shojaei</surname><given-names>A</given-names></name></person-group><article-title>Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder</article-title><source>Pharmacotherapy</source><year>2007</year><volume>27</volume><fpage>1253</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1592/phco.27.9.1253</pub-id><?supplied-pmid 17723079?><pub-id pub-id-type="pmid">17723079</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seneca</surname><given-names>N</given-names></name><name><surname>Gulyas</surname><given-names>B</given-names></name><name><surname>Varrone</surname><given-names>A</given-names></name><name><surname>Schou</surname><given-names>M</given-names></name><name><surname>Airaksinen</surname><given-names>A</given-names></name><name><surname>Tauscher</surname><given-names>J</given-names></name><etal/></person-group><article-title>Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S, S)-[18F]FMeNER-D2</article-title><source>Psychopharmacology</source><year>2006</year><volume>188</volume><fpage>119</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1007/s00213-006-0483-3</pub-id><?supplied-pmid 16896954?><pub-id pub-id-type="pmid">16896954</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carboni</surname><given-names>E</given-names></name><name><surname>Silvagni</surname><given-names>A</given-names></name></person-group><article-title>Experimental investigations on dopamine transmission can provide clues on the mechanism of the therapeutic effect of amphetamine and methylphenidate in ADHD</article-title><source>Neural Plast</source><year>2004</year><volume>11</volume><fpage>77</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1155/NP.2004.77</pub-id><?supplied-pmid 15303307?><pub-id pub-id-type="pmid">15303307</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Ding</surname><given-names>YS</given-names></name><name><surname>Fowler</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Logan</surname><given-names>J</given-names></name><name><surname>Gatley</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain</article-title><source>Arch Gen Psychiatry</source><year>1995</year><volume>52</volume><fpage>456</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1995.03950180042006</pub-id><?supplied-pmid 7771915?><pub-id pub-id-type="pmid">7771915</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>JM</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD</article-title><source>Behav Brain Res</source><year>2002</year><volume>130</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/S0166-4328(01)00433-8</pub-id><?supplied-pmid 11864720?><pub-id pub-id-type="pmid">11864720</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanson</surname><given-names>JM</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name></person-group><article-title>Serum and brain concentrations of methylphenidate: implications for use and abuse</article-title><source>Neurosci Biobehav Rev</source><year>2003</year><volume>27</volume><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2003.08.013</pub-id><?supplied-pmid 14624806?><pub-id pub-id-type="pmid">14624806</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilens</surname><given-names>TE</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name></person-group><article-title>The stimulants revisited</article-title><source>Child Adolesc Psychiatr Clin N Am.</source><year>2000</year><volume>9</volume><fpage>573</fpage><lpage>603</lpage><?supplied-pmid 10944658?><pub-id pub-id-type="pmid">10944658</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannestad</surname><given-names>J</given-names></name><name><surname>Gallezot</surname><given-names>JD</given-names></name><name><surname>Planeta-Wilson</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>SF</given-names></name><name><surname>Williams</surname><given-names>WA</given-names></name><name><surname>van Dyck</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo</article-title><source>Biol Psychiatry</source><year>2010</year><volume>68</volume><fpage>854</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2010.06.017</pub-id><?supplied-pmid 20691429?><pub-id pub-id-type="pmid">20691429</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Teylan</surname><given-names>MA</given-names></name><name><surname>Baron</surname><given-names>M</given-names></name><name><surname>Sands</surname><given-names>A</given-names></name><name><surname>Nairn</surname><given-names>AC</given-names></name><name><surname>Greengard</surname><given-names>P</given-names></name></person-group><article-title>Methylphenidate-induced dendritic spine formation and DeltaFosB expression in nucleus accumbens</article-title><source>Proc Natl Acad Sci USA</source><year>2009</year><volume>106</volume><fpage>2915</fpage><lpage>2920</lpage><pub-id pub-id-type="doi">10.1073/pnas.0813179106</pub-id><?supplied-pmid 19202072?><pub-id pub-id-type="pmid">19202072</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaliere</surname><given-names>C</given-names></name><name><surname>Cirillo</surname><given-names>G</given-names></name><name><surname>Bianco</surname><given-names>MR</given-names></name><name><surname>Adriani</surname><given-names>W</given-names></name><name><surname>De Simone</surname><given-names>A</given-names></name><name><surname>Leo</surname><given-names>D</given-names></name><etal/></person-group><article-title>Methylphenidate administration determines enduring changes in neuroglial network in rats</article-title><source>Eur Neuropsychopharmacol</source><year>2012</year><volume>22</volume><fpage>53</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2011.04.003</pub-id><?supplied-pmid 21550213?><pub-id pub-id-type="pmid">21550213</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adriani</surname><given-names>W</given-names></name><name><surname>Leo</surname><given-names>D</given-names></name><name><surname>Greco</surname><given-names>D</given-names></name><name><surname>Rea</surname><given-names>M</given-names></name><name><surname>di Porzio</surname><given-names>U</given-names></name><name><surname>Laviola</surname><given-names>G</given-names></name><etal/></person-group><article-title>Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>1946</fpage><lpage>1956</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300962</pub-id><?supplied-pmid 16319916?><pub-id pub-id-type="pmid">16319916</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>JA</given-names></name><name><surname>Chapin</surname><given-names>DS</given-names></name><name><surname>Moore</surname><given-names>KE</given-names></name></person-group><article-title>Differential effects of d-amphetamine, beta-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerebroventricular perfusates of rats</article-title><source>Life Sci</source><year>1983</year><volume>33</volume><fpage>1899</fpage><lpage>1907</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(83)90674-4</pub-id><?supplied-pmid 6645784?><pub-id pub-id-type="pmid">6645784</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guix</surname><given-names>T</given-names></name><name><surname>Hurd</surname><given-names>YL</given-names></name><name><surname>Ungerstedt</surname><given-names>U</given-names></name></person-group><article-title>Amphetamine enhances extracellular concentrations of dopamine and acetylcholine in dorsolateral striatum and nucleus accumbens of freely moving rats</article-title><source>Neurosci Lett</source><year>1992</year><volume>138</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/0304-3940(92)90490-X</pub-id><?supplied-pmid 1407652?><pub-id pub-id-type="pmid">1407652</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heal</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>SL</given-names></name><name><surname>Gosden</surname><given-names>J</given-names></name><name><surname>Nutt</surname><given-names>DJ</given-names></name></person-group><article-title>Amphetamine, past and present&#x02014;a pharmacological and clinical perspective</article-title><source>J Psychopharmacol</source><year>2013</year><volume>27</volume><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1177/0269881113482532</pub-id><?supplied-pmid 23539642?><pub-id pub-id-type="pmid">23539642</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mantle</surname><given-names>TJ</given-names></name><name><surname>Tipton</surname><given-names>KF</given-names></name><name><surname>Garrett</surname><given-names>NJ</given-names></name></person-group><article-title>Inhibition of monoamine oxidase by amphetamine and related compounds</article-title><source>Biochem Pharmacol</source><year>1976</year><volume>25</volume><fpage>2073</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(76)90432-9</pub-id><?supplied-pmid 985546?><pub-id pub-id-type="pmid">985546</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bymaster</surname><given-names>FP</given-names></name><name><surname>Katner</surname><given-names>JS</given-names></name><name><surname>Nelson</surname><given-names>DL</given-names></name><name><surname>Hemrick-Luecke</surname><given-names>SK</given-names></name><name><surname>Threlkeld</surname><given-names>PG</given-names></name><name><surname>Heiligenstein</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder</article-title><source>Neuropsychopharmacology</source><year>2002</year><volume>27</volume><fpage>699</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(02)00346-9</pub-id><?supplied-pmid 12431845?><pub-id pub-id-type="pmid">12431845</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludolph</surname><given-names>AG</given-names></name><name><surname>Udvardi</surname><given-names>PT</given-names></name><name><surname>Schaz</surname><given-names>U</given-names></name><name><surname>Henes</surname><given-names>C</given-names></name><name><surname>Adolph</surname><given-names>O</given-names></name><name><surname>Weigt</surname><given-names>HU</given-names></name><etal/></person-group><article-title>Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations</article-title><source>Br J Pharmacol</source><year>2010</year><volume>160</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00707.x</pub-id><?supplied-pmid 20423340?><pub-id pub-id-type="pmid">20423340</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udvardi</surname><given-names>PT</given-names></name><name><surname>Fohr</surname><given-names>KJ</given-names></name><name><surname>Henes</surname><given-names>C</given-names></name><name><surname>Liebau</surname><given-names>S</given-names></name><name><surname>Dreyhaupt</surname><given-names>J</given-names></name><name><surname>Boeckers</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain&#x02014;an in vivo study</article-title><source>Drug Des Devel Ther</source><year>2013</year><volume>7</volume><fpage>1433</fpage><lpage>1446</lpage><?supplied-pmid 24348020?><pub-id pub-id-type="pmid">24348020</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><mixed-citation publication-type="other">Buitelaar J, Asherson P, Soutullo C, Colla M, Adams DH, Tanaka Y, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2015.</mixed-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamo</surname><given-names>NJ</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2010</year><volume>49</volume><fpage>1011</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2010.06.015</pub-id><?supplied-pmid 20855046?><pub-id pub-id-type="pmid">20855046</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Dudley</surname><given-names>AG</given-names></name></person-group><article-title>Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder</article-title><source>Behav Brain Funct</source><year>2005</year><volume>1</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1744-9081-1-2</pub-id><?supplied-pmid 15916700?><pub-id pub-id-type="pmid">15916700</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>GD</given-names></name><name><surname>Lavin</surname><given-names>A</given-names></name></person-group><article-title>Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>594</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300818</pub-id><?supplied-pmid 15999146?><pub-id pub-id-type="pmid">15999146</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marquand</surname><given-names>AF</given-names></name><name><surname>O&#x02019;Daly</surname><given-names>OG</given-names></name><name><surname>De Simoni</surname><given-names>S</given-names></name><name><surname>Alsop</surname><given-names>DC</given-names></name><name><surname>Maguire</surname><given-names>RP</given-names></name><name><surname>Williams</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: a multi-class pattern recognition approach</article-title><source>Neuroimage</source><year>2012</year><volume>60</volume><fpage>1015</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.058</pub-id><?supplied-pmid 22266414?><pub-id pub-id-type="pmid">22266414</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KP</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Bedard</surname><given-names>AC</given-names></name><name><surname>Clerkin</surname><given-names>SM</given-names></name><name><surname>Ivanov</surname><given-names>I</given-names></name><name><surname>Tang</surname><given-names>CY</given-names></name><etal/></person-group><article-title>Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder</article-title><source>Arch Gen Psychiatry</source><year>2012</year><volume>69</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2011.2053</pub-id><?supplied-pmid 22945622?><pub-id pub-id-type="pmid">22945622</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbaresi</surname><given-names>WJ</given-names></name><name><surname>Katusic</surname><given-names>SK</given-names></name><name><surname>Colligan</surname><given-names>RC</given-names></name><name><surname>Weaver</surname><given-names>AL</given-names></name><name><surname>Leibson</surname><given-names>CL</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name></person-group><article-title>Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study</article-title><source>J Dev Behav Pediatr</source><year>2006</year><volume>27</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1097/00004703-200602000-00001</pub-id><?supplied-pmid 16511362?><pub-id pub-id-type="pmid">16511362</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Harding</surname><given-names>M</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>D</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Wilens</surname><given-names>TE</given-names></name></person-group><article-title>Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays?</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1996</year><volume>35</volume><fpage>1460</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1097/00004583-199611000-00014</pub-id><?supplied-pmid 8936912?><pub-id pub-id-type="pmid">8936912</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barkley</surname><given-names>RA</given-names></name><name><surname>McMurray</surname><given-names>MB</given-names></name><name><surname>Edelbrock</surname><given-names>CS</given-names></name><name><surname>Robbins</surname><given-names>K</given-names></name></person-group><article-title>Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation</article-title><source>Pediatrics</source><year>1990</year><volume>86</volume><fpage>184</fpage><lpage>192</lpage><?supplied-pmid 2196520?><pub-id pub-id-type="pmid">2196520</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonuga-Barke</surname><given-names>EJ</given-names></name><name><surname>Coghill</surname><given-names>D</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>DeBacker</surname><given-names>M</given-names></name><name><surname>Swanson</surname><given-names>J</given-names></name></person-group><article-title>Adverse reactions to methylphenidate treatment for attention-deficit/hyperactivity disorder: structure and associations with clinical characteristics and symptom control</article-title><source>J Child Adolesc Psychopharmacol</source><year>2009</year><volume>19</volume><fpage>683</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1089/cap.2009.0024</pub-id><?supplied-pmid 20035586?><pub-id pub-id-type="pmid">20035586</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maldonado</surname><given-names>R</given-names></name></person-group><article-title>Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2013</year><volume>9</volume><fpage>1001</fpage><lpage>1014</lpage><pub-id pub-id-type="doi">10.1517/17425255.2013.786041</pub-id><?supplied-pmid 23611637?><pub-id pub-id-type="pmid">23611637</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>KR</given-names></name><name><surname>Waterhouse</surname><given-names>BD</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name></person-group><article-title>Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons</article-title><source>Biol Psychiatry</source><year>2012</year><volume>72</volume><fpage>880</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.04.018</pub-id><?supplied-pmid 22609367?><pub-id pub-id-type="pmid">22609367</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>KR</given-names></name><name><surname>Li</surname><given-names>YC</given-names></name><name><surname>Gao</surname><given-names>WJ</given-names></name></person-group><article-title>Treatment with a clinically-relevant dose of methylphenidate alters NMDA receptor composition and synaptic plasticity in the juvenile rat prefrontal cortex</article-title><source>Neurobiol Learn Mem</source><year>2013</year><volume>101</volume><fpage>65</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.nlm.2013.01.004</pub-id><?supplied-pmid 23333502?><pub-id pub-id-type="pmid">23333502</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>GJ</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>Kollins</surname><given-names>SH</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Telang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e63023</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0063023</pub-id><?supplied-pmid 23696790?><pub-id pub-id-type="pmid">23696790</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bukstein</surname><given-names>OG</given-names></name><name><surname>Head</surname><given-names>J</given-names></name></person-group><article-title>Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder</article-title><source>Expert Opin Pharmacother</source><year>2012</year><volume>13</volume><fpage>2207</fpage><lpage>2213</lpage><pub-id pub-id-type="doi">10.1517/14656566.2012.721778</pub-id><?supplied-pmid 22957772?><pub-id pub-id-type="pmid">22957772</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>McBurnett</surname><given-names>K</given-names></name><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>Steeber</surname><given-names>J</given-names></name><name><surname>Lopez</surname><given-names>FA</given-names></name></person-group><article-title>Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents</article-title><source>Clin Ther</source><year>2013</year><volume>35</volume><fpage>1778</fpage><lpage>1793</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2013.09.005</pub-id><?supplied-pmid 24139092?><pub-id pub-id-type="pmid">24139092</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Melmed</surname><given-names>RD</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>McBurnett</surname><given-names>K</given-names></name><name><surname>Donahue</surname><given-names>J</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name></person-group><article-title>Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD</article-title><source>CNS Spectr</source><year>2008</year><volume>13</volume><fpage>1047</fpage><lpage>1055</lpage><?supplied-pmid 19179940?><pub-id pub-id-type="pmid">19179940</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Melmed</surname><given-names>RD</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>McBurnett</surname><given-names>K</given-names></name><name><surname>Konow</surname><given-names>J</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>Pediatrics</source><year>2008</year><volume>121</volume><fpage>e73</fpage><lpage>e84</lpage><pub-id pub-id-type="doi">10.1542/peds.2006-3695</pub-id><?supplied-pmid 18166547?><pub-id pub-id-type="pmid">18166547</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>DF</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Kollins</surname><given-names>SH</given-names></name><name><surname>Sallee</surname><given-names>F</given-names></name><name><surname>Lopez</surname><given-names>FA</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of guanfacine extended release on oppositional symptoms in children aged 6&#x02013;12&#x000a0;years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial</article-title><source>CNS Drugs</source><year>2010</year><volume>24</volume><fpage>755</fpage><lpage>768</lpage><?supplied-pmid 20806988?><pub-id pub-id-type="pmid">20806988</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>McGough</surname><given-names>JJ</given-names></name></person-group><article-title>Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2009</year><volume>19</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1089/cap.2008.0080</pub-id><?supplied-pmid 19519256?><pub-id pub-id-type="pmid">19519256</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallee</surname><given-names>FR</given-names></name><name><surname>McGough</surname><given-names>J</given-names></name><name><surname>Wigal</surname><given-names>T</given-names></name><name><surname>Donahue</surname><given-names>J</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name></person-group><article-title>Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2009</year><volume>48</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1097/CHI.0b013e318191769e</pub-id><?supplied-pmid 19106767?><pub-id pub-id-type="pmid">19106767</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hervas</surname><given-names>A</given-names></name><name><surname>Huss</surname><given-names>M</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>McNicholas</surname><given-names>F</given-names></name><name><surname>van Stralen</surname><given-names>J</given-names></name><name><surname>Sreckovic</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, Phase III trial</article-title><source>Eur Neuropsychopharmacol</source><year>2014</year><volume>24</volume><fpage>1861</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.09.014</pub-id><?supplied-pmid 25453486?><pub-id pub-id-type="pmid">25453486</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilens</surname><given-names>TE</given-names></name><name><surname>Bukstein</surname><given-names>O</given-names></name><name><surname>Brams</surname><given-names>M</given-names></name><name><surname>Cutler</surname><given-names>AJ</given-names></name><name><surname>Childress</surname><given-names>A</given-names></name><name><surname>Rugino</surname><given-names>T</given-names></name><etal/></person-group><article-title>A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2012</year><volume>51</volume><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2011.10.012</pub-id><?supplied-pmid 22176941?><pub-id pub-id-type="pmid">22176941</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Stein</surname><given-names>MA</given-names></name><name><surname>Childress</surname><given-names>AC</given-names></name><name><surname>Youcha</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Enright</surname><given-names>G</given-names></name><etal/></person-group><article-title>Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2013</year><volume>52</volume><fpage>921</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1016/j.jaac.2013.06.006</pub-id><?supplied-pmid 23972694?><pub-id pub-id-type="pmid">23972694</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><mixed-citation publication-type="other">Wilens TE, McBurnett K, Turnbow J, Rugino T, White C, Youcha S. Morning and evening effects of guanfacine extended release adjunctive to psychostimulants in pediatric ADHD: results from a Phase III multicenter trial. J Atten Disord. 2013 <bold>(Epub ahead of print)</bold>.</mixed-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikirica</surname><given-names>V</given-names></name><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>Signorovitch</surname><given-names>J</given-names></name><name><surname>Erder</surname><given-names>MH</given-names></name><name><surname>Dammerman</surname><given-names>R</given-names></name><name><surname>Hodgkins</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology</article-title><source>CNS Drugs</source><year>2013</year><volume>27</volume><fpage>943</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1007/s40263-013-0102-x</pub-id><?supplied-pmid 23975660?><pub-id pub-id-type="pmid">23975660</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>S</given-names></name><name><surname>Clavenna</surname><given-names>A</given-names></name><name><surname>Reale</surname><given-names>L</given-names></name><name><surname>Capuano</surname><given-names>A</given-names></name><name><surname>Rossi</surname><given-names>F</given-names></name><name><surname>Bonati</surname><given-names>M</given-names></name></person-group><article-title>Guanfacine for attention deficit and hyperactivity disorder in pediatrics: a systematic review and meta-analysis</article-title><source>Eur Neuropsychopharmacol</source><year>2014</year><volume>24</volume><fpage>1578</fpage><lpage>1590</lpage><pub-id pub-id-type="doi">10.1016/j.euroneuro.2014.08.001</pub-id><?supplied-pmid 25156577?><pub-id pub-id-type="pmid">25156577</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Satin</surname><given-names>L</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Corcoran</surname><given-names>M</given-names></name><name><surname>Purkayastha</surname><given-names>J</given-names></name><etal/></person-group><article-title>A thorough QT study of guanfacine</article-title><source>Int J Clin Pharmacol Ther</source><year>2015</year><volume>53</volume><fpage>301</fpage><lpage>316</lpage><?supplied-pmid 25109412?><pub-id pub-id-type="pmid">25109412</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fossa</surname><given-names>AA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Purkayastha</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name></person-group><article-title>Use of ECG restitution (beat-to-beat QT-TQ interval analysis) to assess arrhythmogenic risk of QTc prolongation with guanfacine</article-title><source>Ann Noninvasive Electrocardiol</source><year>2014</year><volume>19</volume><fpage>582</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1111/anec.12202</pub-id><?supplied-pmid 25200912?><pub-id pub-id-type="pmid">25200912</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangs</surname><given-names>ME</given-names></name><name><surname>Tauscher-Wisniewski</surname><given-names>S</given-names></name><name><surname>Polzer</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Acharya</surname><given-names>N</given-names></name><name><surname>Desaiah</surname><given-names>D</given-names></name><etal/></person-group><article-title>Meta-analysis of suicide-related behavior events in patients treated with atomoxetine</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2008</year><volume>47</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1097/chi.0b013e31815d88b2</pub-id><?supplied-pmid 18176331?><pub-id pub-id-type="pmid">18176331</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><mixed-citation publication-type="other">Eli Lilly and Co. Strattera PI. 2014. <ext-link ext-link-type="uri" xlink:href="http://pi.lilly.com/us/strattera-pi.pdf">http://pi.lilly.com/us/strattera-pi.pdf</ext-link>. Accessed 13 Nov 2014.</mixed-citation></ref><ref id="CR187"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Greenbaum</surname><given-names>M</given-names></name><name><surname>Ginsberg</surname><given-names>LD</given-names></name><name><surname>Murphy</surname><given-names>WR</given-names></name></person-group><article-title>Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2009</year><volume>19</volume><fpage>501</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1089/cap.2008.0152</pub-id><?supplied-pmid 19877974?><pub-id pub-id-type="pmid">19877974</pub-id></element-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huss</surname><given-names>M</given-names></name><name><surname>Hervas</surname><given-names>A</given-names></name><name><surname>Newcorn</surname><given-names>J</given-names></name><name><surname>Harpin</surname><given-names>V</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Robertson</surname><given-names>B</given-names></name><etal/></person-group><article-title>Guanfacine extended release for attention-deficit/hyperactivity disorder following inadequate response to prior methylphenidate (P.7.d.013)</article-title><source>Eur Neuropsychopharmacol</source><year>2014</year><volume>24</volume><fpage>S727</fpage><lpage>S728</lpage><pub-id pub-id-type="doi">10.1016/S0924-977X(14)71172-1</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warikoo</surname><given-names>N</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>Background, clinical features and treatment of attention deficit hyperactivity disorder in children</article-title><source>Expert Opin Pharmacother</source><year>2013</year><volume>14</volume><fpage>1885</fpage><lpage>1906</lpage><pub-id pub-id-type="doi">10.1517/14656566.2013.818977</pub-id><?supplied-pmid 23865438?><pub-id pub-id-type="pmid">23865438</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloch</surname><given-names>MH</given-names></name><name><surname>Panza</surname><given-names>KE</given-names></name><name><surname>Landeros-Weisenberger</surname><given-names>A</given-names></name><name><surname>Leckman</surname><given-names>JF</given-names></name></person-group><article-title>Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2009</year><volume>48</volume><fpage>884</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1097/CHI.0b013e3181b26e9f</pub-id><?supplied-pmid 19625978?><pub-id pub-id-type="pmid">19625978</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>DJ</given-names></name><name><surname>Detlor</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>JG</given-names></name><name><surname>Shaywitz</surname><given-names>BA</given-names></name></person-group><article-title>Clonidine ameliorates Gilles de la Tourette syndrome</article-title><source>Arch Gen Psychiatry</source><year>1980</year><volume>37</volume><fpage>1350</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1001/archpsyc.1980.01780250036004</pub-id><?supplied-pmid 6255888?><pub-id pub-id-type="pmid">6255888</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Tourette&#x02019;s Syndrome Study Group</collab></person-group><article-title>Treatment of ADHD in children with tics: a randomized controlled trial</article-title><source>Neurology</source><year>2002</year><volume>58</volume><fpage>527</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1212/WNL.58.4.527</pub-id><pub-id pub-id-type="pmid">11865128</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>R</given-names></name><name><surname>Gulisano</surname><given-names>M</given-names></name><name><surname>Cali</surname><given-names>PV</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name></person-group><article-title>Tourette syndrome and comorbid ADHD: current pharmacological treatment options</article-title><source>Eur J Paediatr Neurol</source><year>2013</year><volume>17</volume><fpage>421</fpage><lpage>428</lpage><pub-id pub-id-type="doi">10.1016/j.ejpn.2013.01.005</pub-id><?supplied-pmid 23473832?><pub-id pub-id-type="pmid">23473832</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chappell</surname><given-names>PB</given-names></name><name><surname>Riddle</surname><given-names>MA</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Lynch</surname><given-names>KA</given-names></name><name><surname>Schultz</surname><given-names>R</given-names></name><name><surname>Arnsten</surname><given-names>A</given-names></name><etal/></person-group><article-title>Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette&#x02019;s syndrome: preliminary clinical experience</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1995</year><volume>34</volume><fpage>1140</fpage><lpage>1146</lpage><pub-id pub-id-type="doi">10.1097/00004583-199509000-00010</pub-id><?supplied-pmid 7559307?><pub-id pub-id-type="pmid">7559307</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Chappell</surname><given-names>PB</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Schultz</surname><given-names>RT</given-names></name><name><surname>Katsovich</surname><given-names>L</given-names></name><name><surname>Shepherd</surname><given-names>E</given-names></name><etal/></person-group><article-title>A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder</article-title><source>Am J Psychiatry</source><year>2001</year><volume>158</volume><fpage>1067</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.158.7.1067</pub-id><?supplied-pmid 11431228?><pub-id pub-id-type="pmid">11431228</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weisman</surname><given-names>H</given-names></name><name><surname>Qureshi</surname><given-names>IA</given-names></name><name><surname>Leckman</surname><given-names>JF</given-names></name><name><surname>Scahill</surname><given-names>L</given-names></name><name><surname>Bloch</surname><given-names>MH</given-names></name></person-group><article-title>Systematic review: pharmacological treatment of tic disorders&#x02014;efficacy of antipsychotic and alpha-2 adrenergic agonist agents</article-title><source>Neurosci Biobehav Rev</source><year>2013</year><volume>37</volume><fpage>1162</fpage><lpage>1171</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2012.09.008</pub-id><?supplied-pmid 23099282?><pub-id pub-id-type="pmid">23099282</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pringsheim</surname><given-names>T</given-names></name><name><surname>Doja</surname><given-names>A</given-names></name><name><surname>Gorman</surname><given-names>D</given-names></name><name><surname>McKinlay</surname><given-names>D</given-names></name><name><surname>Day</surname><given-names>L</given-names></name><name><surname>Billinghurst</surname><given-names>L</given-names></name><etal/></person-group><article-title>Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy</article-title><source>Can J Psychiatry</source><year>2012</year><volume>57</volume><fpage>133</fpage><lpage>143</lpage><?supplied-pmid 22397999?><pub-id pub-id-type="pmid">22397999</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roessner</surname><given-names>V</given-names></name><name><surname>Plessen</surname><given-names>KJ</given-names></name><name><surname>Rothenberger</surname><given-names>A</given-names></name><name><surname>Ludolph</surname><given-names>AG</given-names></name><name><surname>Rizzo</surname><given-names>R</given-names></name><name><surname>Skov</surname><given-names>L</given-names></name><etal/></person-group><article-title>European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment</article-title><source>Eur Child Adolesc Psychiatry</source><year>2011</year><volume>20</volume><fpage>173</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1007/s00787-011-0163-7</pub-id><?supplied-pmid 21445724?><pub-id pub-id-type="pmid">21445724</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>RD</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Asbell</surname><given-names>MD</given-names></name></person-group><article-title>An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1995</year><volume>34</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1097/00004583-199501000-00013</pub-id><?supplied-pmid 7860456?><pub-id pub-id-type="pmid">7860456</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Signorovitch</surname><given-names>J</given-names></name><name><surname>Erder</surname><given-names>MH</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Sikirica</surname><given-names>V</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name><name><surname>Hodgkins</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder</article-title><source>Pharmacoepidemiol Drug Saf</source><year>2012</year><volume>21</volume><issue>Suppl 2</issue><fpage>130</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1002/pds.3246</pub-id><?supplied-pmid 22552988?><pub-id pub-id-type="pmid">22552988</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Findling</surname><given-names>RL</given-names></name><name><surname>McBurnett</surname><given-names>K</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Youcha</surname><given-names>S</given-names></name></person-group><article-title>Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>J Child Adolesc Psychopharmacol</source><year>2014</year><volume>24</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1089/cap.2013.0103</pub-id><?supplied-pmid 24945085?><pub-id pub-id-type="pmid">24945085</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Wilens</surname><given-names>T</given-names></name></person-group><article-title>Growth deficits in children with attention deficit hyperactivity disorder</article-title><source>Pediatrics</source><year>1998</year><volume>102</volume><fpage>501</fpage><lpage>506</lpage><?supplied-pmid 9685453?><pub-id pub-id-type="pmid">9685453</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Monuteaux</surname><given-names>MC</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects</article-title><source>J Pediatr</source><year>2010</year><volume>157</volume><issue>635&#x02013;40</issue><fpage>e1</fpage><?supplied-pmid 20605163?><pub-id pub-id-type="pmid">20605163</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulton</surname><given-names>A</given-names></name><name><surname>Briody</surname><given-names>J</given-names></name><name><surname>McCorquodale</surname><given-names>T</given-names></name><name><surname>Melzer</surname><given-names>E</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Baur</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Weight loss on stimulant medication: how does it affect body composition and bone metabolism? A prospective longitudinal study</article-title><source>Int J Pediatr Endocrinol.</source><year>2012</year><volume>2012</volume><fpage>30</fpage><pub-id pub-id-type="doi">10.1186/1687-9856-2012-30</pub-id><?supplied-pmid 23216890?><pub-id pub-id-type="pmid">23216890</pub-id></element-citation></ref><ref id="CR205"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasnain</surname><given-names>M</given-names></name><name><surname>Vieweg</surname><given-names>WV</given-names></name></person-group><article-title>Weight considerations in psychotropic drug prescribing and switching</article-title><source>Postgrad Med</source><year>2013</year><volume>125</volume><fpage>117</fpage><lpage>129</lpage><pub-id pub-id-type="doi">10.3810/pgm.2013.09.2706</pub-id><?supplied-pmid 24113670?><pub-id pub-id-type="pmid">24113670</pub-id></element-citation></ref><ref id="CR206"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassareo</surname><given-names>PP</given-names></name><name><surname>Mercuro</surname><given-names>G</given-names></name></person-group><article-title>Pediatric hypertension: an update on a burning problem</article-title><source>World J Cardiol</source><year>2014</year><volume>6</volume><fpage>253</fpage><lpage>259</lpage><?supplied-pmid 24944755?><pub-id pub-id-type="pmid">24944755</pub-id></element-citation></ref><ref id="CR207"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lurbe</surname><given-names>E</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Cruickshank</surname><given-names>JK</given-names></name><name><surname>Dillon</surname><given-names>MJ</given-names></name><name><surname>Ferreira</surname><given-names>I</given-names></name><name><surname>Invitti</surname><given-names>C</given-names></name><etal/></person-group><article-title>Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension</article-title><source>J Hypertens</source><year>2009</year><volume>27</volume><fpage>1719</fpage><lpage>1742</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e32832f4f6b</pub-id><?supplied-pmid 19625970?><pub-id pub-id-type="pmid">19625970</pub-id></element-citation></ref><ref id="CR208"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>MG</given-names></name><name><surname>Tong</surname><given-names>X</given-names></name><name><surname>Wigington</surname><given-names>C</given-names></name><name><surname>Gillespie</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>Y</given-names></name></person-group><article-title>Hypertension screening in children and adolescents&#x02014;National Ambulatory Medical Care Survey, National Hospital Ambulatory Medical Care Survey, and Medical Expenditure Panel Survey, United States, 2007&#x02013;2010</article-title><source>Morb Mortal Wkly Rep</source><year>2014</year><volume>63</volume><fpage>47</fpage><lpage>53</lpage></element-citation></ref><ref id="CR209"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Oepen</surname><given-names>J</given-names></name><name><surname>Reinehr</surname><given-names>T</given-names></name><name><surname>Wabitsch</surname><given-names>M</given-names></name><name><surname>Claussnitzer</surname><given-names>G</given-names></name><name><surname>Waldeck</surname><given-names>E</given-names></name><etal/></person-group><article-title>Ethnicity and cardiovascular risk factors: evaluation of 40,921 normal-weight, overweight or obese children and adolescents living in Central Europe</article-title><source>Int J Obes (Lond)</source><year>2015</year><volume>39</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/ijo.2014.167</pub-id><pub-id pub-id-type="pmid">25214149</pub-id></element-citation></ref><ref id="CR210"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wigal</surname><given-names>SB</given-names></name></person-group><article-title>Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults</article-title><source>CNS Drugs</source><year>2009</year><volume>23</volume><issue>Suppl 1</issue><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2165/00023210-200923000-00004</pub-id><?supplied-pmid 19621975?><pub-id pub-id-type="pmid">19621975</pub-id></element-citation></ref><ref id="CR211"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>AC</given-names></name><name><surname>Rijsdijk</surname><given-names>F</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Kuntsi</surname><given-names>J</given-names></name></person-group><article-title>Inferring causation from cross-sectional data: examination of the causal relationship between hyperactivity-impulsivity and novelty seeking</article-title><source>Front Genet</source><year>2011</year><volume>2</volume><fpage>6</fpage><pub-id pub-id-type="doi">10.3389/fgene.2011.00006</pub-id><?supplied-pmid 22303305?><pub-id pub-id-type="pmid">22303305</pub-id></element-citation></ref><ref id="CR212"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basar</surname><given-names>K</given-names></name><name><surname>Sesia</surname><given-names>T</given-names></name><name><surname>Groenewegen</surname><given-names>H</given-names></name><name><surname>Steinbusch</surname><given-names>HW</given-names></name><name><surname>Visser-Vandewalle</surname><given-names>V</given-names></name><name><surname>Temel</surname><given-names>Y</given-names></name></person-group><article-title>Nucleus accumbens and impulsivity</article-title><source>Prog Neurobiol</source><year>2010</year><volume>92</volume><fpage>533</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2010.08.007</pub-id><?supplied-pmid 20831892?><pub-id pub-id-type="pmid">20831892</pub-id></element-citation></ref><ref id="CR213"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphreys</surname><given-names>KL</given-names></name><name><surname>Eng</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name></person-group><article-title>Stimulant medication and substance use outcomes: a meta-analysis</article-title><source>JAMA Psychiatry</source><year>2013</year><volume>70</volume><fpage>740</fpage><lpage>749</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.1273</pub-id><?supplied-pmid 23754458?><pub-id pub-id-type="pmid">23754458</pub-id></element-citation></ref><ref id="CR214"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Bobeica</surname><given-names>I</given-names></name><name><surname>Gamo</surname><given-names>NJ</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name></person-group><article-title>Effects of alpha-2A adrenergic receptor agonist on time and risk preference in primates</article-title><source>Psychopharmacology</source><year>2012</year><volume>219</volume><fpage>363</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2520-0</pub-id><?supplied-pmid 21979441?><pub-id pub-id-type="pmid">21979441</pub-id></element-citation></ref><ref id="CR215"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fliers</surname><given-names>EA</given-names></name><name><surname>Buitelaar</surname><given-names>JK</given-names></name><name><surname>Maras</surname><given-names>A</given-names></name><name><surname>Bul</surname><given-names>K</given-names></name><name><surname>Hohle</surname><given-names>E</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><etal/></person-group><article-title>ADHD is a risk factor for overweight and obesity in children</article-title><source>J Dev Behav Pediatr</source><year>2013</year><volume>34</volume><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1097/DBP.0b013e3182a50a67</pub-id><?supplied-pmid 24131879?><pub-id pub-id-type="pmid">24131879</pub-id></element-citation></ref><ref id="CR216"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortese</surname><given-names>S</given-names></name><name><surname>Comencini</surname><given-names>E</given-names></name><name><surname>Vincenzi</surname><given-names>B</given-names></name><name><surname>Speranza</surname><given-names>M</given-names></name><name><surname>Angriman</surname><given-names>M</given-names></name></person-group><article-title>Attention-deficit/hyperactivity disorder and impairment in executive functions: a barrier to weight loss in individuals with obesity?</article-title><source>BMC Psychiatry</source><year>2013</year><volume>13</volume><fpage>286</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-13-286</pub-id><?supplied-pmid 24200119?><pub-id pub-id-type="pmid">24200119</pub-id></element-citation></ref><ref id="CR217"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whalen</surname><given-names>CK</given-names></name><name><surname>Henker</surname><given-names>B</given-names></name><name><surname>Ishikawa</surname><given-names>SS</given-names></name><name><surname>Jamner</surname><given-names>LD</given-names></name><name><surname>Floro</surname><given-names>JN</given-names></name><name><surname>Johnston</surname><given-names>JA</given-names></name><etal/></person-group><article-title>An electronic diary study of contextual triggers and ADHD: get ready, get set, get mad</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2006</year><volume>45</volume><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1097/01.chi.0000189057.67902.10</pub-id><?supplied-pmid 16429087?><pub-id pub-id-type="pmid">16429087</pub-id></element-citation></ref><ref id="CR218"><label>218.</label><mixed-citation publication-type="other">Rugino TA. Effect on primary sleep disorders when children with ADHD are administered guanfacine extended release. J Atten Disord. 2014 <bold>(Epub ahead of print)</bold>.</mixed-citation></ref><ref id="CR219"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corkum</surname><given-names>P</given-names></name><name><surname>Moldofsky</surname><given-names>H</given-names></name><name><surname>Hogg-Johnson</surname><given-names>S</given-names></name><name><surname>Humphries</surname><given-names>T</given-names></name><name><surname>Tannock</surname><given-names>R</given-names></name></person-group><article-title>Sleep problems in children with attention-deficit/hyperactivity disorder: impact of subtype, comorbidity, and stimulant medication</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1999</year><volume>38</volume><fpage>1285</fpage><lpage>1293</lpage><pub-id pub-id-type="doi">10.1097/00004583-199910000-00018</pub-id><?supplied-pmid 10517062?><pub-id pub-id-type="pmid">10517062</pub-id></element-citation></ref><ref id="CR220"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Rugino</surname><given-names>T</given-names></name><name><surname>Dammerman</surname><given-names>R</given-names></name><name><surname>Lyne</surname><given-names>A</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name></person-group><article-title>Efficacy of guanfacine extended release assessed during the morning, afternoon, and evening using a modified conners&#x02019; parent rating scale-revised: short form</article-title><source>J Child Adolesc Psychopharmacol</source><year>2014</year><volume>24</volume><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1089/cap.2013.0134</pub-id><?supplied-pmid 25286026?><pub-id pub-id-type="pmid">25286026</pub-id></element-citation></ref><ref id="CR221"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Catecholamine and second messenger influences on prefrontal cortical networks of &#x0201c;representational knowledge&#x0201d;: a rational bridge between genetics and the symptoms of mental illness</article-title><source>Cereb Cortex</source><year>2007</year><volume>17</volume><issue>Suppl 1</issue><fpage>i6</fpage><lpage>i15</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhm033</pub-id><?supplied-pmid 17434919?><pub-id pub-id-type="pmid">17434919</pub-id></element-citation></ref><ref id="CR222"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Petty</surname><given-names>CR</given-names></name><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Woodworth</surname><given-names>KY</given-names></name><name><surname>Bhide</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Examining the nature of the comorbidity between pediatric attention deficit/hyperactivity disorder and post-traumatic stress disorder</article-title><source>Acta Psychiatr Scand</source><year>2013</year><volume>128</volume><fpage>78</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/acps.12011</pub-id><?supplied-pmid 22985097?><pub-id pub-id-type="pmid">22985097</pub-id></element-citation></ref><ref id="CR223"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>SG</given-names></name><name><surname>Podell</surname><given-names>DM</given-names></name><name><surname>Arnsten</surname><given-names>AF</given-names></name></person-group><article-title>Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats</article-title><source>Pharmacol Biochem Behav</source><year>2000</year><volume>67</volume><fpage>397</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/S0091-3057(00)00306-3</pub-id><?supplied-pmid 11164065?><pub-id pub-id-type="pmid">11164065</pub-id></element-citation></ref><ref id="CR224"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Connor</surname><given-names>DF</given-names></name><name><surname>Grasso</surname><given-names>DJ</given-names></name><name><surname>Slivinsky</surname><given-names>MD</given-names></name><name><surname>Pearson</surname><given-names>GS</given-names></name><name><surname>Banga</surname><given-names>A</given-names></name></person-group><article-title>An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents</article-title><source>J Child Adolesc Psychopharmacol</source><year>2013</year><volume>23</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1089/cap.2012.0119</pub-id><?supplied-pmid 23683139?><pub-id pub-id-type="pmid">23683139</pub-id></element-citation></ref><ref id="CR225"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhotra</surname><given-names>PA</given-names></name><name><surname>Parton</surname><given-names>AD</given-names></name><name><surname>Greenwood</surname><given-names>R</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name></person-group><article-title>Noradrenergic modulation of space exploration in visual neglect</article-title><source>Ann Neurol</source><year>2006</year><volume>59</volume><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1002/ana.20701</pub-id><?supplied-pmid 16261567?><pub-id pub-id-type="pmid">16261567</pub-id></element-citation></ref><ref id="CR226"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh-Curry</surname><given-names>V</given-names></name><name><surname>Malhotra</surname><given-names>P</given-names></name><name><surname>Farmer</surname><given-names>SF</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name></person-group><article-title>Attention deficits following ADEM ameliorated by guanfacine</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><fpage>688</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2009.195792</pub-id><?supplied-pmid 20562462?><pub-id pub-id-type="pmid">20562462</pub-id></element-citation></ref><ref id="CR227"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAllister</surname><given-names>TW</given-names></name><name><surname>McDonald</surname><given-names>BC</given-names></name><name><surname>Flashman</surname><given-names>LA</given-names></name><name><surname>Ferrell</surname><given-names>RB</given-names></name><name><surname>Tosteson</surname><given-names>TD</given-names></name><name><surname>Yanofsky</surname><given-names>NN</given-names></name><etal/></person-group><article-title>Alpha-2 adrenergic challenge with guanfacine one month after mild traumatic brain injury: altered working memory and BOLD response</article-title><source>Int J Psychophysiol</source><year>2011</year><volume>82</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.ijpsycho.2011.06.022</pub-id><?supplied-pmid 21767584?><pub-id pub-id-type="pmid">21767584</pub-id></element-citation></ref><ref id="CR228"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kauser</surname><given-names>H</given-names></name><name><surname>Sahu</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><name><surname>Panjwani</surname><given-names>U</given-names></name></person-group><article-title>Guanfacine ameliorates hypobaric hypoxia induced spatial working memory deficits</article-title><source>Physiol Behav</source><year>2014</year><volume>123</volume><fpage>187</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1016/j.physbeh.2013.10.028</pub-id><?supplied-pmid 24184415?><pub-id pub-id-type="pmid">24184415</pub-id></element-citation></ref><ref id="CR229"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruxel</surname><given-names>EM</given-names></name><name><surname>Akutagava-Martins</surname><given-names>GC</given-names></name><name><surname>Salatino-Oliveira</surname><given-names>A</given-names></name><name><surname>Contini</surname><given-names>V</given-names></name><name><surname>Kieling</surname><given-names>C</given-names></name><name><surname>Hutz</surname><given-names>MH</given-names></name><etal/></person-group><article-title>ADHD pharmacogenetics across the life cycle: new findings and perspectives</article-title><source>Am J Med Genet B Neuropsychiatr Genet</source><year>2014</year><volume>165</volume><fpage>263</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/ajmg.b.32240</pub-id><pub-id pub-id-type="pmid">24804845</pub-id></element-citation></ref><ref id="CR230"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgkins</surname><given-names>P</given-names></name><name><surname>Dittmann</surname><given-names>RW</given-names></name><name><surname>Sorooshian</surname><given-names>S</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name></person-group><article-title>Individual treatment response in attention-deficit/hyperactivity disorder: broadening perspectives and improving assessments</article-title><source>Exp Rev Neurother</source><year>2013</year><volume>13</volume><fpage>425</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1586/ern.13.31</pub-id></element-citation></ref><ref id="CR231"><label>231.</label><mixed-citation publication-type="other">clinicaltrials.gov. NCT01081145. 2014. <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov/ct2/show/study/NCT01081145?sect=X01256">http://clinicaltrials.gov/ct2/show/study/NCT01081145?sect=X01256</ext-link>. Accessed 4 Aug 2014.</mixed-citation></ref><ref id="CR232"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pliszka</surname><given-names>S</given-names></name></person-group><article-title>Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2007</year><volume>46</volume><fpage>894</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1097/chi.0b013e318054e724</pub-id><?supplied-pmid 17581453?><pub-id pub-id-type="pmid">17581453</pub-id></element-citation></ref><ref id="CR233"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmann</surname><given-names>PA</given-names></name><name><surname>Theye</surname><given-names>FW</given-names></name><name><surname>Berg</surname><given-names>R</given-names></name><name><surname>Linquist</surname><given-names>AJ</given-names></name><name><surname>Van Erem</surname><given-names>AJ</given-names></name><name><surname>Campbell</surname><given-names>LR</given-names></name></person-group><article-title>Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects</article-title><source>Pediatrics</source><year>2001</year><volume>107</volume><fpage>E10</fpage><pub-id pub-id-type="doi">10.1542/peds.107.1.e10</pub-id><?supplied-pmid 11134474?><pub-id pub-id-type="pmid">11134474</pub-id></element-citation></ref><ref id="CR234"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>DH</given-names></name><name><surname>Shin</surname><given-names>YJ</given-names></name><name><surname>Cho</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial</article-title><source>Aust N Z J Psychiatry</source><year>2007</year><volume>41</volume><fpage>222</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1080/00048670601057767</pub-id><?supplied-pmid 17464703?><pub-id pub-id-type="pmid">17464703</pub-id></element-citation></ref><ref id="CR235"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Kratochvil</surname><given-names>CJ</given-names></name><name><surname>Allen</surname><given-names>AJ</given-names></name><name><surname>Casat</surname><given-names>CD</given-names></name><name><surname>Ruff</surname><given-names>DD</given-names></name><name><surname>Moore</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response</article-title><source>Am J Psychiatry</source><year>2008</year><volume>165</volume><fpage>721</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1176/appi.ajp.2007.05091676</pub-id><?supplied-pmid 18281409?><pub-id pub-id-type="pmid">18281409</pub-id></element-citation></ref><ref id="CR236"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenhill</surname><given-names>LL</given-names></name><name><surname>Swanson</surname><given-names>JM</given-names></name><name><surname>Vitiello</surname><given-names>B</given-names></name><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Clevenger</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2001</year><volume>40</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1097/00004583-200102000-00012</pub-id><?supplied-pmid 11211366?><pub-id pub-id-type="pmid">11211366</pub-id></element-citation></ref><ref id="CR237"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilens</surname><given-names>T</given-names></name><name><surname>McBurnett</surname><given-names>K</given-names></name><name><surname>Stein</surname><given-names>M</given-names></name><name><surname>Lerner</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>T</given-names></name><name><surname>Wolraich</surname><given-names>M</given-names></name></person-group><article-title>ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2005</year><volume>44</volume><fpage>1015</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1097/01.chi.0000173291.28688.e7</pub-id><?supplied-pmid 16175106?><pub-id pub-id-type="pmid">16175106</pub-id></element-citation></ref><ref id="CR238"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smalley</surname><given-names>SL</given-names></name><name><surname>McGough</surname><given-names>JJ</given-names></name><name><surname>Moilanen</surname><given-names>IK</given-names></name><name><surname>Loo</surname><given-names>SK</given-names></name><name><surname>Taanila</surname><given-names>A</given-names></name><name><surname>Ebeling</surname><given-names>H</given-names></name><etal/></person-group><article-title>Prevalence and psychiatric comorbidity of attention-deficit/hyperactivity disorder in an adolescent Finnish population</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2007</year><volume>46</volume><fpage>1575</fpage><lpage>1583</lpage><pub-id pub-id-type="doi">10.1097/chi.0b013e3181573137</pub-id><?supplied-pmid 18030079?><pub-id pub-id-type="pmid">18030079</pub-id></element-citation></ref><ref id="CR239"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gau</surname><given-names>SS</given-names></name><name><surname>Ni</surname><given-names>HC</given-names></name><name><surname>Shang</surname><given-names>CY</given-names></name><name><surname>Soong</surname><given-names>WT</given-names></name><name><surname>Wu</surname><given-names>YY</given-names></name><name><surname>Lin</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><fpage>135</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.3109/00048670903282733</pub-id><?supplied-pmid 20113302?><pub-id pub-id-type="pmid">20113302</pub-id></element-citation></ref><ref id="CR240"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinhausen</surname><given-names>HC</given-names></name><name><surname>Novik</surname><given-names>TS</given-names></name><name><surname>Baldursson</surname><given-names>G</given-names></name><name><surname>Curatolo</surname><given-names>P</given-names></name><name><surname>Lorenzo</surname><given-names>MJ</given-names></name><name><surname>Rodrigues</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Co-existing psychiatric problems in ADHD in the ADORE cohort</article-title><source>Eur Child Adolesc Psychiatry</source><year>2006</year><volume>15</volume><issue>Suppl 1</issue><fpage>I25</fpage><lpage>I29</lpage><pub-id pub-id-type="doi">10.1007/s00787-006-1004-y</pub-id><?supplied-pmid 17177012?><pub-id pub-id-type="pmid">17177012</pub-id></element-citation></ref><ref id="CR241"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlander</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>O</given-names></name><name><surname>Rothenberger</surname><given-names>A</given-names></name><name><surname>Roessner</surname><given-names>V</given-names></name></person-group><article-title>Tic disorders: administrative prevalence and co-occurrence with attention-deficit/hyperactivity disorder in a German community sample</article-title><source>Eur Psychiatry.</source><year>2011</year><volume>26</volume><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1016/j.eurpsy.2009.10.003</pub-id><?supplied-pmid 20427154?><pub-id pub-id-type="pmid">20427154</pub-id></element-citation></ref><ref id="CR242"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zavadenko</surname><given-names>NN</given-names></name><name><surname>Suvorinova</surname><given-names>NI</given-names></name></person-group><article-title>Disorders comorbid to attention deficit hyperactivity syndrome in children</article-title><source>Zh Nevrol Psikhiatr Im S S Korsakova</source><year>2007</year><volume>107</volume><fpage>30</fpage><lpage>35</lpage><?supplied-pmid 18379479?><pub-id pub-id-type="pmid">18379479</pub-id></element-citation></ref><ref id="CR243"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anckarsater</surname><given-names>H</given-names></name><name><surname>Lundstrom</surname><given-names>S</given-names></name><name><surname>Kollberg</surname><given-names>L</given-names></name><name><surname>Kerekes</surname><given-names>N</given-names></name><name><surname>Palm</surname><given-names>C</given-names></name><name><surname>Carlstrom</surname><given-names>E</given-names></name><etal/></person-group><article-title>The child and adolescent twin study in Sweden (CATSS)</article-title><source>Twin Res Hum Genet</source><year>2011</year><volume>14</volume><fpage>495</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1375/twin.14.6.495</pub-id><?supplied-pmid 22506305?><pub-id pub-id-type="pmid">22506305</pub-id></element-citation></ref><ref id="CR244"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiri</surname><given-names>S</given-names></name><name><surname>Fakhari</surname><given-names>A</given-names></name><name><surname>Golmirzaei</surname><given-names>J</given-names></name><name><surname>Mohammadpoorasl</surname><given-names>A</given-names></name><name><surname>Abdi</surname><given-names>S</given-names></name></person-group><article-title>Tourette&#x02019;s syndrome, chronic tics, and comorbid attention deficit/hyperactivity disorder in elementary students</article-title><source>Arch Iran Med.</source><year>2012</year><volume>15</volume><fpage>76</fpage><lpage>78</lpage><?supplied-pmid 22292574?><pub-id pub-id-type="pmid">22292574</pub-id></element-citation></ref><ref id="CR245"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name></person-group><article-title>The Massachusetts General Hospital studies of gender influences on attention-deficit/hyperactivity disorder in youth and relatives</article-title><source>Psychiatr Clin N Am</source><year>2004</year><volume>27</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.psc.2003.12.004</pub-id></element-citation></ref><ref id="CR246"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>K</given-names></name><name><surname>Russ</surname><given-names>SA</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name><name><surname>Halfon</surname><given-names>N</given-names></name></person-group><article-title>Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007</article-title><source>Pediatrics</source><year>2011</year><volume>127</volume><fpage>462</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1542/peds.2010-0165</pub-id><?supplied-pmid 21300675?><pub-id pub-id-type="pmid">21300675</pub-id></element-citation></ref><ref id="CR247"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lebowitz</surname><given-names>ER</given-names></name><name><surname>Motlagh</surname><given-names>MG</given-names></name><name><surname>Katsovich</surname><given-names>L</given-names></name><name><surname>King</surname><given-names>RA</given-names></name><name><surname>Lombroso</surname><given-names>PJ</given-names></name><name><surname>Grantz</surname><given-names>H</given-names></name><etal/></person-group><article-title>Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder</article-title><source>Eur Child Adolesc Psychiatry</source><year>2012</year><volume>21</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1007/s00787-012-0278-5</pub-id><?supplied-pmid 22543961?><pub-id pub-id-type="pmid">22543961</pub-id></element-citation></ref><ref id="CR248"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>RD</given-names></name></person-group><article-title>Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome</article-title><source>Eur Child Adolesc Psychiatry</source><year>2007</year><volume>16</volume><issue>Suppl 1</issue><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/s00787-007-1003-7</pub-id><?supplied-pmid 17665279?><pub-id pub-id-type="pmid">17665279</pub-id></element-citation></ref><ref id="CR249"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalifa</surname><given-names>N</given-names></name><name><surname>von Knorring</surname><given-names>AL</given-names></name></person-group><article-title>Psychopathology in a Swedish population of school children with tic disorders</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2006</year><volume>45</volume><fpage>1346</fpage><lpage>1353</lpage><pub-id pub-id-type="doi">10.1097/01.chi.0000251210.98749.83</pub-id><?supplied-pmid 17075357?><pub-id pub-id-type="pmid">17075357</pub-id></element-citation></ref><ref id="CR250"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadesjo</surname><given-names>B</given-names></name><name><surname>Gillberg</surname><given-names>C</given-names></name></person-group><article-title>Tourette&#x02019;s disorder: epidemiology and comorbidity in primary school children</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>2000</year><volume>39</volume><fpage>548</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1097/00004583-200005000-00007</pub-id><?supplied-pmid 10802971?><pub-id pub-id-type="pmid">10802971</pub-id></element-citation></ref><ref id="CR251"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghanizadeh</surname><given-names>A</given-names></name><name><surname>Mosallaei</surname><given-names>S</given-names></name></person-group><article-title>Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome</article-title><source>Brain Dev</source><year>2009</year><volume>31</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.braindev.2008.03.010</pub-id><?supplied-pmid 18558469?><pub-id pub-id-type="pmid">18558469</pub-id></element-citation></ref><ref id="CR252"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahle</surname><given-names>WT</given-names></name><name><surname>Clancy</surname><given-names>RR</given-names></name><name><surname>Moss</surname><given-names>EM</given-names></name><name><surname>Gerdes</surname><given-names>M</given-names></name><name><surname>Jobes</surname><given-names>DR</given-names></name><name><surname>Wernovsky</surname><given-names>G</given-names></name></person-group><article-title>Neurodevelopmental outcome and lifestyle assessment in school-aged and adolescent children with hypoplastic left heart syndrome</article-title><source>Pediatrics</source><year>2000</year><volume>105</volume><fpage>1082</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1542/peds.105.5.1082</pub-id><?supplied-pmid 10790466?><pub-id pub-id-type="pmid">10790466</pub-id></element-citation></ref><ref id="CR253"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strine</surname><given-names>TW</given-names></name><name><surname>Lesesne</surname><given-names>CA</given-names></name><name><surname>Okoro</surname><given-names>CA</given-names></name><name><surname>McGuire</surname><given-names>LC</given-names></name><name><surname>Chapman</surname><given-names>DP</given-names></name><name><surname>Balluz</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Emotional and behavioral difficulties and impairments in everyday functioning among children with a history of attention-deficit/hyperactivity disorder</article-title><source>Prev Chronic Dis</source><year>2006</year><volume>3</volume><fpage>A52</fpage><?supplied-pmid 16539793?><pub-id pub-id-type="pmid">16539793</pub-id></element-citation></ref><ref id="CR254"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spencer</surname><given-names>TJ</given-names></name><name><surname>Faraone</surname><given-names>SV</given-names></name><name><surname>Surman</surname><given-names>CB</given-names></name><name><surname>Petty</surname><given-names>C</given-names></name><name><surname>Clarke</surname><given-names>A</given-names></name><name><surname>Batchelder</surname><given-names>H</given-names></name><etal/></person-group><article-title>Toward defining deficient emotional self-regulation in children with attention-deficit/hyperactivity disorder using the Child Behavior Checklist: a controlled study</article-title><source>Postgrad Med</source><year>2011</year><volume>123</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3810/pgm.2011.09.2459</pub-id><?supplied-pmid 21904086?><pub-id pub-id-type="pmid">21904086</pub-id></element-citation></ref><ref id="CR255"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sjowall</surname><given-names>D</given-names></name><name><surname>Roth</surname><given-names>L</given-names></name><name><surname>Lindqvist</surname><given-names>S</given-names></name><name><surname>Thorell</surname><given-names>LB</given-names></name></person-group><article-title>Multiple deficits in ADHD: executive dysfunction, delay aversion, reaction time variability, and emotional deficits</article-title><source>J Child Psychol Psychiatry</source><year>2013</year><volume>54</volume><fpage>619</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1111/jcpp.12006</pub-id><?supplied-pmid 23061803?><pub-id pub-id-type="pmid">23061803</pub-id></element-citation></ref><ref id="CR256"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastopoulos</surname><given-names>AD</given-names></name><name><surname>Smith</surname><given-names>TF</given-names></name><name><surname>Garrett</surname><given-names>ME</given-names></name><name><surname>Morrissey-Kane</surname><given-names>E</given-names></name><name><surname>Schatz</surname><given-names>NK</given-names></name><name><surname>Sommer</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Self-regulation of emotion, functional impairment, and comorbidity among cildren with AD/HD</article-title><source>J Atten Disord.</source><year>2011</year><volume>15</volume><fpage>583</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1177/1087054710370567</pub-id><?supplied-pmid 20686097?><pub-id pub-id-type="pmid">20686097</pub-id></element-citation></ref><ref id="CR257"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stringaris</surname><given-names>A</given-names></name><name><surname>Goodman</surname><given-names>R</given-names></name></person-group><article-title>Mood lability and psychopathology in youth</article-title><source>Psychol Med</source><year>2009</year><volume>39</volume><fpage>1237</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1017/S0033291708004662</pub-id><?supplied-pmid 19079807?><pub-id pub-id-type="pmid">19079807</pub-id></element-citation></ref><ref id="CR258"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sobanski</surname><given-names>E</given-names></name><name><surname>Banaschewski</surname><given-names>T</given-names></name><name><surname>Asherson</surname><given-names>P</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><etal/></person-group><article-title>Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence</article-title><source>J Child Psychol Psychiatry</source><year>2010</year><volume>51</volume><fpage>915</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1111/j.1469-7610.2010.02217.x</pub-id><?supplied-pmid 20132417?><pub-id pub-id-type="pmid">20132417</pub-id></element-citation></ref><ref id="CR259"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goez</surname><given-names>H</given-names></name><name><surname>Back-Bennet</surname><given-names>O</given-names></name><name><surname>Zelnik</surname><given-names>N</given-names></name></person-group><article-title>Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder</article-title><source>J Child Neurol</source><year>2007</year><volume>22</volume><fpage>538</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1177/0883073807303221</pub-id><?supplied-pmid 17690058?><pub-id pub-id-type="pmid">17690058</pub-id></element-citation></ref><ref id="CR260"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ter-Stepanian</surname><given-names>M</given-names></name><name><surname>Grizenko</surname><given-names>N</given-names></name><name><surname>Zappitelli</surname><given-names>M</given-names></name><name><surname>Joober</surname><given-names>R</given-names></name></person-group><article-title>Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders</article-title><source>Can J Psychiatry</source><year>2010</year><volume>55</volume><fpage>305</fpage><lpage>312</lpage><?supplied-pmid 20482957?><pub-id pub-id-type="pmid">20482957</pub-id></element-citation></ref><ref id="CR261"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harty</surname><given-names>SC</given-names></name><name><surname>Miller</surname><given-names>CJ</given-names></name><name><surname>Newcorn</surname><given-names>JH</given-names></name><name><surname>Halperin</surname><given-names>JM</given-names></name></person-group><article-title>Adolescents with childhood ADHD and comorbid disruptive behavior disorders: aggression, anger, and hostility</article-title><source>Child Psychiatry Hum Dev</source><year>2009</year><volume>40</volume><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1007/s10578-008-0110-0</pub-id><?supplied-pmid 18597170?><pub-id pub-id-type="pmid">18597170</pub-id></element-citation></ref><ref id="CR262"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurtig</surname><given-names>T</given-names></name><name><surname>Ebeling</surname><given-names>H</given-names></name><name><surname>Taanila</surname><given-names>A</given-names></name><name><surname>Miettunen</surname><given-names>J</given-names></name><name><surname>Smalley</surname><given-names>S</given-names></name><name><surname>McGough</surname><given-names>J</given-names></name><etal/></person-group><article-title>ADHD and comorbid disorders in relation to family environment and symptom severity</article-title><source>Eur Child Adolesc Psychiatry</source><year>2007</year><volume>16</volume><fpage>362</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1007/s00787-007-0607-2</pub-id><?supplied-pmid 17401612?><pub-id pub-id-type="pmid">17401612</pub-id></element-citation></ref><ref id="CR263"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Souza</surname><given-names>I</given-names></name><name><surname>Pinheiro</surname><given-names>MA</given-names></name><name><surname>Denardin</surname><given-names>D</given-names></name><name><surname>Mattos</surname><given-names>P</given-names></name><name><surname>Rohde</surname><given-names>LA</given-names></name></person-group><article-title>Attention-deficit/hyperactivity disorder and comorbidity in Brazil: comparisons between two referred samples</article-title><source>Eur Child Adolesc Psychiatry</source><year>2004</year><volume>13</volume><fpage>243</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1007/s00787-004-0402-2</pub-id><?supplied-pmid 15365895?><pub-id pub-id-type="pmid">15365895</pub-id></element-citation></ref><ref id="CR264"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>August</surname><given-names>GJ</given-names></name><name><surname>Realmuto</surname><given-names>GM</given-names></name><name><surname>MacDonald</surname><given-names>AW</given-names><suffix>III</suffix></name><name><surname>Nugent</surname><given-names>SM</given-names></name><name><surname>Crosby</surname><given-names>R</given-names></name></person-group><article-title>Prevalence of ADHD and comorbid disorders among elementary school children screened for disruptive behavior</article-title><source>J Abnorm Child Psychol</source><year>1996</year><volume>24</volume><fpage>571</fpage><lpage>595</lpage><pub-id pub-id-type="doi">10.1007/BF01670101</pub-id><?supplied-pmid 8956085?><pub-id pub-id-type="pmid">8956085</pub-id></element-citation></ref><ref id="CR265"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biederman</surname><given-names>J</given-names></name><name><surname>Ball</surname><given-names>SW</given-names></name><name><surname>Monuteaux</surname><given-names>MC</given-names></name><name><surname>Surman</surname><given-names>CB</given-names></name><name><surname>Johnson</surname><given-names>JL</given-names></name><name><surname>Zeitlin</surname><given-names>S</given-names></name></person-group><article-title>Are girls with ADHD at risk for eating disorders? Results from a controlled, five-year prospective study</article-title><source>J Dev Behav Pediatr</source><year>2007</year><volume>28</volume><fpage>302</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1097/DBP.0b013e3180327917</pub-id><?supplied-pmid 17700082?><pub-id pub-id-type="pmid">17700082</pub-id></element-citation></ref><ref id="CR266"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rastam</surname><given-names>M</given-names></name><name><surname>Taljemark</surname><given-names>J</given-names></name><name><surname>Tajnia</surname><given-names>A</given-names></name><name><surname>Lundstrom</surname><given-names>S</given-names></name><name><surname>Gustafsson</surname><given-names>P</given-names></name><name><surname>Lichtenstein</surname><given-names>P</given-names></name><etal/></person-group><article-title>Eating problems and overlap with ADHD and autism spectrum disorders in a nationwide twin study of 9- and 12-year-old children</article-title><source>Sci World J</source><year>2013</year><volume>2013</volume><fpage>315429</fpage><pub-id pub-id-type="doi">10.1155/2013/315429</pub-id></element-citation></ref><ref id="CR267"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname><given-names>AG</given-names></name><name><surname>Dalsgaard</surname><given-names>S</given-names></name></person-group><article-title>Prevalence of smoking, alcohol and substance use among adolescents with attention-deficit/hyperactivity disorder in Denmark compared with the general population</article-title><source>Nord J Psychiatry</source><year>2014</year><volume>68</volume><fpage>53</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3109/08039488.2013.768293</pub-id><?supplied-pmid 23428143?><pub-id pub-id-type="pmid">23428143</pub-id></element-citation></ref><ref id="CR268"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>LT</given-names></name><name><surname>Gersing</surname><given-names>K</given-names></name><name><surname>Burchett</surname><given-names>B</given-names></name><name><surname>Woody</surname><given-names>GE</given-names></name><name><surname>Blazer</surname><given-names>DG</given-names></name></person-group><article-title>Substance use disorders and comorbid Axis I and II psychiatric disorders among young psychiatric patients: findings from a large electronic health records database</article-title><source>J Psychiatr Res</source><year>2011</year><volume>45</volume><fpage>1453</fpage><lpage>1462</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2011.06.012</pub-id><?supplied-pmid 21742345?><pub-id pub-id-type="pmid">21742345</pub-id></element-citation></ref><ref id="CR269"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovens</surname><given-names>JG</given-names></name><name><surname>Cantwell</surname><given-names>DP</given-names></name><name><surname>Kiriakos</surname><given-names>R</given-names></name></person-group><article-title>Psychiatric comorbidity in hospitalized adolescent substance abusers</article-title><source>J Am Acad Child Adolesc Psychiatry</source><year>1994</year><volume>33</volume><fpage>476</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1097/00004583-199405000-00005</pub-id><?supplied-pmid 8005900?><pub-id pub-id-type="pmid">8005900</pub-id></element-citation></ref></ref-list></back></article>